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ABSTRACT
Generally the pharmaceutical industry operates in a heavily regulated and controlled
environment. In South Africa, the regulations governing prescription drugs do not
allow the pharmaceutical companies to advertise the prescription drugs directly to the
consumers. As a consequence, the greater part of the marketing efforts of the
pharmaceutical companies is directed at the medical practitioners, who occupy the
crucial decision-making position for the prescription drugs.
The study broadly investigates the relative influence of the varIOUS promotional
factors that may influence the General Practitioner's choice of prescription drug and
more specifically, focuses on the characteristics of the pharmaceutical sales
representatives that may influence the prescribing behaviour of the General
Practitioners.
An area sample of 67 general practitioners in Pietermaritzburp, South Africa,. was
carried out. A total of 58 responses were analysed to determine the perceived
influence of various factors on the GPs' choice of new and.. existing prescription
drugs. A specific attempt was made to determine the key influential factors with
respect to the promotion by the pharmaceutical representatives and GPs' appreciation
ofbasic statistics used in the presentations by the pharmaceutical representatives.
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H The best advertised drugs are the ones that sell, not the best drug"
Clara MacKay (Thomson, 2001).
1.1 BACKGROUND
Today marketing permeates virtually all activities related to the sale of products, might it be
physical goods and/or services. Marketing has an influence on almost all, if not all, of the
goods and services purchased by us. However, the marketing of pharmaceutical drugs has
atypical aspects that differentiate them from the marketing of the usual general goods. The
noticeable differences are the extremely regulated and controlled environment of the
pharmaceutical industry and the crucial decision-making position of the medical practitioners
for the consumers (the patients) of the pharmaceutical drugs. The regulations governing
prescription drugs do not allow the pharmaceutical companies to advertise the prescription
drugs directly to the consumers. Generally they are available to the consumers only from the
pharmacists once authorised by a doctor's prescription. Although the patients essentially use
and mayor may not pay for the prescription pharmaceutical drugs, they have minor, if any
influence in the choice of the drug prescribed by the doctor. In many cases a third party, such
as healthcare funders (medical aid societies in South Africa), rather than the patients
(consumers) themselves that carry out the payment of these prescription drugs.
Pharmaceutical drugs are classified as either ethical or generic. Ethical drugs are drugs
produced under patent for a specific purpose by the company who holds the rights to the
patent. Generic drugs are drugs whose patents have expired and which can be produced by
many manufacturers. Both categories of drugs, depending upon their registered "schedule"
with the relevant governing institution, can al~ be known as Prescription only Medicines.
Over-the-counter (OTC) medicines are drugs that are considered safe (by the relevant
regulatory bodies) for self-medication by the lay public, i.e. they do not require a prescription
from a doctor.
The pharmaceutical drugs can also be classified as scheduled or non-scheduled drugs. In
South Africa, there are now eight schedules (categories) of drugs. Different schedules have
varying restrictions attached to them. Generally, drugs that fall into schedule three and higher
require a doctor's prescription. The pharmacist, without a prescription, can dispense schedule
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two drugs. Schedule one and the non-schedule drugs are available as self-medication. The
different schedules also have various advertising restrictions associated with them.
As a consequence of the regulations governing the prescnptIon drugs and the severe
restrictions on direct-to-consumer advertising of prescription drugs, the greater part of the
marketing efforts of the pharmaceutical companies is directed at the medical practitioners.
"Acceptance of a scheduled pharmaceutical product by doctors is a sine qua non for its
success" (Pitt and Nel, 1988: 8).
IMS Health is an organisation that tracks the actual sales of approximately 90% of all
pharmaceutical drugs in more than seventy countries. (lMS Health, paragraph 2). The global
audited sale of pharmaceutical drugs, as reported in the IMS Health World Review for 2002,
was $400.6 billion (lMS Health, paragraph 1). According to the Pharmaceutical
Manufacturers' Association (PMA) Draft Annual Report: May 2002 - March 2003, the South
African pharmaceutical industry's gross output for 2001, was R6.23 billion. According to the
same report, the pharmaceutical industry's share of South Africa's Gross Domestic Product
(GDP), in 2001, was 0.6%. As a comparison, in 2000, the National Association of
Pharmaceutical Manufacturers (NAPM) in South Africa approximated the total
pharmaceutical revenues ofprescription drugs to be R4, 172 billion. The ethical drugs formed
84% (R3, 958bn) of this total value. NAPM estimates the value of the pharmaceutical
industry at over RIO billion, with over 80% of revenues coming from the private sector
(NAPM- Fast Facts, paragraph 1).
The majority of the pharmaceutical companies operate both, in the private and public health
sectors in South Africa. There is a vast difference in the cost of prescription drugs to the
private and public health sectors in South Africa. The public health sector (government-
managed institutions), work on the basis of submission of tenders by the pharmaceutical
companies, for their purchase of pharmaceutical drugs. The various pharmaceutical
companies submit tenders to the government health department, and the government generally
obtain an extremely low cost price for a significantly large volume ofprescription drugs. The
benefit to the pharmaceutical companies is an increase in the brand awareness and prescriber
experience especially amongst the newly qualified or junior doctors working at the
government institutions. Many of these young doctors may enter the private sector in the
future and would hopefully continue to prescribe the drugs that they are familiar with. The
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greater the number of doctors prescribing a particular prescription drug in the private sector
and greater the repeat prescription by the doctors, the greater the return on investment for the
relevant pharmaceutical company.
The pharmaceutical companies derive substantial profits from the private sector. Public
healthcare, whilst accounting for most of the demand for the pharmaceuticals with minimal
contribution to the pharmaceutical sector's value, is largely funded by the means of tax
(NAPM-Overview, paragraph 2). Gunning (1988:51) found that "70 percent ofmedicine went
to government but it only accounted for 30 percent of the income ofthe industry." As a result,
it is a commonly held belief amongst the private medical practitioners in South Africa that the
private sector makes it possible for the government hospitals to enjoy the supply of
prescription drugs at an immense discount.
It is not easy to obtain the exact data of the promotional spending by the pharmaceutical
companies due to the confidential nature of such information in the highly competitive
industry. According to Maureen Kirkman of PMA (SA), the research and development to
bring a pharmaceutical drug onto the market in the US is about R6- billion (Keeton, 2003:5).
It is also estimated that the pharmaceutical companies spend about twice as much on
promoting and marketing their drugs as on researching them. (Salleh, 2002). The bulk of this
promotional spending is on the prescription drugs. This involves both subtle and not so subtle
persuasion of health care professionals. The health care professionals are the decision makers
for the consumers of the prescription pharmaceutical drugs, i.e. the medical practitioners are
the sole decision makers as to which prescription drugs the consumers (patients) receive.
According to IMS Health data for 2001, the pharmaceutical companies spent $16.4 billion on
promotional activities targeted to reach and influence the medical practitioners (IMS Health,
2002, paragraph 5). Obviously, the promotional efforts of the pharmaceutical companies must
be having more than a little influence on the prescribing behaviour of the medical
practitioners, in order to justify such a considerable expense.
Some popular promotional tools used by the pharmaceutical companies to influence the
prescribing behaviour ofthe doctors are:
• Pharmaceutical sales representative ('sales reps') calling on the medical practitioners
(missionary selling);
• Advertising in medical print media such as the medical journals and news letters;
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• Sponsorship of medical lectures, seminars, and continuing professional development
(CPD)/continuing medical education (CME) activities;
• Sales promotional materials such as drug sampling, product related give-aways/gifts
such as pens bearing brand/corporate names;
• Direct mail advertising to health care professionals; and
• Direct-to-consumer advertising.
1.2 REASONS FOR UNDERTAKING THIS SURVEY
The purpose of this study is to expand the existing understanding of the impact of the
pharmaceutical companies' promotional activities on general practitioners' (GPs') prescribing
behaviour. The study broadly investigates the relative influence of the various factors that
may influence the GP's choice of prescription drug and more specifically, focuses on the
characteristics of the pharmaceutical sales representatives that may influence the prescribing
behaviour ofthe GPs in Pietermaritzburg.
Compared to other industries, there are very few preceding studies into the impact and
effectiveness of pharmaceutical promotional activities. Pitt and Nel (1988) surveyed 210
general practitioners to ascertain their perceptions of the influence of pharmaceutical
promotional activities/tools on their prescribing behaviour. They found that, "of promotional
tools, sales calls by pharmaceutical firms' sales representatives are perceived to be the most
influential" (Pitt and Nel, 1988: 7-14).
The knowledge and understanding of the various factors of this specific promotional activity
is very useful to the pharmaceutical companies in planning their promotional undertaking
more effectively. Personal selling is generally a far more expensive type of promotional
activity compared to the other types. "Because personal selling is often a company's single
largest operating expense, it's important to understand the decisions in this area" (McCarthy
and Perreault, 1991 :302). The information is of vital importance to pharmaceutical companies
for their marketing planning, as the sales force budget usually accounts for over 50% of the
average pharmaceutical company's promotional budget (Koekemoer, 1987: 468). In addition,
as it is too expensive to reach every possible prescriber, it is important to improve the
marketing approaches used by the pharmaceutical companies (Corstjens, 1991: 8).
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It could also be useful to the medical practitioners to enable them to become more aware of
the extent ofthe influence of the various factors on their prescribing habits. This in turn would
help promote rational/appropriate prescribing. Currently in South Africa, the medical
practitioners can prescribe and/or dispense medication directly to the patients. Inappropriate
prescribing includes practices such as: prescribing medication that has no proven benefit in a
particular situation, over or under prescribing of medications, and situations where newer
more expensive ethical drug(s) are prescribed instead of the equivalent older or generic
drug(s). According to Steve Hulme, cited by MacLean (2001), a literature survey showed that
''the more doctors rely on commercial source of information, the less appropriate and less
cost-effective are their prescribing decisions."
The research will also determine if there are any significant changes since Pitt and Nel
undertook their study in 1988. Furthermore, to my knowledge, there is no preceding similar
research in this region of South Africa.
As a medical practitioner with twelve years of experience, the latter eight years as a general
practitioner in Pietermaritzburg, the study will also draw upon the researcher's personal
experience ofthe various promotional activities utilised by the pharmaceutical companies.
STATEMENT OF THE PROBLEM
What are the perceived influences of the various pharmaceutical promotional tools on the
General Practitioner's choice of prescription drugs and what are the key factors pertaining to
the pharmaceutical representatives influencing this choice?
1.3 OBJECTIVES OF THE SURVEY
1. To determine the factors influencing the General Practitioners' (GPs') choice of
prescription drug.
2. To determine the GPs' perception ofthe effect of the various promotional activities on
their prescribing behaviour.
3. To identify and determine the extent of the impact ofvarious factors ofpharmaceutical
sales representative promotional activity on GPs' prescribing habits in
Pietermaritzburg.
5
4. To determine the most important factors of the pharmaceutical representatives'
promotional activity, as perceived by the GPs in Pietermaritzburg.
5. To determine the GPs' awareness of basic statistics in order to assess their ability to
understand the use of statistical information by the pharmaceutical representatives in
their presentations/personal selling.
1.4 STRUCTURE
The study is structured as follows:
Chapter 1, INTRODUCTION, provides brief background information on prescription drugs,
reasons for undertaking the study, and the research objectives of the study.
Chapter 2, THEORY OF PROMOTION, describes the general marketing theories with
respect to promotion. It further looks at the theoretical models of the communication process,
models of decision making and consumer buying behaviour. The promotional activity of
personal selling is described in detail.
Chapter 3, THE PHARMACEUTICAL INDUSTRY AND THE MARKETPLACE,
describes the pharmaceutical industry and the marketplace in South Africa and its relationship
to the global pharmaceutical industry.
Chapter 4, PROMOTION OF PHARMACEUTICAL DRUGS, looks at the promotion of
pharmaceutical drugs and the most common promotional tools used by the pharmaceutical
companies. The process of prescribing of pharmaceutical drugs by the medical practitioners
and the factors influencing this decision process are also discussed. Greater focus is given to
the effects of the pharmaceutical representative's promotional activity on the prescribing
behaviour of the general (family) medical practitioners.
Chapter 5, LEGISLATIONS AND ETHICS, looks at the influence ofthe policies ofvarious
government and regulatory bodies on the promotion of pharmaceutical drugs and briefly
examines the ethical issues ofpharmaceutical promotion.
Chapter 6, RESEARCH METHODOLOGY, gives a detailed description of the research
methodology.
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Chapter 7, ANALYSIS OF RESULTS, presents the results and the analyses of the primary
research and compares the results to the literature survey.
Chapter 8, CONCLUSIONS AND RECOMMENDATIONS, presents the conclusions of
the study as it relates to the literature survey. Recommendations are made based on the
fmdings. Limitations ofthe study as well as areas for future research are also discussed.
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CHAPTER 2: THEORY OF PROMOTION
This chapter describes the general marketing theories with respect to promotion. It further
looks at the theoretical models of the communication process, models ofdecision making, and
consumer buying behaviour. The promotional activity ofpersonal selling is described in detail
as a background to offer understanding of the pharmaceutical representative's role in
pharmaceutical promotion.
2.1 PROMOTION
Promotion is one element of the well described "four Ps" of the marketing mIX. The
remaining "Ps" being Product, Price and Place (Etzel et aI, 1997:60; Kotler and Armstrong,
2001: 67; Solomon and Stuart, 1997: 11).
Ludi Koekemoer (1998: 8) defines promotion as:
"The collective activities and tools used by a marketer to inform or remind
prospective customers about a particular product offering and to attempt to
persuade them to purchase or use if'.
According to McCarthy and Perreault (1991: 284), the overall objectives ofpromotion are: (1)
reinforce present attitudes that lead to favourable behaviour or (2) actually change the
attitudes and behaviour of the firm's target market. Promotion thus represents the
communication efforts ofthe marketer to influence the beliefs, attitudes and buying behaviour
ofprospective customers.
In addition, Koekemoer (1998: 28) provides a wider perspective and contends that one or
more ofthe following, are the specific objective(s) ofpromotion:
• To build primary demand: For example, the pharmaceutical representative strives to
convince the doctors to use his/her company product instead of the competitor's
product.
• To create brand awareness: For example, the sales representatives endeavour to create
secondary demand for their brands in order to increase their market share.
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• To provide relevant information (knowledge): For example, the sales rep provides
information on the particular drug that he/she is 'detailing' (detailing is one of the
terms used to describe the activity ofpersonal selling to medical practitioners). He/she
focuses on the unique selling points (USPs) in order to differentiate the drug from the
competitor's. The medical practitioners require greater information in order to choose
between the different brands.
• To influence attitudes and feelings: For example, the use of different positioning
strategies by the pharmaceutical companies to develop positive brand impressions to
influence the attitudes ofthe doctors.
• To create desires: For example, the promotional communication attempts to create a
positive feeling towards a particular brand.
• To create preferences: For example, a pharmaceutical drug offering more value-added
benefits than the competitors such as free patient education for chronic disease such as
diabetes and hypertension, and or free periodic newsletters to patients joining the
education/supportive programmes.
• To facilitate purchase and trial: For example, the sales rep leaving behind a sample for
the doctor to give to the relevant patient or offering 'rep discount' if placing an order
through the representative in the case of dispensing doctors. The discounted price
offered is lower than that offered by the wholesaler.
• To create loyal customers: For example, by encouraging repeat prescriptions/ repeated
usage.
2.2 TYPES OF PROMOTIONS:
The major types of promotions are advertising, sales promotion, publicity, public relations,
and personal selling (Etzel et ai, 1997: 447). In addition, Koekemoer (1998: 9) also includes
sponsorship as a separate category ofpromotion. Moreover, direct marketing is also classified
as one of the elements of promotion, instead ofpublicity (Koekemoer, 1998: 10; Kotler and
Armstrong, 2001: 512).
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Definitions of the different promotional tools are provided below:
• Advertising is defined as "any paidform ofnonpersonal presentation and promotion
of ideas, goods, or services by an identified sponsor" (Kotler and Armstrong, 2001:
512).
• Personal selling is defmed as "the direct presentation ofa product to a prospective
customer by a representative ofan organisation selling if' (Etzel et aI, 1997: 440).
• Sales promotion is defmed as " any activity that offers incentives for a limited time
period to induce a desired response, such as a trial or purchase, from those who are
targeted' (Koekemoer, 1998: 10).
• Publicity is defmed as " any unpaidform ofnonpersonal presentation if ideas, goods,
or services" (McCarthy and Perrreault, 1991: 282).
• Public Relations is defined as " building good relations with the company's various
publics by obtaining favourable publicity, building up a good corporate image, and
handling or heading off unfavourable rumours, stories, and events" (Kotler and
Armstrong, 2001: 512).
• Sponsorship is defined as "the marketing communications activity whereby a
sponsor contractually provides financial and/or other support to an organisation or
individual in return for rights to use the sponsor's name (company, product, brand)
and logo in connection with a sponsored event or activity" (Koekemoer, 1998: 11).
• Direct marketing is defmed as "direct communication with carefully targeted
individual consumers to obtain an immediate response, and cultivate lasting customer
relationships" (Kotler and Armstrong, 2001: 512).
The marketer will therefore use varying amounts of each type ofpromotion according to what
the marketer perceives to be an ideal promotional mix. Essentially the marketers can choose
either a push or a pull promotion strategy (Kotler and Armstrong, 2001: 531). The
promotional mix targeting the middlemen is considered a push strategy and that which targets
the end users is called a pull strategy (Etzel et ai, 1997: 451). The relative extent of the
specific promotion tools will vary depending on the strategy selected. Generally, personal
selling and sales promotion such as contests for sales staff: predominates a push strategy
whilst heavy advertising and sales promotion, such as samples, predominates a pull strategy
(Etzel et ai, 1997: 451). The legislations controlling prescription drugs restrict the
pharmaceutical companies to operate predominantly a 'push' promotional strategy, I.e.
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promotion to healthcare professionals and not directly to the general public (Reast and
Carson, 2000: 397).
Other factors influencing the promotional mIX are: the target market, the nature of the
product, the stage in the product's life cycle, and the amount of money budgeted for the
promotion (Etzel et ai, 1997: 447). Thus, (i) the characteristics of the target market including
their readiness to buy, (ii) the level of value-adding features of the product, (iii) whether the
product is in the introductory/growth! maturity or decline stage of its life-cycle, (iv) the
amount of money available for promotion, will also have an effect on the extent to which each
element ofpromotion is utilised (Etzel et ai, 1997: 447).
2.3 COMMUNICATION
As discussed earlier, promotion represents the communication efforts of the marketer.
Effective communication will increase the chances of more successful promotion whilst
ineffective communication will result in the failure of promotion. How well a drug is
communicated to medical practitioners can mean a difference between its commercial success
and failure. An understanding of the communication process is important to ascertain the
determinants ofan effective communication (KotIer and Armstrong, 2001:518).
Most authors of marketing related books and articles describe the following as the five basic
components of the communication process: the sender/the source, the message, the
medium/channel, the receiver, and the feedback/receiver's response. The process consists of
the sender encoding the message using words, pictures, symbols that are then transmitted via
a chosen medium to the intended receiver who in turn decodes it based upon his/her prior
experience and personality trait (Koekemoer, 1998: 34; Kotler and Armstrong, 2001: 518;
Schiffinan and Kanuk, 1994: 284). They further classify the communication as interpersonal
or impersonal/mass communication.
Various factors can influence the effectiveness of the communication. The marketer cannot
control the target audience's response, however the marketer can exert influence on the
source, the message and the channel of intended communication (Koekemoer, 1998: 34).
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According to Koekemoer (1998: 45-49) the key variables influencing persuasIve
communication are:
1. Source related variables: the sender's credibility and attractiveness. The reputation,
expertise and knowledge of the sender are important determinants of the credibility.
The spokesperson such as the sales rep has a major influence on the credibility of the
message, e.g. the spokesperson that engenders confidence and creates an impression of
honesty and integrity is more successful in persuading the prospect. Most of the
pharmaceutical companies employ and train pharmaceutical sales representatives from
medically allied fields such as nursing, medical technology, and health sciences to
improve their credibility to the medical practitioners. "If the source is well respected
and highly thought of by the intended audience, the message is more likely to be
believed" (Schiffman and Kanuk, 1994: 288). The pharmaceutical companies
regularly use well-known specialists in various disciplines to give talks at seminars
and meetings sponsored by the company.
Attractiveness includes similarity, familiarity and likeability. According to Koekemoer
(1998), the communication is more likely to be persuasive when the receiver finds the
source attractive. The pharmaceutical companies use attractive well-groomed sales-
persons, especially ladies, to increase the persuasiveness of their message. The
repeated visits by the sales reps allow them to identify similarities and increase
familiarity with the medical practitioners, which can be used to increase the
effectiveness ofthe communication.
2. Message related variables: the type of appeal, message style, inclusions and
omi~sions and the order ofpresentation. Pharmaceutical promotion most commonly
uses repetition type of appeal as it increases the likelihood of the message being
remembered. The other types of appeal utilised by the pharmaceutical companies are
rational and emotional appeals. A Rational appeal emphasizes the efficacy and
quality of the medication whilst an emotional appeal is directed at the physicians' ego,
prestige and self-esteem. Kotler and Armstrong, (2001: 522) assert that emotional
appeals evoke either positive or negative emotions that influence the purchase.
Message style concerns how the message is presented and the skills of the presenter.
Inclusions and omissions deal with what is included and what the receiver is left to
deduce. Presenting the strongest argument at the beginning of the presentation results
12
in "first impression" effect whilst presenting it at the end results in "recency effect'
(Schiffman and Kanuk, 1994: 289). "First impression" effect is whereby the details
presented first are remembered best and the "recency effect" results in the details
presented last being the most persuasive.
3. Channel related variables: the receiver's direct experience with the product versus
the communication about it, communication modality and media effectiveness. The
receiver's own experience with the product is more persuasive than the promotion
communication. This was vindicated by Piu and Nel (1988), who found that the
physician's own experience with the medications had the strongest influence on their
prescribing when considering all influential variables. Promotion ofprescription drugs
is generally limited to print and personal selling due to governing regulations.
Pharmaceutical companies use personal selling as well as brochures and print
advertising (detail-aids) to transmit complex technical information.
The medical practitioners in Pietermaritzburg generally use one or more of the three
languages in their communications with the patients and the pharmaceutical
representatives, depending upon their ethnic background. The three commonest
languages used are English, isiZulu, and Afrikaans. According to Koekemoer (1998),
the sender's command and articulation of the language used by the receiver, has a
strong influence on the perception of the message by the receiver.
4. Receiver related variables: the degree ofreceiver participation, demographic factors
and personality characteristics. "If a receiver is highly involved the message gives
rise to a cognitive change leading to a change in attitude and behaviour" (Koekemoer,
1998: 49). The age and gender of the receiver are also believed to influence the extent
to which the receiver can be persuaded. The receivers with higher intelligence and
self-esteem are more critical in evaluating the message being received. Therefore, the
medical practitioners generally tend to be highly involved in the communication
process and are also more critical in their evaluation of the message.
Furthermore, communication effectiveness is also influenced by 'noise' (Schiffman and
Kanuk, 1994: 288). McCarthy and Perreault (1991: 286) define "noise" as any factor that
reduces the effectiveness of the communication. "The best way for a sender to overcome
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noise is simply to repeat the message several times" (Schiffinan and Kanuk, 1994: 288).
Many pharmaceutical companies thus use more than one sales representative and frequent
visits to deliver the same message to the target medial practitioners. The frequent visits
also help build a relationship with the medical practitioners.
2.4 CONSUMER BEHAVIOUR MODELS OF MAN
The consumer behaviour models of man offer insight as to why different consumers will
make differing decisions for the same situation. Schiffman and Kanuk (1994: 555-558)
discuss the following theoretical models of man: (1) economic man, (2) passive man, (3)
cognitive man, and (4) emotional man.
1. Economic man. The model of an economic man is based upon the economic
marketplace model of perfect competition whereby the consumer will make a
rational decision based upon the knowledge of all available alternatives. As
consumers live in an imperfect world, they do not 'maximise' their decisions
but aim for a 'satisfactory' decision. The model is thus regarded as unrealistic.
2. Passive man. This model assumes that the consumers will readily submit to
the promotional activities of the seller. This model is also regarded as
unrealistic since the consumers obtain information on and evaluate the
alternative products rather than blindly believe a single marketer's
promotional message.
3. Cognitive man. This model explains the decision-making behaviour of the
consumer as a problem-solving process. It focuses on the method by which the
consumers gather and assess information. The cognitive model also explains
the consumer as using a 'preference formation strategy' whereby the
consumers allow another person such as an expert retail salesperson to
establish product and/or brand preference for them The consumer is seen to
make an "adequate" decision based upon "sufficient" information on available
alternatives. This model is viewed to most realistic compared to other models.
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4. Emotional man. This model theorises that the consumers make certain
purchase decisions to satisfy certain emotional need(s) depending upon his/her
mood with less emphasis on evaluating the available alternatives. The
satisfaction of the emotional need does not necessarily constitute an irrational
decision. The consumers' mood is seen to have an important impact on their
decision-malcing.
The model that best fits the medical practitioner is 'cognitive man' as the medical practitioner
follows the problem-solving approach to arrive at a diagnosis, and then recommends
treatment from the available alternatives based upon his knowledge. It is difficult to assess
whether or not, and to what extent the emotional factors play a role in this decision.
2.5 BUYING DECISION
2.5.1 INDIVIDUAL BUYING-DECISION:
The buying process refers to the stages that the consumer goes through in reaching a decision
as to whether to continue/discontinue the use of a product or to initiate a trial use or not
(Schiffman and Kanuk, 1994: 541).
The buying-decision process model has been well described in the various marketing books
(Etzel et aI, 1997: 111; Koekemoer, 1998: 209; Kotler and Armstrong, 2001: 193; Solomon
and Stuart, 1997: 210). They describe the buying-decision process to comprise of the
following steps:
1. Need recognition. The consumer is moved to action by a need. The medical
practitioner is moved by his primary need to improve the patient's health.
2. Identification of alternatives. The consumer identifies and collects information on
alternate products and brands. The medical practitioner will identify the different
therapeutic alternatives.
3. Evaluation of the alternatives. The pros and cons of each alternative are then
evaluated.
4. Decision. One ofthe alternatives is selected.
5. Post- purchase behaviour. The consumer seeks reassurance that the correct choice was
made.
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The level of involvement of the consumer has a significant influence on the above model with
low-involvement situations including fewer stages whilst high-involvement situations
including all five stages of decision-making process (Etzel et aI, 1997: 129). The decision-
making by a medical practitioner is a high-involvement situation as the therapeutic option
(type of therapy) chosen is viewed as providing significant benefit(s) and or potential risk(s)
from adverse effects to the patient.
Kotler and Armstrong (2001: 200) define a new product as "a good, service, or a idea that is
perceived by some potential customer as new". Lidstone and Collier (1987: 93) describe the
buying process for a product to consist ofthe following stages: Unawareness7 Awareness7
Interest7 Evaluation7 Trial7 Usage7 Repeated usage. This is based on the 'Hierarchy of
Effects' model, which describes the chain of events that have to happen before a prescription
is made (Vaughn, 1980: 27 - 33). The stages, as described by Lidstone and Collier (1987: 93-
95) are:
• Unawareness to Awareness: The doctor moves from a stage of ignorance about a
product to becoming familiar with the product. The pharmaceutical representative
informs the doctor about the existence of the product and creates a therapeutic
association between the product and the ailment it is aimed at.
Generally, the majority of doctors are aware of the most new pharmaceutical products
available in the market. The key task of the promotion at this stage is to achieve 'top
of mind' awareness and not just passive awareness, i.e. promoted to the extent
whereby the specific drug being promoted, is considered foremost ahead of the
competitors' drugs (Corstjens, 1991: 221).
• Awareness to Interest: The doctor seeks more information about the
medication/product during this stage. The promotional objectives are to get the
prescriber's attention, create interest (motivation), and provide information. The sales
rep arouses the doctor's interest through the Unique Selling Points (USPs) of the
medication and provides more information.
The doctor considers very few therapeutic alternatives following diagnosing a specific
illness in the patient. In order to become part of this narrow selection of therapeutic
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alternatives, the positioning of the drug is very important (Corstjens, 1991: 222). The
USPs are thus critical for this stage.
• Interest to Evaluation: The doctor will consider the information received from the
sales rep and under the influence of personal and non-personal/external factors the
doctor will evaluate whether the drug meets patient's needs or not.
• Evaluation to trial: The doctor has decided to try the product/drug when the
opportunity arises. The sales rep has to identify, all clear indications for the use ofthe
drug and encourage usage when these opportunities occur (Lidstone and Collier, 1987:
94). The sales rep generally leaves a sample of the drug with the doctor. The
availability of the drug encourages trial.
• Trial to Usage: The sample together with the evidence from the clinical trials -
communicated to the doctors via sales reps, medical journals, and medical conferences
- are the key marketing instruments to induce prescriber to try the product (Corstjens,
1991: 222). The doctor will prescribe or dispense the sample drug for a patient. The
sales rep accentuates the USPs in their presentation and offer anecdotal evidence of
other doctors experiencing success with the drug (Lidstone and Collier, 1987: 95).
• Usage to Repeated Usage: The objective is to generate repeat prescriptions from the
doctor, i.e. to make the drug a habitual choice for the doctor when faced with the same
indications. If the initial trial-use is successful in meeting the doctor's need(s), he/she
will prescribe the drug for another patient. The sales rep will continue to stress the
USPs at each visit and strengthen the relationship with the doctor.
The prescribing doctors are sensitive to further information to reinforce their beliefs
about the product benefits and the satisfied doctors can further contribute to the
success ofthe drug via the 'word ofmouth' to their colleagues (Corstjens, 1991: 223).
The pharmaceutical representative thus attempts to guide the medical practitioner through all
stages ofthe promotional process, viz. from unawareness ofthe product through repeated use.
The activities ofpharmaceutical representatives will be discussed in detail in chapter 4.
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2.5.2 BUSINESS BUYING-DECISION:
The medical practitioners can also be viewed as "businesses" since the patients are the final
consumers of the medications (products) and the prescribing doctors are the "middle-men".
The patients thus derive the demand for the medication. This demand is relatively price
inelastic as the welfare of the patients is the most important consideration instead of the price
of the medication. The patients do not automatically use more of the medication because it is
cheaper. However, the prescribing/dispensing doctor will take the affordability of the patient
or the rules of the healthcare funders into consideration when selecting the medication for the
patient.
In a normal business there will be many participants in the buying-decision making process.
These participants include: the users of the product, the influencers who often provide
information for the evaluation, the deciders who approve the final purchase, the actual buyers
of the product, and the gatekeepers who control the access of information and/or the sales
person to the others (Kotler and Armstrong, 2001:219). In the case of the medical
practitioners, they have unique and often multiple roles in the buying-decision of
pharmaceutical products (Piu and Nel, 1988).
The various roles, ofa medical practitioner, identified by Piu and Nel (1988) are: the role of a
user (e.g. when purchasing syringes and needles for the process of administering injections),
the role of an influencer (e.g. when advising the patient on over-the-counter /non-prescription
medication), the role ofa buyer (e.g. when purchasing the medication for injection purposes),
the role of a decider (e.g. when deciding which medication to prescribe or dispense), and the
role of a gatekeeper (e.g. access to and control of important information). The understanding
of these various roles played by the medical practitioner is of paramount importance to the
marketers ofprescription drugs.
2.6 PERSONAL SELLING
Koekemoer (1998: 196) defines personal selling as "a person-to-person process by which the
seller learns about the prospective buyer's wants and seeks to satisfy them by offering suitable
goods or services and making a sale". Similarly, Solomon and Stuart (1997: 680) define it as
the component of the promotional mix that involves a direct contact between a representative
of the company and the customer for the purposes of persuading the customer to make a
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purchase. Therefore, it can be deduced from the above stated definitions that persuasive
communication is the essence ofpersonal selling.
Personal selling is divided into three tasks: order getting, order taking, and supporting
(McCarthy and Perreault, 1991: 304). Order- getters use sale-presentations to sell a product
or service. Order getters' tasks are to find new customers, provide information on the
company's products to the existing and new customers, and persuade the customers of the
benefits of using their products (Solomon and Stuart, 1997: 688). Pharmaceutical
representatives use detail-aids (sale-presentations) to persuade the medical practitioners that
their product (drug and/or service) can better satisfy the practitioners' needs than their
competitors can. The order getters also help establish and build relationships with the
customers. Order-takers generally complete the sales transaction. The dispensing doctor may
place an order for prescription drugs with the pharmaceutical representative, who in turn puts
the order through the medical wholesalers. This method of ordering results in a cost saving to
the doctor through the varying discounts and bonus deals offered only via the representatives.
Supporting salespersons provide assistance to the sales-force but are not involved in the actual
sale. They may provide specialised service(s) and information. The supporting salespersons
can be the missionary salespersons, the technical specialists, or the sales team (Solomon and
Stuart, 1997: 689).
Missionary salespersons promote the company and stimulate an indirect demand for their
products. "In the pharmaceutical industry, missionary salespeople known as detailers keep
physicians up to date on the latest medicines. By answering questions and providing
informational pamphlets and samples, missionary salespeople give valuable assistance to
physicians and influence what drugs they will prescribe" (Solomon and Stuart, 1997: 689).
The technical specialists, usually scientists and engineers provide technical knowledge of the
company's products to assist the order-getters (McCarthy and Perreault, 1991: 309). The sales
team consist of the salespersons ofdiffering expertise working together to promote the drug to
a specific customer. A variation of this, concerning the pharmaceutical promotion, is the use
of more than one sales rep by the pharmaceutical companies to emphasize different benefits
of a particular prescription drug. The product manager and the sales manager supervise the
team effort.
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Koekemoer (1998: 196-197) describe the following advantages and disadvantages ofpersonal
selling over other forms ofpromotion:
ADVANTAGES:
1. Obligation. The prospect/customer is likely to feel obliged to pay attention to the
message being conveyed in the face-to-face encounter with the salesperson.
2. Tailor message. The salesperson can tailor the message according to the needs of the
customer. The pharmaceutical representative can decide on whether to concentrate on
the effectiveness, the price, or the convenience of the prescription drug depending
upon the doctor that is being detailed.
3. Prompt feedback. Based on the verbal and non-verbal cues of the doctor, the sales
reps can immediately adjust their presentation.
4. Complex information. The sales reps are able to communicate to the doctors a great
deal of complex information not feasible via other means such as advertising III
medical journals.
5. Demonstrations. The use of detail-aids and product samples allow the sales reps to
give emphasis to the message.
6. Customer education. The sales reps educate and remind the doctors ofthe benefits and
adverse effects ofthe prescription drug.
7. Closing the sale. At the end of the detailing process, the sales reps attempt to obtain
commitment from the doctor to use the specific drug being promoted when the
opportunity arises.
DISADVANTAGES:
1. Expensive. Because the sales reps can only interact with a small number ofdoctors per
day, a relatively large sales-force is required for the promotional effort. This is
comparatively far more costly than other promotional modalities.
Personal selling by means of a higWy trained sales force is one of the most important
promotional tools of the pharmaceutical companies. "Given the nature of pharmaceutical
products, personal communication with prescribers is a key success factor in the industry"
(Corstjens, 1991: 218).
The following chapter 3 will look at the pharmaceutical industry and the marketplace to
provide information on the enormity and the importance ofthe pharmaceutical industry.
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CHAPTER 3: THE PHARMACEUTICAL INDUSTRY AND THE
MARKETPLACE
This chapter describes the pharmaceutical industry and the marketplace in South Africa and
its relationship to the global pharmaceutical industry.
3.1 THE PHARMACEUTICAL INDUSTRY
The current South African pharmaceutical industry is valued at above RIO billion, with more
than 80% of the revenues generated by the private sector (NAPM-Fast Facts, paragraph 1).
The South African pharmaceutical industry's gross output was R6.23 billion in 2001 (PMA,
2003: 9). Between 1994 and 2001, the consumption of medicinal and pharmaceutical
preparations rose by 41% in real terms when compared to semi-durable goods at 34% and
non-durable goods at 14% (pMA, 2003: 12). The SA pharmaceutical industry is fairly well
developed, catering for 60% of local demand and exporting around 20% of its output
(NAPM-Overview, paragraph 1).
According to the South African Statistics 2001 cited in PMA Draft Annual Report (2003: 10),
the South African pharmaceutical industry, for the period 1992 - 1999, showed a significant
upward trend in all industrial indicators considered, viz. production, exports, imports,
employment, salaries and wages, and labour productivity, when compared to the chemical
sector in general. Between 1994 and 2001 the South African pharmaceutical exports rose by
342% and the imports rose by 319% (pMA, 2003: 13). South Africa exports predominantly to
African countries (mainly Zimbabwe) and to a lesser extent to Australasia, Europe and North
America. Importation is mainly from Germany, followed by United Kingdom, France and
United States (NAPM-Overview, paragraph 7).
The leading foreign trade partners of South Africa for pharmaceuticals in 1999 and 2000 are
depicted in Figure 1. It also shows that the largest importation of pharmaceuticals was from
Germany (19.1%), United Kingdom (16.1%), France (12.0%), and USA (9.3%). This is
probably due to the fact that the leading pharmaceutical companies are headquartered in one
of these countries and is responsible for the majority of research and development of
pharmaceuticals (pMA, 2003: 13).
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TOP 10 TRADING PARTNERS

















Figure: 1. Source: Department of trade and Industry 2002.
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Figure: 2. Source: Department of Trade and Industry 2002.
Figure 2 shows that for the period 1999-2000,38% of South African pharmaceutical exports
were to Zimbabwe with the majority of the top 10 export destinations of South African
pharmaceutical products being other African countries.
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Globally the pharmaceutical industry is characterised by incredibly expensive research and
development costs and extremely long lead-times from the product development phase to the
approval of the drug for prescription to patients. In 1988, the American pharmaceutical
companies spent more than $5 billion on research and development (Corstjens, 1991: 7). The
lead-time can be up to twelve years (Bartlett, 1988-as cited in Gillingham, 1995: 30;
Corstjens, 1991: 10). According to Simons (2003: 28) "the cost of ushering in a single drug
nearly quintupled to $800 million in the past decade." To develop the pharmaceutical drug
Cialis®, it cost the pharmaceutical company Lilly, approximately $1-billion and took 10
years (Moodie, 2003:1). It is estimated that only one out of every five to ten thousand
compounds that are examined for medicinal use, actually reach the market (Corstjens, 1991:
12). The commercial success of the pharmaceutical company depends upon developing
innovative drugs and improving the existing medical drugs to maintain or increase their
market share.
3.1.1 THE EXTERNAL ENVIRONMENT
The external environments, similarly to other industries, also influence the pharmaceutical
industry. The external factors having a particularly strong influence on the pharmaceutical
companies are the governmental, legal, and the technological factors. In many countries the
government tends to be the main customer of the pharmaceutical drugs. Changes in the
legislations influencing the various facets of the healthcare delivery of the country and
regulations controlling the registration of drugs, profits, pricing and promotional methods of
the pharmaceutical companies have a tremendous impact on the structure, size and the
profitability ofthe pharmaceutical industry. The innovative/technological breakthrough by the
competitors also has a major impact on the company and the industry. The competitiveness
and the survival of the research-based multi-national pharmaceutical companies are closely
tied to their innovative capacity (Kalake, 1999: 10).
The social factors such as income per capita, education/literacy rate and the level of
infrastructure of a country have an important influence on the disease/illness profile of the
country and indirectly the pharmaceutical industry. The age distribution of the population,
life-styles, and attitudes of the people including the medical practitioners will also influence
the demand for the various pharmaceutical products.
23
In South Africa the managed healthcare (medical aid schemes) exerts a very strong influence
on the pharmaceutical industry via their rules. The rules of the medical schemes not only
influence but also restrict the medical practitioners, the pharmacists, and the patients as to
which pharmaceuticals can be prescribed or dispensed. In instances where the cost of the
medication(s) is to be reimbursed by the medical schemes, the prescribing doctor is restricted
to prescribing medications that are listed by the medical schemes on their formulary/essential
drug list (EDL). A formulary/EDL is a continuously revised list of medications that have been
approved by the managed healthcare organisations for prescription by the medical
practitioners.
If the medical practitioner chooses to ignore the relevant EDL, then the pharmacist is forced
to substitute the prescribed drug with the one that will be reimbursed by the medical schemes,
unless the patient chooses to pay for the prescribed drug with cash. Some medical scheme
administrators such as 'Medscheme ' are offering incentives to the medical practitioners to
alter their prescribing to include more generic drugs. The medical practitioner is required to
sign a contract with the said administrator that restricts himlher to the use of drugs on the
scheme's formulary and allows for therapeutic substitution of ethical pharmaceuticals with
generics. The compliance with the contract results in a slightly higher reimbursement for
consultation for the contracted doctor than the non-contracted doctor. In this situation, the
promotion of prescription drugs that are not on the EDL will have minimal influence on the
prescribing behaviour ofthe contracted medical practitioners.
3.1.2 THE INTERNAL ENVIRONMENT
"As a consequence ofthe essentially uncontrollable nature ofboth the external
environment and the patient population, the activities of the pharmaceutical
manufacturer towards changing his internal environment tends to be reactive in
nature, paralleling the external, uncontrollable changes" (Smith, 1975: 11).
Therefore, each pharmaceutical company will develop its marketing mix of product, place,
price, and promotion according to what it perceive to be the optimal response in light of the
influencing external factors.
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3.2 THE MARKETPLACE FOR PHARMACEUTICAL DRUGS:
The pharmaceutical market broadly covers a range of markets. It can be classified according
to: ethical versus (vs.) generic drugs, prescription vs. non-prescription drugs, public vs.
private sector, distribution channel (dispensing doctors! retail pharmacies! wholesalers/
private hospital/ public hospital), and therapeutic product classes (e.g. cardiovascular/
respiratory/ psychotropic/ analgesics) (Corstjens, 1991: 20).
As mentioned previously, the pharmaceutical market differs from other consumer goods
markets as a result of the nature of the product itself and the various regulations and
restrictions placed on its marketing. The main role players are the pharmaceutical companies,
the medical practitioners, the pharmacists, the patients, managed healthcare organisations
(medical aid schemes), and the government. The number ofprescription drugs and their prices
vary from country to country depending upon their success in registering with the relevant
bodies and the country's regulations.
The social and cultural differences ofthe country influence the demand for the pharmaceutical
drugs. Mapes (1980: 9) and Reekie and Weber (1979: 28) identified five key indicators that
determine the rate and character of the demand for pharmaceuticals in a country:
1. Demography: the size, age distribution and growth ofthe population.
2. Morbidity patterns: the epidemiology of the diseases and their susceptibility to the
available pharmaceuticals.
3. Health care facilities: The availability and the adequacy of the health care
infrastructure in the country.
4. Health care expectations: personal and group health care norms and expectations of
the population determine the degree of impetus given to the government to provide
comprehensive healthcare. As the knowledge of the population with respect to
diseases and medications increases, so too do their expectations of the treatment
received from the doctor increase.
5. Propensity to purchase: the availability of resources (governmental/insurance/private)
to purchase healthcare products.
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WORLD MARKET FOR PHARMACEUTICALS AT EX-FACTORY PRICES
(USD MILLION)



















Table 1. Source: IMS Health 1996 - 2002, cited in PMA (2003).
The world market for pharmaceutical at ex-factory prices was $364 200million in 2001,
whilst the South African share of this was only 0.35% (Table 1). From 1997 to 2001, the
South African market share of the world market for pharmaceuticals was less than 0.5%
(Table 1). South Africa's medicine costs as a percentage of the total health care bill amounted
to 20.0% in 2000 (PMA, 2003: 8).
Generally, the market is defmed corporately. The twenty largest multi-national
pharmaceutical companies (Table 2) comprise of: eight American, ten European, and two
Japanese. It also shows that there is no observable dominant or monopolistic behaviour in the
pharmaceutical industry.
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The twenty largest pharmaceutical companies in the world in 2001 were:
TOP 20 LEADING PHARMACEUTICAL COMPANIES, 2001
,







Johnson & Johnson 4.4 5





American Home Products 3.1 11










Table 2. Source: IMS Health 2002, cited in PMA (2003)
Pfizer is the leading pharmaceutical manufacturer ofprescription medicines with over 11% of
the global market in 2002 (Ryan, 2003:15). Pfizer's global pharmaceutical revenue was $45-
billion in 2002, ofwhich, the South African operation represented 0.3% (RI. I-billion) (Ryan,
2003:15). The critical success factor for Pfizer is its armoury often brands, each worth $1-
billion, and only one ofthese leading ten brands' patent expires in 2005 (Ryan, 2003: 15).
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The majority of multi-national pharmaceutical companies are operational in South Africa
(SA). The multi-nationals operate in SA through establishing local subsidiaries or by having a
licensing agreement with local companies. This is induced by the incapacity of the limited
domestic markets alone to support, through sales, the high research and development cost of
medicines (Reekie, 1975, as cited in Kalake, 1999: 10).
Most of the pharmaceutical companies operate both in the private and public health sectors in
South Africa. As discussed in chapter 1, there is a vast difference in the cost of the
pharmaceutical drugs to the public and private sectors. The pharmaceutical companies derive
majority oftheir profits from the private sector.
SA MARKET SHARES BY NATIONALITY OF CORPORATE OWNERSHIP
(Values - Percent)
: _M_A_R_K_ET I
RSA 27.74 RSA 24.40
USA 27.69 USA 17.70
UK 10.45 SWITZERLAND 13.90
SWITZERLAND 10.35 GERMANY 13.70
GERMANY 10.03 FRANCE 13.20
FRANCE 9.07 UK 7.00
DENMARK 2.08 DENMARK. 6.40
BELGIUM 0.93 INDIA 2.90
INDIA 1.26 NETHERLANDS 0.20
OTHER 0.40 OTHER 0.60
r-------------------------------
i Total 100.0 Total 100.0,
I
~ffirms in 2002 220 ~umber offirms in 2002 86-----.
Table 3. Source: !MS health 2002, cited in PMA (2003)
There were 220 firms operating in the private sector and 86 firms operating in the public
sector (Table 3). From the above table, it can also be seen that the South African
pharmaceutical companies have roughly a quarter of the market share in both the private and
public sectors with the remaining shared by the multi-national companies.
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South Africa's spending on pharmaceuticals as a percentage of total healthcare spending for
the last decade, as compared to most first world countries, is shown in figure 3. Over the last
decade, this increased from 17.7% in 1990 to 20.0% in 2000. From the comparative graph, it
can be seen that only Germany, of all countries considered, managed to decrease its
pharmaceutical spending as a percentage of its total healthcare spending (from 14.3% to
13.6%).











0.0 5.0 10.0 15.0 20.0 25.0
Figure. 3 Source: OECD Health Data 2002; Registrars of Medical Schemes Annual Reports
1990- 2001; IMS Health 2002, cited in PMA (2003).
Notes: (I) OECD figures represent gross expenditures (including all distribution costs).
(2) Figures are estimated by weighting the actual medical schemes spending (including
private hospitals) and the estimated State spending by market size. The assumptions
were made that private hospitals and dispensing doctors dispensed with zero mark-up
and that dispensing, bulk breaking and other State pharmacy activities came to ]5% of
State expenditure at factory gate level. In calculating the figure for ]990, it was assumed
that reimbursement of medicines dispensed through private hospitals came to 4.5% (as
observed for the period] 997-2000) ofall benefits paid by medical schemes/insurers.
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TOTAL MARKET ESTIMATES AT MANUFACTURER SELLING LEVEL
2000 9703.69 4457.83 226.57 2267 1408.62 1343.67
% 100.00 45.94 2.33 23.37 14.52 13.85
2001 10957.26 5126.5 260.55 2448.62 1549.5 1572.09
% 100.00 46.79 2.38 22.34 14.14 14.35
2002 12328.77 5890 291.82 2618.90 1 704.43 1823.62
% 100.00 47.77 2.37 21.24 13.82 14.79
Table 4: Source: IMS Health 2002, cited in PMA (2003).
The estimated sales of pharmaceutical products at manufacturer selling level for year 2000 to
2002, as divided through various channels, are shown in Table 4. From these estimates, it can
be seen that the retail pharmacies were responsible for approximately 50% of the total sale
with ethical pharmaceuticals having an approximately 94% share of this. The public sector
accounted for about 25%, the dispensing doctors about 14%, and the private hospitals about
15% ofthe total industry sales of the pharmaceuticals at the manufacturer level.
ETHICAL AND GENERIC PHARMACEUTICALS AS SHARES OF THE TOTAL
PRESCRIPTION MARKET
79 21
54 46 81 19
49 51 79 21
55 45 65 35
Table 5: Source: IMS Health 2001·2003, cited in PMA (2003)
Note: The prescription market covers medicines issued on prescription. It comprises of patented products (i.e.
referred to as ethical in the table) and multi-source medicines (referred to as generic in the table). Multi.
source medicines may be marketed under their generic names or as branded generics.
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The share ofgenerics has gradually increased at the expense ofethical pharmaceuticals (Table
5). This is because of forced change in prescribing behaviour of the medical practitioners via
the EDLs of state institutions in the public sector and the managed healthcare organisations in
the case ofthe private sector.
Currently, the pharmaceutical industry is facing challenging times with many companies
consolidating and adapting to the global economic slowdown and increasing difficulty in
achieving product differentiation (Ryan, 2003: 15). In South Africa, the industry faces its
toughest challenge from the new legislation (Act 59 of2003) that was promulgated on May 2,
2003. The relevant sections of this legislation will be discussed in chapter 5.
Having discussed the magnitude and the importance of the pharmaceutical industry and the
marketplace, the following chapter 4 will specifically focus on the promotion of
pharmaceutical drugs.
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CHAPTER 4: PROMOTION OF PHARMACEUTICAL DRUGS
"The key feature influencing the demand for any individual product is the extent
to which the product gains doctor acceptance. This will depend on a large number
offactors including the product's therapeutic value (i.e. product quality), the state
ofart in medicine, and sales promotion undertaken by the manufacturer"
(Slatter, 1977: 23).
This chapter looks at the promotion of pharmaceutical drugs and the most common
promotional tools used by the pharmaceutical companies. The process of prescribing of
pharmaceutical drugs by the medical practitioners and the factors influencing this decision
process are also discussed. Greater focus is given to the effects of the pharmaceutical
representative's promotional activity on the prescribing behaviour of the general (family)
medical practitioners.
The various legislations, regulations, pharmaceutical and advertising industries' own rules
and guidelines, World Health Organisation (WHO) guidelines for the ethical promotion of
pharmaceutical drugs, and other ethical issues will be discussed in chapter 5.
The fundamental marketing concepts and principles are also applicable to the pharmaceutical
industry. The marketing of the over-the-counter (OTC) drugs is similar to the marketing of
consumer goods and the marketing of prescription medication shares some common
characteristics with the industrial goods and consumer good (Corstjens, 1991: 10). The
similarity with consumer goods is due to the fact that the pharmaceutical drugs are often
aimed at a large population of consumers and the multiple roles played by the doctor, as a
business-buying centre, is similar to industrial goods (Corstjens, 1991: 10). The physician is
like an industrial purchasing agent, i.e. the decision on drug therapy is not what to buy, but
instead, what to prescribe (Smith, 1975: 63). For the purposes of this study, the focus will be
on the promotion rather than on the entire marketing ofpharmaceutical drugs.
World Health Organisation's Ethical Criteria for Medicinal Drug Promotion (1988:6) defines
pharmaceutical promotion as:
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"All informational and persuasive activities by manufacturers and
distributors, the effect of which is to induce the prescription, supply,
purchase and/or use ofmedicinal drugs. "
The pharmaceutical promotion of prescription drugs is designed to influence and create a
favourable attitude towards a particular drug. The most important objective being to bring
about a behavioural change in the doctor to prescribe the particular drug being promoted.
Successful promotion, defmed as brand preference or insistence, is as a result of an
educational or learning experience that brings about a change in prescribing habit
(Koekemoer, 1987: 483).
PHARMACEUTICAL PROMOTIONAL EXPENDITURE
Pharmaceutical promotional expenditure in South Africa, as a percentage of total
pharmaceutical sales for the period 1976 - 1980, was 22% (Koekemoer, 1987: 467).
According to Corstjens (1991: 224), the promotional expenditure for a typically large
pharmaceutical company can be up to 15% to 20% of sales. On average, pharmaceutical
companies spend 20% or more oftheir total sales on promotion (Mansfield, 1997:590).
Before the discussion on the different promotional tools used in pharmaceutical promotion, a
briefoverview ofthe prescribing process itself and the motivating factors is presented.
4.1 PRESCRIBING PROCESS
" Allpeople are the same. It's only their habits that are different"
Confucius.
To paraphrase Confucius, all doctors are the same; it's only their prescribing habits that are
different.
Mapes (1980: 9) discusses the following models ofpharmaceutical drug prescribing process:
1. The Medical model: This is the model most commonly held by the medically trained
people. According to such a model, the ill patient consults the doctor, who prescribes
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medication(s) following questioning, examination, and making the diagnosis of the
illness. The patient then takes the medication(s) in the prescribed manner.
2. The Perceptual model: This model is based upon perception of the doctor, by the
patient, as an expert who prescribes in response to an informed diagnosis.
Mapes (1980) argues that there are other diverse factors, which are not related to the models
described above that influence the prescribing process. These are, in addition to the medical
criteria, factors such as promotional practices of the pharmaceutical companies, colleagues,
personality of the prescribing doctor, and the pressures exerted by the patients and society that
influence the prescribing behaviour. " The process ofprescribing is very much influenced by
social systems and structure in which these operates" (Mapes, 1980: 9). That is, the demand
pattern for prescription drugs will vary in different countries depending upon the social and
cultural differences, and the type ofhealthcare infrastructures.
Prescribing of medication(s) usually ends the consultation process. When a patient consults a
doctor, he/she expects the doctor to do something about his/her problem (in most cases this
involves the prescribing of medication). The patients therefore expect some tangible benefits
from the doctor's service. At the end of the consultation, the doctor is required to fulfil the
patient's expectations of taking the necessary steps to alleviate the patient's symptoms.
Generally, the public is becoming more knowledgeable about pharmaceutical drugs and
diseases, which in turn have increased their expectations of the treatment by their doctors
(Reekie and Weber, 1979: 42).
Commonly the patient starts the consultation process by communicating the troublesome
symptoms. The doctor typically uses a problem solving approach to arrive at a diagnosis. The
doctor than decides on the appropriate therapeutic alternatives. The doctor decides whether to
prescribe or not. If the choice is yes, then a further decision is made concerning the selection
of the pharmaceutical drug. The factors considered with respect to the selection of the
pharmaceutical drug are: the efficacy of the drug, safety ofthe drug (therapeutic risk), cost of
the drug versus (vs.) the affordability of the patient, ethical vs. generic drug, and the doctor's
personal experience with the considered alternatives. The various personal factors such as the
mental state of the doctor at that time and the marketing of the pharmaceutical drug further
influence this typical selection process.
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The efficacy, safety, and cost of the available alternative pharmaceutical drugs will depend
upon the doctor's personal knowledge about them. The doctor's sources of pharmaceutical
information will be discussed later. The effectiveness and the safety of the selected drug are
also reliant upon the adherence of the patient to take the medication in the prescribed manner.
The practitioner is concerned about his choice of therapeutic drug, as failure of therapy to
alleviate the patient's symptoms may result in the patient's loss of confidence in the doctor's
capabilities and may well hurt the doctor's reputation. As a consequence of failure, the doctor
may not only lose that particular patient from the private practice, but may also potentially
lose other patients through the 'word-of mouth' from that patient.
"The reasons for selecting a specific drug or a specific brand are even more complex and less
understood" (Mapes, 1980: 21). The medical practitioners' decisions are often the result ofa
mixture ofrational and emotional motivations (Smith, 1975: 66).
The doctor's motivating factors for prescribing are generally a mixture ofmodels ofeconomic
man, cognitive man and emotional man discussed in chapter 2, i.e. in terms of rational,
problem-solving approach and emotional factors. The problem solving approach consists of
history taking, examination, investigation (where necessary), diagnosis and choice of therapy
(including whether to prescribe or not to prescribe). This is same as the Medical model
discussed above. This is influenced by the doctor's own emotions and the emotional appeals
of pharmaceutical promotion (Mapes, 1980: 23). The behaviour of the decision-maker can
also be classified into rational and emotional (Smith, 1975: 63). The rational decision-maker
evaluates all alternatives with respect to his! her ability to fulfil the therapeutic needs, whilst
an emotional decision-maker is swayed by the product attributes or promotion of the product
that have nothing to do with the actual need-satisfying property of the product (Smith, 1975:
63). Corstjens' (1991: 220) views support Mapes and Smith in stating, "for some product
categories the prescription decision is based upon rational arguments, whereas for some other
product categories less rational approaches (e.g. company and product loyalty, impact of the
product on the patient's self image, habit) are prevalent." Thus, although the doctor's
decision-making is largely rational (based on objective assessment of presenting symptoms
and signs), there are factors that let a measure ofemotion to influence his/her decision.
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4.2 SOURCES OF INFORMATION:
"It is naive to think that all doctors will be continually up to date from other
sources of information; most will admit to a pile of unread journals. It is
also naive to think that good drugs will automatically sell themselves; they
need promoting" Stephen (1999).
The medical practitioners require both objective information on the particular drug itself and
comparative information on the alternatives in order to make the fmal prescribing decision.
However in reality it is difficult, if not nearly impossible, for the doctors to have
comprehensive information on all available drugs.
In South Africa, the medical practitioners have recourse to textbooks such as South African
Medical Formulary and MIMS for product specific information. These textbooks contain
information on the indications, pharmacokinetics, dosage and direction for use, adverse
effects, warnings, special precautions, contraindications, and drug interactions of the various
drugs and are broadly classified under therapeutic classes. These books however are updated
annually and do not provide comparative information.
It is the pharmaceutical companies, and not the doctors, that have complete information on
their drugs. Thus, the educational activities carried out by the pharmaceutical representatives,
as a component of promotional practices of the pharmaceutical companies, are major sources
of information of various drugs for the medical practitioners. This is especially important in
the case of the new drugs. Initially, only the manufacturing companies have clinical studies on
the efficacy, safety, and adverse effects and so forth concerning the new drug. The
pharmaceutical representatives play a critical role in conveying these finding to the medical
practitioners. Traditionally, the pharmaceutical reps are viewed as the most important source
of information about a new drug (MacLean, 2001; Reekie and Weber, 1979: 120).
The medical practitioners possess the initial pharmaceutical information from their medical
training, which is thereafter supplemented by other sources. The supplementary sources of
drug information are textbooks, medical journals, lectures and medical meetings sponsored by
the drug companies, educational updates carried out by professional institutions such as
medical schools, specialists, and the pharmaceutical representatives.
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Wilson et a/ (1963) looked at "Influence of different sources of therapeutic information on
prescribing by general practitioners." Their study revealed the following sources of drug
information: 32 percent of the information from the doctors' medical training; 28 percent of
the information from the pharmaceutical companies; and the remaining 40 percent from the
miscellaneous sources of textbooks, journals and specialists. The study also showed that the
more recently qualified general practitioners were less dependent upon the pharmaceutical
companies for their information. lones, et a/ (2001) found that there was a difference in the
reasons for introducing new drugs in the disease management armamentarium by the general
practitioners and the specialists. The specialist relied more on the scientific evidence and the
critical appraisal of the literature, whilst the general practitioners were more influenced by the
pharmaceutical promotion and the specialists.
4.3 FACTORS INFLUENCING THE CHOICE OF PRESCRIPTION DRUG
"When a young physician starts, he knows twenty drugs for one disease. An
experiencedphysician knows one drug for twenty diseases" Unknown.
The following are some of the factors that may influence the medical practitioner's choice of
prescription drug. These factors have been identified based upon the researcher's personal
experience as a general practitioner and from the researcher's discussions with the colleagues.
The discussion and explanations ofeach factor are also based upon the latter. The factors are:
• The efficacy of the drug,
• The safety profile ofthe drug (i.e. potential adverse effects versus benefit),
• The ease of administration (i.e. directions for use and its appeal to both prescribing
doctor and the patient,
• The price ofthe drug and the affordability of the patient,
• Ethical versus generic drug,
• Presence/absence of restrictions from a third party such as medical aid scheme
(managed health care organisations),
• Whether or not the patient demands a particular brand of drug based on the patient's
knowledge and previous experience with the drug,
• The prescriber's knowledge and previous experience with the drug,
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• The prescriber's personal judgment of the manufacturer and the degree of faith in the
manufacturer,
• Whether the drug is recommended by the specialist consultant for management of
similar conditions,
• Discussions with colleagues, and
• Promotional practices of the pharmaceutical companies.
The factors relating to the efficacy, safety, and dosage convenience of the drug are the most
important considerations. The prescribing doctor is more likely to choose the drug whose
efficacy and safety profile is superior to the alternatives under deliberation. The doctor is also
more likely to select the dosage regime that will result in greater compliance with the
directions for use, rather than risk non-compliance.
The price of the drug is also an important consideration in the choice of prescription drug.
The cost of the prescription drug and the patient's affordability are self-explanatory from the
patient's viewpoint. The issues of ethical versus generic drugs, the inclusion or exclusion of
the prescription drugs from the managed health care organisation's EDL, and the new
legislation are also closely linked to the price factor. Generic drugs are cheaper than the
ethical drugs as the company manufacturing the generic drug did not incur any research and
development costs. The managed health care organisations are increasingly insisting on only
paying for generic drugs, where available. If the patient insists on the ethical drug when a
cheaper generic is available, then he/she is expected to pay the difference in cost not covered
by the managed health care organisation. The mandatory generic substitution stipulated by the
new legislation will be discussed in chapter 5.
The patients may also view their medical practitioners more favourably, if they display added
awareness and empathy in considering the patient's fmancial situation and the rules of their
managed healthcare organisations when choosing among prescription drugs of similar
efficacy for their ailments (Gonul et aI, 2001: 80). The patient can interpret this consideration
of their price-sensitivity as a tangible indicator of the care rendered by the doctor and can
further enhance the doctor-patient relationship (Gonul et aI, 2001: 80).
The advances in telecommunication and increased coverage of health related matters in
general mass media have raised the awareness and the knowledge of the members of the
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public with respect to diseases and their therapy. Kotler and Clarke (1987) comment that the
fundamental doctor-patient relationship has changed with consumerism entering the health
care field. As a result, many patients today request a specific prescription drug instead of
allowing the doctor to choose from the available alternatives. The medical practitioner is more
likely to choose a particular drug when he/she has greater knowledge ofthe drug compared to
the alternatives and has experienced better responses to the drug in patients when compared to
the alternatives. The drug chosen by the specialist consultant (opinion leader), to whom the
patient was referred by the general practitioner, is more likely to be chosen by the general
practitioner when encountering a similar illness in other patients.
A study by Bauer (1964), cited in Mapes (1980: 21), showed that there is a strong relationship
between the doctor's preference for a company and the preference for a drug manufactured by
that company and that such a preference may even predispose the doctor to an early trial of a
new drug introduced by the said company. The study also found that as the therapeutic risk of
adverse events increased, the doctors preferred professional sources of drug information
rather than the pharmaceutical company. Corstjens (1991: 73) found that "the 'halo' effect
can severely bias product perceptions. For example, the perception of Pfizer drug is strongly
influenced by the overall image of Pfizer in addition to the technical profile of the product
itself."
In addition, according to Bauer's study, when it came to the adoption of a new drug, medical
practitioners who interact through professional discussions and advice networks appeared to
influence each other (Smith, 1975: 70).
Wysong (1998) carried out a study of resident physicians in family practice and general
internal medicine at West Virginia University (Chicago), to determine the effect of the
amount of time spent with the drug representatives, what the doctors believed their
prescribing practices were, and what they actually prescribed. Wysong's research showed that
"the more time the doctors spend with the drug representatives, the more likely they are to
prescribe the newer, more expensive drugs. Yet the doctors seem to believe their prescribing
habits are not influenced by drug company representatives."
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Gonul et al (2001: 79-90) investigated whether and how pricing and promotional activities
influence prescribing behaviour of 157 physicians in USA for the period of four years from
January 1991 to December 1994. Their findings were that:
• Physicians tended to favour certain brands differently in the absence of external
factors such as price and promotion. However, the authors were unable to determine
the factors responsible for the dissimilar brand preferences.
• Physicians appeared to be less price-sensitive for health maintenance organisations
(HMOs) patients than for private insurance patients. The authors believe this
surprising fmding was as a result of: (i) physicians being restricted by HMO's drug
formularies, (ii) HMO patients paid nothing or little towards the cost of the drug, and
(iii) the existence of great variability in private insurance plans' extent of drug
coverage. The physicians' price-sensitivity came second to considerations about drug
efficacy and the gravity ofpatient's illness.
• Detailing and samples have a mostly informative effect on the physicians. Excessive
detailing and samples can result in adverse outcome for the pharmaceutical company.
They attributed the adverse outcome to "frustration caused by waste of time, fatigue
with promotion, or perception that the drug manufacturer is too desperate or too
aggressive."
Srivastava's (2003) research of reasons for better acceptance ofpharmaceutical drugs by the
doctors, found the following top four factors in 2002, listed according to their ranking:
1. Better Efficacy,
2. Regular reminder by medical representatives,
3. Economical, and
4. Tolerability.
In addition, Srivastava's (2003) research also revealed that brand recall is improved by the
following activities (listed according to their ranking):
1. Repeat visits by medical reps
2. Gift, samples etc.
3. Clinical meetings




4.4 PHARMACEUTICAL PROMOTIONAL TOOLS
As discussed earlier, the promotion of pharmaceutical prescription drugs is different from
other industries in that the product is not promoted directly to the public but to the medical
practitioners. The following list shows the various promotional tools used by the
pharmaceutical companies for this purpose. It is also important to bear in mind that the
various forms ofpromotion support and complement each other.
1. Personal selling: Pharmaceutical representatives who visit medical practitioners.
2. Advertising:
2.1. Advertising in medical journals and medical chronicles (newspapers).
2.2. Direct mail advertising to targeted medical practitioners.
2.3. Direct-to-consumer advertising. Corporate advertising in national periodicals and
television.
2.4. Product advertising objects such as pens, writing pads, and other non-medical
objects bearing the product name.
2.5. Advertising handouts left with the doctor at the end ofthe personal presentations.
2.6. Product advertising banners and posters at CME meetings and medical
conferences.
3. Sales promotion: provision ofdrug samples, competitions for doctors, and
doctors.
4. Publicity: Media articles on certain innovative drugs such as Viagra (anti-Impotence
drug).
5. Public relations: includes sponsorships of CME meeting, company sponsored
workshops and seminars, and professional services.
The promotional activity of personal selling will be described and discussed in detail whilst
the remaining promotional activities will be discussed briefly.
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4.4.1 PERSONAL SELLING: PHARMACEUTICAL REPRESENTATIVE
The pharmaceutical sales representatives are also known as detailers, detail men, drug reps,
and sales reps. According to Koekmoer (1987) the basic objectives of the sales reps are to
change the prescribing doctor's attitude to the pharmaceutical drug being promoted or to
reinforce the existing favourable attitude. "The medical representative is to the ethical product
what television and radio are to the consumer product" (Koekemoer, 1987: 467). "Given the
nature of pharmaceutical products, personal communication with prescribers is a key success
factor in the industry" (Corstjens, 1991: 218). Corstjens (1991) further states that together
with the quality of the pharmaceutical drugs, the strength of the pharmaceutical company's
sales force is the most critical factor for successful product penetration and profitability.
Personal selling allows the pharmaceutical representative to vary the content of the message
to different doctors as compared to the preset message conveyed by other promotional tools.
GENERAL DESCRIPTION OF THE PERSONAL SELLING (DETAILING)
PROCESS BY THE PHARMACEUTICAL REPRESENTATIVE
The following description is based upon the researcher's personal encounters with the
pharmaceutical representatives from 1995 to date of this research report. The personal selling
activity consists of the pharmaceutical representatives (sales reps) visiting the doctors either
by appointment or as a walk-in basis without an appointment. In some instances, the doctor's
receptionist acts as a 'gate-keeper' controlling the access of the pharmaceutical reps to the
doctor.
The actual process itself generally begins with the sales rep introducing him/her self and the
company that they represent. This is followed by requesting for permission to 'detail' the
medical practitioner. Most commonly, the scientific information (existing and/or new) and/or
the doctor's own experiences with the drug are discussed. The sales rep would often try to
establish the level ofdoctor's interest in a particular disease or the number ofpatients with the
particular disease consulting the doctor (for which the sales rep's drug is a therapeutic
alternative) and the current therapeutic agents favoured by the practitioner. Next, the sales rep
may try to establish the reasons behind the practitioner's choice of a therapeutic drug. If the
drug of choice mentioned represents the sales rep's drug, then the remainder of the time is
spent on reinforcing the benefits ofusing the drug and closing by requesting the practitioner's
commitment to continue the usage ofthe drug. However, if the drug being promoted is not the
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practitioner's drug ofchoice, then the sales rep will try to establish the reason(s) thereof The
sales rep presenting 'evidence' as to why his/her drug should be the fIrst choice for a
particular disease generally follows this.
Many sales reps do not attempt to fInd out the doctor's preferences, but rather get on directly
with the presentation with the hope of persuading the doctor to use their drugs when an
opportunity arises. The process would end by the sales rep trying to get commitment from the
practitioner to prescribe the drug being promoted. Most sales reps require the doctor to sign a
register confIrming the sale rep's visit to the doctor. Recently some pharmaceutical companies
have provided their sales force with hand-held computers (palmtops) that capture electronic
signature from the doctor. Finally, the medical practitioner and the practice receptionist are
thanked for their time.
During the detailing process, the sales reps use various detail-aids showing the supenor
benefIts, and or greater efficacy, and or improved cost effectiveness, and or better safety of
their drug as compared to the competitors' products, i.e. the sales reps emphasize the USPs.
This is done via quoting data from either independent studies or company-sponsored clinical
trials. The pertinent clinical data is presented in large graphical formats (usually bar charts).
There is strong emphasis on visual differences (in percentages) of the particular aspects under
discussion concerning the drug being promoted and the industry leader or the competitor. The
detail-aids themselves can vary from a simple pamphlet to sophisticated presentation on
Digital Video Disc (DVD) player. Some reps may even casually remark to the practitioner
that their drug is the preferred drug of choice by the local specialist or a regionally/nationally
known specialist in the fIeld.
At the conclusion of the process, some sales reps may leave behind with the practitioner
written material such as a journal article or a small product-advertising gift (e.g. a ball-point
pen inscribed with the product name) or an advertising pampWet/leaflet. Prior to the recent
change in regulation governing promotion of pharmaceutical drugs in South Africa, it was a
common practice to leave behind a sample of the drug (sampling) with the practitioner. The
sales rep may also use this time to invite the doctor to other drug promotion events or
sponsored medical symposia.
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Based upon the researcher's experience in a general medical practice, where the sales reps
visit on walk-in basis, and from the researcher's interviews of the sales reps, on average the
sales reps take approximately five to ten minutes for the detailing process. The duration ofthe
process varies depending upon the number of patients still waiting to be seen by the
practitioner, the degree of involvement in the process by the practitioner, and the established
level ofrelationship between the rep and the practitioner.
The researcher's personal interviews with the sales reps and their sales managers revealed that
most sales reps classify the family medical practitioners into three categories based on the
estimated numbers of patients seen by the doctors on a daily basis. The estimations are based
on the information from the doctors' receptionists where available, through the sales reps'
personal observations whilst waiting to see the doctor, and through discussions with other
sales reps calling on the same doctors. Doctors in category'A' see forty or more patients per
day, category 'B' doctors see between twenty five to forty patients per day, and category 'C'
doctors see less than twenty five patients per day. The sales reps generally target about forty
doctors, in hislher given territory, to 'detail' on average once every six weeks. Each sales rep
is given the freedom to determine his/her own target segment of doctors. The list of targeted
doctors is reviewed on quarterly basis together with the sales manager.
The sales reps objectives are to target both the high/frequent and low/infrequent prescribers in
the particular product category. High/frequent prescribers are those doctors who prescribe
greater number of pharmaceutical drugs per day than their colleagues in the area. The sales
reps' task at hand is to support and reassure the frequent prescribers oftheir drug choice and
try and covert the infrequent prescribers into frequent prescribers.
Some of the other methods of segmenting doctors for targeting are: according to their price-
sensitivity, loyal versus non-loyal prescribers, use occasions or situations, and in terms of the
benefits sought by the doctor populations (Corstjens, 1991: 53).
According to a UK market research company, Taylor-Nelson, six types of doctors can be
distinguished based on life-style criteria (Costjens, 1991:54-55). They are:
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1. Disillusioned: Doctors that pursued medical profession for idealistic reasons, but have
now become disillusioned. They tend to disapprove of existing drugs and look upon
new drugs as contributing towards the patient's health.
2. Overstretched: These doctors are more demotivated than the disillusioned group due
to being overworked. They do not have the time to absorb detailed scientific
information, instead preferring concise presentations. They tend to be above average
prescribers ofexisting drugs.
3. Postgraduates: They prefer formal sources of education such as medical journals and
postgraduate courses. They do not readily adopt new drugs and prefer generics.
4. Experimentalists: They consider pharmaceutical industry as a source of information
and are confident in trying new drugs.
5. Progressive: These are broad-minded doctors who prefer clinical-trials as a source of
drug information.
6. Self-satisfied: These are successful doctors who have become complacent and do not
see the need for further education. They are self-satisfied and do not readily see
pharmaceutical reps.
A telephonic interview with Mr Baron Tanner (2003) oflnnovex, a company specializing in
training of pharmaceutical reps and outsourcing of the sales reps to pharmaceutical
companies, revealed another segmentation approach used by the pharmaceutical reps. The
sales reps are taught to profile the doctors based upon the qualitative personal assessment of
the doctors' consulting rooms and staff: types of patients seen by the doctors, and the
mannerism and conversation style of the doctors. Based upon this profile, the doctors are
classified into four personality types. They are (1) Driver, (2) Analytic, (3) Expressive, and
(4) Amiable. The'driver' and the'analytic' types generally require scientific and clinical data
as proof of the drug's alleged superiority to the competitors. The 'expressive' and the
'amiable' types are more friendly and people orientated, and value personal relationships as,
if not more, important as the scientific data. It was also felt that from the sales rep's point of
view, the 'amiable' type was often the worst doctor to call on, as he was least likely to
prescribe your drug often enough, although appearing amiable during the detailing process.
The sales reps are also taught to analyse their own personality type and adapt to the
personality type ofthe doctor during their detailing process.
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During the sales reps' training, most are taught to follow the "IDEALS" principle in their
detailing ofdoctors (Tanner, 2003). "IDEALS" stands for:
• IdentifY the disease area.
• Discover the doctor's needs.
• Explain how the product suits the doctor's needs.
• Ask for commitment to use the product.
• Leave behind - for example free sample and product reminders.
• Setting up next meeting.
The sales rep's effectiveness is most commonly evaluated based on the sale ofthe company's
drug in the sale territory serviced by the sales rep. The pharmaceutical companies purchase
this information from various organisations such as IMS Health (SA) and Territory
Management Systems (TMS). These organisations in turn compile the sales information based
upon the information from the pharmaceutical wholesalers, prescription data from the
pharmacies and medical aid schemes, and from the electronic data interchange (EDI) service
providers for doctors utilising electronic claim submissions to healthcare funders. The IMS
report (appendix 11) shows the total sales of a particular class of prescription drugs in each
region, the market shares of the company's drug and its competitors in the region, and the
comparative sales figure for month to date and year to date. The report from TMS (appendix
11) provides the "Monthly Call and Penetration Analysis". This report is compiled from the
call-registers signed by the doctors at the end of the presentation by the pharmaceutical
representatives. The TMS report provides a measure of the sales rep's 'productivity rate' and
'doctor call rate' according to the different categories (A, B, and C) of the doctors as
discussed previously. These reports allows the sales team to assess the relative growth or
decline of the company's product per region and take appropriate action based on the
information.
Other propriety reports purchased by the pharmaceutical companies include GP Monitor@
from Battaerd Mansley (SA) Pty Company (Hallow, 2003). The company supplies propriety
diaries to approximately 200 general practitioners (GPs) in South Africa The participating
GPs, based on their experience, complete the assessment forms following an encounter with a
pharmaceutical rep. The diaries are returned to Battaerd Mansley, on a monthly basis, in the
self-addressed envelopes provided. The GP Monitor@ evaluates the p~maceutical
representative's presentation and provides (amongst other) information on the doctors'
46
perception of the usefulness of the sales rep's presentation, sales rep's expertise,
communication styles, time spent with the doctor, the specific issues discussed in the
presentations, and if and how the presentation influenced the doctor's prescribing of the
particular drug discussed during the detailing process.
Lidstone and Colliers (1987: 107-108) describe four types of visits made by the
pharmaceutical reps:
1. Product introduction visit. The sales rep generally makes use of a structured
presentation to make the doctor aware ofa new drug (product) during this visit.
2. Persuasion visit. On this visit, the sales rep's objective is to overcome the resistance to
prescribe the company's drug by a doctor who is aware of the drug but has low
motivation to prescribe it.
3. Support visit. The purpose of this visit is to reinforce and encourage more use of the
company's drug by using positive motivating factors.
4. Cultivation visit. The doctor is a regular prescriber ofthe company's drug by now and
the sales rep's objective is to exploit new references by discussing new clinical trials
with the drug.
Based on their findings, Gonul et al (2001) recommend that the scope ofpersonal selling be
more carefully scheduled in terms of frequency of sales calls on physicians and the length of
the detailing visits.
MacLean (2001: 1) comments, "no single source of prescribing information exceeds the rep's
influence on the prescribing ofGPs."
4.4.2 ADVERTISING OF PHARMACEUTICAL DRUGS
As discussed previously, the atypical nature ofmarketing ofpharmaceutical drugs restricts the
manner and the channels chosen to advertise. The various regulations and restrictions, be
discussed in chapter 5, disallow direct communication with the consumers. Therefore,
common mass advertising mediums such as television, radio, magazines and newspapers
(local and national); with the exception of corporate advertising; cannot be used for branded
product advertising.
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The advertising channels most commonly used are: medical journals and newspapers, direct
mail, medical conferences and sponsored meetings, non-medical promotional objects (objects
such as pens and note pads bearing product name), and wall posters and leaflets or brochures
left with the doctors. The amount of information that can be provided via these channels is
limited compared to personal selling. Most advertisements are thus intended to create brand
awareness and convey the key properties/unique selling point(s) ofthe drug.
Advertising in medical journals and newspapers is used to establish and enhance the
reputation of the pharmaceutical company and its products (Slatter, 1977: 34). Although it
can reach many doctors rapidly and at a relatively low cost, its effectiveness is questionable
(Slatter, 1977: 34). According to Tunmer (1989) there are about 30 local medical publication
carrying pharmaceutical adverts.
Surveys of advertisement (ad) recall and awareness, as advertising campaign evaluations,
consistently produced the following results: 40% of readers notice the ad, 35% of readers
remember the ad, 10% read part of the ad, and 5% read all of the ad (Lidstone and Collier,
1987: 105).
Lidstone and Collier (1987: 96) further contend that advertising campaigns can not increase
the sale of the pharmaceutical drugs since "in the health-care market the effects ofadvertising
stops at the point where the target audience is receptive but requires the personal interface to
be tempted to trial." According to them the advertising campaigns can create a favourable
climate for the pharmaceutical reps and can help maintain usage of the drug where the doctor
requITes reassurance.
The survey carried out by Pitt and Nel (1988) found the advertisements in medical journals,
objects bearing product name, and direct mail advertising to have less influence on the
doctors' prescribing decisions than visits by pharmaceutical representatives and
seminars/conferences/lectures arranged by the pharmaceutical companies.
Professor Henry, in an editorial of September 2002 issue ofThe Medical Journal of Australia
comments that "doctors are 'powerfully' influenced by advertisements, even to the point of
prescribing a new drug that offers no advantage over existing treatments" (Salleh, 2002).
48
Recently in South Africa, some of the pharmaceutical companies have started using direct-to-
consumer corporate advertising. This is because currently the advertising of prescription only
medication directly to the public is prohibited by regulations. Generally, this advert is of an
informative nature. It focuses on a particular disease (e.g. obesity, erectile dysfunction) and
informs the public that there is new/improved treatment available, and that the public should
enquire about this new treatment from their doctor. The actual brand of the drug is not
mentioned in the advert, however the advert generally bears the manufacturing
pharmaceutical company's logo and name. This type of corporate advertising increases public
awareness about a particular disease and informs the public that a treatment is available. The
mass media oftelevision, radio, magazines, and the national newspapers have been used.
Although the mam emphasis in pharmaceutical promotion is on the product (brand)
positioning, corporate positioning also plays an important role (Corstjens, 1991:70). The
favourable company image created by corporate advertising develops credibility and trust,
and helps to reduce risks associated with prescribing pharmaceutical drugs (Corstjens,
1991 :70). Thomson (2001) reports that in 1999, $1.8-billion was spent on direct-to-consumer
advertising in USA and that many of the big pharmaceutical companies were increasingly
allocating greater amount of their promotion budget to advertising direct-to-consumers rather
than professional promotion. Petroshius et al (1995), in their research of USA physicians'
attitudes to direct-to-consumer advertising ofprescription drugs, found the USA physicians to
generally support direct-to-consumer advertising.
The regulations prohibiting direct advertising to consumers is difficult and impractical to
apply to the Internet. US legislation allows direct-to-consumer advertising of branded
prescription drugs and access to US prescription drug websites and the ability to purchase on-
line, is available from anywhere in the world, including countries where direct-to-consumer
advertising is illegal (Reast and Carson, 2000: 398).
Currently there are no studies into the effect of corporate advertising on the medical
practitioner's prescribing behaviour in South Africa.
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4.4.3 SALES PROMOTION OF PHARMACEUTICAL DRUGS
The sales promotion includes activities such as provision of drug sample, competitions for
doctors and gifts for doctors.
Lidstone and Collier (1987: 109) advocate the use of sales promotion for a pharmaceutical
drug in the following situations where there is:
• Poor usage by doctors.
• Poor repeat usage.
• Inability of the field force to sell in.
• Short-term switching and not sustained brand loyalty.
• Higher expenditure by the competitor.
Smith (1975: 329) states that the use of prescription drug samples for pharmaceutical
promotion has been highly controversial. The issues of concern are the inadequate control of
the sample distribution, fraudulent sale of the sample by the doctor and the pharmacist to the
patient, and the possibility of the doctors feeling the need to reciprocate this gesture from the
pharmaceutical companies in the form ofexcessive or inappropriate prescribing.
Sampling (activity ofleaving with the GP a small quantity of the drug to initiate a trial use) is
also associated with increased awareness, preference and rapid prescribing of a new drug, in
addition to promoting a positive attitude towards the pharmaceutical rep (MacLean, 2001 :3).
"Drug sampling continues to play a significant role in physicians' prescribing decisions, more
than advertising or other promotional techniques" (IMS Health, 2002, paragraph 4). The
recent changes in the South African legislations (to be discussed in chapter 5) that came into
effect on 2nd May 2003 now prohibit drug sampling.
According to USA studies quoted in MacLean (2001:3), as many as 70 % of the physicians'
prescribing could be compromised by accepting gifts and that receiving gifts of high
relevance to the practice resulted in positive attitude towards the promoted drug.
50
4.4.4 PUBLICITY
More commonly, publicity (i.e. not paid for by the pharmaceutical company) in mass media
such as television, newspaper, and magazines is associated with certain innovative drugs that
happen to be the first such drug in its class (e.g. Viagra™ for treatment of impotence). Other
occasions when a drug may receive, publicity is if it is mentioned in health related topics in
various mass media. Discussions, advice and the promotion of health related topics are
increasingly becoming regular features in mass media. The publicity can be favourable or
unfavourable towards the drug and the pharmaceutical company has no control over it except
by means ofa reaction following the occurrence ofthe publicity event.
4.4.5 PUBLIC RELATIONS
Public relations includes sponsorships of Continuing Medical Education (CME) meetings,
company sponsored workshops and seminars, and professional services. Since 1999, it is
compulsory for the medical practitioners to participate in CME and Continuing Professional
Development (CPD) activities for their continued registration with the Health Professions
Council of South Africa (HPCSA). The CME/CPD activities includes for example, answering
and submitting questionnaires in medical journals, attending CME/CPD lectures, conferences,
workshops, and attending clinical rounds at a hospital. Each accredited activity has certain
CPD-points associated with it. The medical practitioner has to earn a minimum of fifty CPD
points per year. Maximums of seventy-five CPD points are allowed to be credited to the
practitioner per year.
A significant number of CME/CPD lectures/conferences/workshops/symposia are arranged
and or sponsored by the pharmaceutical companies. This sponsorship generally includes
hospitality at the venue such as meals and beverages for the doctors. The vast majority ofthe
sponsored meetings tend to be 100 percent covered by the pharmaceutical companies, i.e. the
attending doctors do not pay any fees towards the cost of the meeting and the associated
hospitality. The sponsorship may also allow the sponsoring pharmaceutical company to
influence the choice of speaker(s), the topic(s) for discussion, and in certain cases the content
of the topic(s). The pharmaceutical companies will obviously choose the speaker, and/or the
topic, and/or the content that conveys a favourable viewpoint/position of their drugs. The
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sponsorship of such events is designed to promote goodwill amongst the attending doctors
towards the company and by extension its products.
From the researcher's personal experiences, it has been noted that in most situations, where
the pharmaceutical company is the sponsor, the speaker highlights the company's product by
its brand name or explicitly mentions that the sponsoring company manufactures the drug to
treat the ailment under discussion. Many speakers also report favourable use/experience of
that particular product (drug). Although it is against the governing regulations to mention any
drug by its brand name during the lecture/talk by the speaker, several speakers tend to
overlook this regulation. Since the speaker is invariably a well-known and or locally
practising specialist consultant ("opinion leader"), the positive reference to the drug during
the talk tends to come across as a recommendation to the attending general medical
practitioners to begin or increase the use of the drug.
Many pharmaceutical companies also provide professional services such as counselling of
patients, use of certain diagnostic equipment such as ambulatory blood pressure monitoring
device, and patient education/support programmes.
These activities allow the pharmaceutical representatives to further build/strengthen their
working relationships with the attending doctors as well as seek to evoke the feeling of
obligation in the attending doctors.
4.5 EFFECTIVENESS OF PHARMACEUTICAL PROMOTION
This section looks at the results of various local research studies into the effectiveness of the
various pharmaceutical promotional factors and their relative influence on the doctors'
prescribing habits.
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SOUTH AFRICA: COMMUNICATION ACTIVITIES IN DESCENDING ORDER OF
IMPORTANCE AS THEY AFFECT THE DOCTOR IN HIS PRACTICE
COMMUNICATION ACTIVITIES MEAN SCORE
OUT OF 15
1 Medical journals 11.06
2 Continuing medical education lectures 10,71
3 Medical association organised congresses 9.65
4 Reference works 9.20
5 Company organised seminars 9.19
6 Medical representatives 9.19
7 Medical newspapers 7.99
8 Samples 7.71
9 Company organised social functions 7.22
10 Detailing aids 6.79
11 Product advertising pieces 6.68
12 Medical exhibition 6.56
13 Pharmaceutical company home journals 6.18
14 Product related give-aways 6.18
15 Direct mail 5.76
Table 6. Source: Marplan Pharmaceutical Communication Study, March 1981, as cited in Koekemoer
(1987: 466)
The Marplan Pharmaceutical Communication Study (Koekemoer, 1987:466) researched the
relative importance of the various communication activities on the medical practitioner's
practice. Its findings of the relative influence of the various pharmaceutical communication
activities on the prescribing behaviour of the doctors are shown in Table 6 above.
Pitt and Ne! (1988), in their research study of21O general practitioners in South Africa, found
the following as the factors, according to their perceived influence on the doctors' product
prescription decisions (in descending order of importance according to their mean scores), as
per Table 7 below:
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FACTORS INFLUENCING PRODUCT PRESCRIPTION DECISIONS
Rank Factors
1 Personal experience with the drug.
2 Recommendations made by colleagues in informal discussions.
3 Sales calls made by pharmaceutical representatives.
4 Seminars, conferences, lectures organised by pharmaceutical companies.
5 Advertisements in journals and magazines.
6 Sales promotional material received from pharmaceutical companies, such as small
samples, calendars, diaries, and note pads.
7 Direct mail advertising.
Table 7 Source: Pitt and Nel (1988)
Pitt and Nel (1988), based upon their findings, were unable to comment ''with any statistical
certainty that advertisements in medical journals and magazines are more influential than
sales promotional materials received from pharmaceutical companies." Based on their
fmdings they concluded that the leading two factors that exerted the most influence were not
directly controllable by the pharmaceutical companies' marketing strategies. When they
considered the promotional tools used by the pharmaceutical companies, they found the
pharmaceutical representatives to have the most influence on the general practitioners'
prescribing habits, followed by the lectures arranged by the pharmaceutical companies.
Friedman (1991) researched "Factors influencing general practitioners in their choice of
prescription drugs." Friedman had based his fmdings on a random sample of 28 dispensing
and 29 non-dispensing general practitioners in Northern Johannesburg area. The study
included a section on assessment of the knowledge and use of the drug Diazepam (best known
by its original brand name of Valium®). He found that the most important influence on the
general practitioner's choice of prescription drug was their preference for a brand name with
which they were familiar. The second most important influence was specialist's advice
followed by information gained at medical meetings/symposia in third place. Visit (detailing)







respectively as sources of influence, according to the mean rating
of the various influential factors (Friedman, 1991:73).
Gillingham (1995) researched the "Prescriber evaluation of prescription pharmaceuticals and
associated services". She also used a random sample of 60 private medical practitioners in
Northern Johannesburg area of South Africa.
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Gillingham (1995:62) demonstrated that positive experience with the drug increased the
confidence of the doctor in prescribing the drug again and that personal endorsement by
opinion leaders had greater credibility than advertising. The study also identified that the
pharmaceutical marketers had a definite role to play in continued medical education activities,
and the general practitioners rated the products of research based companies (ethical drugs)
more satisfactory than generic drugs.
From the preceding discussion in this chapter, it is evident that there are many factors
influencing the doctor's prescribing behaviour. The promotional tools used by the
pharmaceutical companies to influence this prescribing behaviour were discussed in detail.
Finally, the perceived effectiveness of the promotional tools was discussed. The primary
research carried out will evaluate the perceived influence ofthe promotional factors discussed
as well as theoretical attributes of personal selling discussed in chapter 2. The following
chapter 5, looks at the important regulations and ethical issues giving the promotion of
prescription drugs its unique character.
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CHAPTER 5: LEGISLATIONS AND ETHICS
This chapter looks at the influence of the policies of various government and regulatory
bodies on the promotion of pharmaceutical drugs and briefly examines the ethical issues of
pharmaceutical promotion.
5.1 LEGISLATIONS INFLUENCING PHARMACEUTICAL PROMOTION
"In nearly every country throughout the world, governments have legislated to curb and
control pharmaceutical companies' profits, prices and promotional activities" (Lidstone and
Collier, 1987: xiii). Reekie and Weber (1979: 63) comment that the main focus of
legislations in the developing world is directed towards (1) raising the standards of drug
safety and efficacy, and (2) reducing prices.
Due to the potential health and ethical risks associated with pharmaceutical drugs, the
pharmaceutical industry is one of the most heavily regulated and controlled industries. These
regulations vary from country to country, are frequently being revised, and reviewed
depending upon the governing political parties and public opinions in the country.
In South Africa, the Medicine Control Council (MCC) controls market entry of new
pharmaceutical drugs. All medicines sold in South Africa must be registered by or listed with
the MCC. Only the drugs that have achieved the required registration with the MCC can be
prescribed or be available to the consumers for use. The MCC looks at the efficacy, safety,
and the quality of the drug amongst many other issues, in deciding whether to approve
registration ofa drug or not.
CODE OF PRACTICE RELATING TO THE MARKETING OF MEDICINES IN
SOUTH AFRICA
The Pharmaceutical Manufacturers Association (PMA) has published the Code ofPractice for
the Marketing of Medicines in South Africa (the Code). The Code incorporates guidelines
from the World Health Organisation (WHO) and the Advertising Standards Authority (ASA)
(Meakings, 1999). The objective ofthe Code as stated in the introduction, is to ensure that the
marketing of medicines to healthcare professionals and the general public is carried out in a
responsible, ethical and professional manner. It also endeavours to ensure that marketing
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activities encourage the rational use of medicines by healthcare professionals and the general
public.
The Code is administered by an industry self-regulatory body, the Authority for the Code of
Practice for the Marketing of Medicines in South Africa (the Authority). The Authority is
responsible for the provision of advice, guidance and training on the Code as well as for
handling complaints and the complaints procedure. It is also responsible for scrutinising
journal advertising and Internet or electronic advertising on a regular basis.
The legal basis for the code is found in the Section 18C ofMedicines and Related Substances
Control Act (Act 101 of 1965 as amended) that is also known as the Medicines Act, which
reads as follows:
"The Minister shall, after consultation with the pharmaceutical industry and
other stakeholders, prescribe a code ofpractice relating to the marketing of
medicines. "
All marketers and suppliers of medicines in South Africa are subject to this Code. The Code
is in line with the principles ofSection 7.7 ofthe National Drug Policy (NDP) (January 1996),
which relates to advertising and marketing ofmedicines.
"The objective is to ensure that advertising and marketing ofdrugs shall be in
keeping with National Drug Policy and in compliance with national regulations
as well as with voluntary industry standards. All promotion-making claims
shall be reliable, accurate, truthful, informative, balanced, up-to-date, capable
of substantiation and in good taste. They shall not contain misleading or
unverified statements or omissions likely to induce medically unjustifiable drug
use or to give rise to undue risks. Promotional material shall not be designed to
disguise its real nature. Promotion in the form offinancial or material benefits
shall not be offered to or sought by health care practitioners to influence them
in the prescribing of drugs. Scientific and educational activities shall not be
deliberately usedfor promotional purposes".
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Part lA of the Code relates to the marketing and promotion of medicines to healthcare
professionals. This includes the marketing and promotion of self-medication (OTC) products
to healthcare professionals when such promotion is aimed at generating prescriptions or
recommendations to patients.
As stated in the Part lA (7) ofthe Code the term 'promotion' means
"Any activity undertaken by or on behalfofany company or person, which
promotes the prescribing, supply, sale or use ofits medicines. It includes:
o Media advertising
o Direct mail advertising
o The activities ofmedical representatives, including detail aids and other
printed material used by representatives
o The provision ofhospitalityfor promotional purposes
o The sponsorship of continuing professional development scientific
meetings, including payment oftravelling and accommodation expenses
in connection therewith
o .The provision of information to the general public, either directly or
indirectly, and all other sales promotion in whatever form, such as
participation in exhibitions, the use of audio-cassettes, films, records,
tapes, video recordings, radio, television, the Internet, cell phone (SMS),
electronic media, interactive data systems and the like
o The provision of inducements to prescribe, supply, administer,
recommend or buy medicines by the gift, offer or promise ofany benefit
or bonus, whether in money or in kind, is not allowed under the
Medicines Act.
o The supply ofsamples to healthcare professionals is not permitted under
the Medicines Act. "
The code also provides guidelines for the pharmaceutical representatives as follows:
" Representatives' Training
Procedures must ensure that:
o Representatives are adequately trained in relation to every product that
they are to promote (Clause 15.1)
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o Representatives are not employed as medical representatives unless they
have passed the relevant examination as provided for in Clauses 16.2
and 16.3 of the Code, or have the benefit ofan exemption, or have been
in such employment (whether with their current employer or not) for less
than two years. Contract representatives are only used if they comply
with the requirements of Clauses 16.2 and 16.3 as regards examination
status.
Representatives should be provided with written instructions on the application of
the Code to their work even if they are also provided with an actual copy of it.
Their instructions should cover such matters as the company's policies on
meetings and hospitality, and the associated allowable expenditure, and the
specific requirements for representatives in Clause 15 of the Code. It should be
made clear how reporting to the 'scientific service' of the company is to be
carried out in relation to information about the medicines that they promote
which comes to their notice, particularly reports ofside-effects (Clause 15.6).
It should be made clear to representatives as to whether, and in what
circumstances, they can themselves write letters (or prepare other written
materials), which mention particular products and are thus almost certain to be
considered promotional material. Such items must be certified, either in advance
by way ofpro-forma letters or by certifying each individual letter or other item,
and must bear prescribing iriformation in accordance with Clause 4.1. "
The introduction of a prescribed course and an examination for the pharmaceutical reps
is a step towards making the personal selling by the pharmaceutical representatives
more professional and ethical. It will also give the pharmaceutical reps more credibility
and bestow greater status to the pharmaceutical reps than currently enjoyed by them.
Meakings (1999) argues that although the Code has been widely distributed by PMA in
South Africa, it "remains a publication, only effective if read and its principles
implemented."
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THE MEDICINES AND RELATED SUBSTANCES AMENDMENT ACT (Act59 of 2003)
The Medicines and Related Substances Amendment Act (Act 59 of 2003) that replaced Act
90 of 1997, which had amended the principle Medicines Act (Act 101 of 1965) and includes
the General Regulations, came into effect on 2nd May 2003 (Sunday Times, 2003). Some
elements of the Act such as those dealing with drug pricing policies are to be held back until
May 2, 2004 and the Act will only become binding on the State on July 1,2005 (Gray, 2003:
4).
Aspects of the new legislation having direct impact on the current pharmaceutical
promotional practices are: banning of drug sampling with immediate effect and the
compulsory offer of generic substitution (i.e. substitute a branded drug with a lower-priced
generic equivalent where available) by pharmacists (Ducasse, 2003: 10; Gray, 2003: 4;
Keeton, 2003: 5; Sunday Times, 2003). The Act 59 also seeks to prohibit a manufacturer's
volume discounts and rebates, which the government considers perverse incentives (Sunday
Times, 2003). The sections dealing with perverse incentives such as bonusing of drugs,
rebates on drug purchase and other forms of incentive schemes is currently awaiting
recommendation from the Pricing Committee and will come into effect on May 2, 2004
(Gray, 2003). The other critical issues are: the issue of pricing of pharmaceutical drugs (a
single exit price is proposed) and the issue of parallel importation of pharmaceutical drugs
(Medical Chronicle, 2002). These issues are also awaiting the Pricing Committee's decision
(Gray, 2003: 4).
The government's position on the issues of generic substitution and parallel importation of
medicines is likely to cause controversy amongst all role players in the health care industry.
The developing countries such as South Africa are in a catch 22 situation in that they cannot
afford to alienate the pharmaceutical multinationals from their markets and at the same time
they cannot afford many ofthe branded medication. The case in point being the raging current
national debate on provision of anti-retroviral drugs by the government for the treatment of
Human Immuno-deficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) in
South Africa.
There are also changes to the requirements for prescription writing, such as addition of the
age and gender of the patient, diagnosis (with patient's permission), and stipulations
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concerning the legibility of the prescription (Gray, 2003: 6). The amendments to drug
Schedules include designating Schedule 0 for the previously unscheduled drugs, combination
of previous Schedules 6 and 7 into new Schedule 6, assigning Schedule 7 to "banned"
substances, and Schedule 8 for "exceptions" (Gray, 2003). A major change is that the
pharmacist, without a prescription, can sell (maximum 30 day's supply) Schedules 2 and 4
drugs to patients for whom they were previously (within preceding six months) prescribed by
an authorised prescriber. The implication for the pharmaceutical companies will be to increase
their promotional efforts directed at the pharmacists.
In terms of the legislation, from May 2, 2004, those medical practitioners that dispense
medicines will be required to be in possession of a dispensing license in order to continue to
dispense (Ducasse, 2003). More importantly, the medical practitioners in urban locations may
not be able to dispense medication, even if they are in possession of the relevant dispensing
license.
5.2 ETHICAL ISSUES OF PHARMACEUTICAL PROMOTION
The World Health Organization, to prevent the occurrences of inappropriate pharmaceutical
promotion, has developed the ethical criteria for drug promotion.
WORLD HEALTH ORGANISATION'S (WHO) ETHICAL CRITERIA FOR
MEDICAL DRUG PROMOTION
The stated objective "is to support and encourage the improvement of healthcare through the
rational use ofmedicinal drugs" (WHO, 1985:1).
Clause 4 of the WHO ethical criteria for medical drug promotion (1985:1) reads as follows:
~'4. These criteria constitute general principles for ethical standards which could
be adapted by governments to national circumstances as appropriate to their
political, economic, cultural, social, educational, scientific and technical
situation, laws and regulations, disease profile, therapeutic traditions and the
level ofdevelopment oftheir health system. They apply to prescription and non-
prescription medicinal drugs {"over-the-counter drugs"}. They also apply
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generally to traditional medicines as appropriate, and to any other product
promoted as a medicine.
The criteria could be used by people in all walks of life; by governments; the
pharmaceutical industry (manufacturers and distributors); the promotion
industry (advertising agencies, market research organizations and the like);
health personnel involved in the prescription, dispensing, supply and distribution
ofdrugs; universities and other teaching institutions; professional associations;
patients' and consumer groups; and the professional and general media
(including publishers and editors ofmedicaljournals and relatedpublications). "
It provides guidelines for the promotional activities of: advertising, medical representatives,
use of free samples of prescription drugs for promotional purposes, symposia and other
scientific meetings, post-marketing surveillance, packaging and labelling, and package inserts
and booklets. It is important to note that these criteria are not legally binding and are merely
guidelines, which mayor may not be adopted/incorporated by the country's legislature or
self-governing bodies.
The Code of Practice for the Marketing of Medicines in South Africa and the Code of
Practices for Pharmaceutical Marketing developed by the International Federation of
Pharmaceutical Manufacturers Association (IFPMA) incorporate the criteria put forward by
WHO.
5.2.1 INDEPENDENT VIEWS ON ETHICAL ISSUES
" Relationships involving medical practitioners and the pharmaceutical industry raise serious
concerns and controversy within both the medical profession and the broader community"
Komesaroffand Kerridge (2002:1).
"Controversy exists over the fact that physicians have regular contact with the pharmaceutical
industry and its sales representatives, who spend a large sum of money each year promoting
to them by way of gifts, free meals, travel subsidies, sponsored teachings, and symposia"
Wazana (2000: 1).
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Komesaroff and Kerridge (2002:2) identify three main ethical concerns resulting from the
relationships between the doctors and the pharmaceutical industry:
1. The possibility of compromising the doctor's primary ethical obligation to patients,
dividing loyalties of doctors and undermining the basic trust on which the clinical
relationships depends. This may occur as a consequence ofthe relationship serving the
commercial objectives of the pharmaceutical industry and covetous interests of the
doctors;
2. The risk ofdrug promotion inappropriately influencing a doctor's decision; and
3. The risk ofdistortions in scientific evidence and prevention of independent assessment
ofdata from the industry's involvement in research.
Waud (1992) found that, with respect to the relationship between medical practitioners and
the pharmaceutical companies, medical practitioners' opinions differed starkly, from belief
that there is minimal ethical risk to the fervent standpoint that all such contacts lead to some
compromise on the part of the practitioners and thus should be avoided.
Wazana (2000) conducted a meta-analysis of 29 studies from a sample of 538 studies, to
identify the extent of and attitudes toward the relationship between physicians and the
pharmaceutical industry and its representatives and its impact on the knowledge, attitudes,
and behaviour of physicians. He concluded that the physician-industry interactions appear to
affect prescribing and professional behaviour by leading to inappropriate prescribing. This
was based on his finding of changes in prescribing practice resulting from physicians'
meetings with pharmaceutical representatives and increased prescription rates ofthe sponsor's
medication from attending sponsored CME by pharmaceutical representative speakers.
Choudhry et al (2002) studied the potential financial conflicts of interest for 100 authors of44
clinical practice guidelines (CPGs) since CPGs are designed to influence the practice of a
large number of physicians. They studied the extent and nature of interaction between the
authors of CPGs and the pharmaceutical industry. Their findings were that 87% of authors
had some form of interaction with the pharmaceutical industry, of whom 58% percent had
received financial support to perform research and 38% had served as employees or
consultants for a pharmaceutical company. However, in published versions of the CPGs, only
2 authors had made specific declarations regarding the personal financial relationships with
the pharmaceutical industry. Their study highlighted the need for appropriate disclosure of
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fmancial conflicts of interest for authors of CPGs and a formal process for discussing these
conflicts prior to CPG development.
Schiiklenk (2001) looked at ethical issues in continuing professional development (CPD)
activities organised or sponsored by pharmaceutical companies. He argues that the
pharmaceutical companies have conflict of interest that effectively rules them out as
organisers ofCPD events. Schiiklenk identified the following unethical practices:
• Academics presenting pharmaceutical company-authored material (designed to
promote the company's drug) as their own work.
• Pharmaceutical companies getting CPD accreditation for presentations with
minimal/no information on the speaker or the content of the topic.
• Doctors getting the speakers requested by them in return for doctors' participation in
marketing events for certain drugs.
• Lack of controls to ensure that the accredited presentation was actually provided as
accredited.
• Some commercially sponsored events not taken seriously by both the company and the
participating doctors.
Schiiklenk's research of other studies (Chren and Landefeld, 1994; Rothman, 2000)
established that sponsorship of CPD events affects the prescribing habits of doctors and that
the doctors' prescription habits are influenced by the latest CPD-accredited marketing
exercises arranged by the pharmaceutical companies. Schiiklenk offers some possible
solutions to the ethical dilemmas, however they are beyond the scope ofthis study.
Gonul et al (2001: 79-90), in their study described earlier, found that there was no evidence of
any ethically objectionable influence, from detailing and free samples, on the physicians. At a
plenary session ofthe Health Professions Council of South Africa (HPCSA) workshop, it was
commented, "clinical and ethical independence of health practitioners should always
supersede corporate and business considerations" Batteman (2003: 477).
The regulations and ethical issues discussed offer insight into the challenges faced by the
pharmaceutical companies. A further debate on these issues is beyond the scope ofthis study.
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CHAPTER 6: RESEARCH METHODOLOGY
6.1 METHODOLOGY
A survey was conducted among the general medical practitioners in private medical practice
in Pietermaritzburg, South Africa. A self-administered questionnaire (survey instrument) was
hand-delivered to all general practitioners (GPs) in the selected two suburbs of
Pietermaritzburg, where the majority of medical practices are located, viz. Central Town and
Raisethorpe. A total of 67 questionnaires together with a covering letter (Appendix I) were
distributed and each general practitioner was asked to spare 10 to 15 minutes oftheir valuable
time to record their responses. A maximum period of three weeks was allowed to complete
the questionnaire. The researcher personally collected each questionnaire.
6.2 THE QUESTIONNAIRE
The survey instrument, a self-administered questionnaire (Appendix I), was designed by the
researcher to accommodate all research objectives. This particular type of survey
methodology was chosen for the cost and time benefits it offered compared to the other forms
of surveys. A covering letter was attached to each questionnaire explaining the purpose of the
research and reassuring the respondents ofconfidentiality and anonymity.
The questionnaire consists of structured questions of the following types: dichotomous
questions, multiple-choice questions, closed-ended questions, open-ended questions, and
scaled-response questions (Nominal scale, Rank-order scale and Likert scale). The
respondents were requested to either cross (X) the relevant answer or apply ranking or select a
ranked answer where applicable. This helped to remove the interviewer and coder bias
(McDaniel and Gates, 1998: 174). It also simplified the coding and data-entry processes.
Scaled-response questions were developed to measure the perceived importance of various
characteristics of pharmaceutical representatives, the preferred frequency and duration of
sales calls by pharmaceutical representatives, and the perceived influence of various factors
on the choice of a prescription drug by the responding medical practitioners. Open-ended
questions were included in certain instances to determine if there were any other variables
besides the ones being included in the questionnaire.
65
The questions were stated in as simple and as clear a form as possible, bearing in mind to
avoid words, which may introduce respondent bias and avoidance of questions that the
respondents may be unwilling to answer (McDaniel and Gates, 1998: 279). The key words
were in bold and some were also in capital letters to facilitate quick focus and understanding
of the question and or instruction. The questionnaire was pilot tested with two medical
colleagues (who were not part of the selected sample) to test for any ambiguities,
misunderstandings, and inclusion of any questions that may be perceived to be of a personal
nature. The questionnaire was further verified with the dissertation supervisor and two of his
colleagues before the fmal version was distributed.
6.3 MEASUREMENT SCALES
Nominal scales were used for questions 1 and 2, which looked at the demographics variables
of the respondents/type of medical practices. A nominal scale partitions the data into
categories that were deemed to be mutually exclusive (McDaniel and Gates, 1998: 228).
Rank-order scales were used for questions 12 and 13 that investigated the three commonest
sources of medical drug information and the three commonest influences on commencing the
use/prescribing of a new drug. The dichotomous-questions were used to evaluate the
respondents understanding of basic statistics and their brief opinion on ethics of
pharmaceutical marketing. Likert scales were used to evaluate the importance of various
characteristics of the pharmaceutical reps and to evaluate the perceived relative influence of
various factors on the respondent's prescribing behaviour.
6.4 SAMPLING
The population of interest was general medical practitioners in Pietermaritzburg. All specialist
medical practitioners were excluded. Two suburbs of Pietermaritzburg, Central Town and
Raisethorpe, were selected as the majority ofgeneral practitioners have their practices in these
areas. The sampling frame consisted of all general medical practitioners practicing in the
selected suburbs.
The local telephone directory was unsuitable as a source of list of names of the GPs, as the
names of many GPs' were absent from the list of medical practitioners in the directory.
Similarly, the medical directory of all doctors including specialist (published in 2001), was
66
also found to have an incomplete list. Thereafter the local private pathology laboratories were
requested to provide a list of all doctors and their practice addresses, as it was assumed that
they would have a complete list since their services are utilised by all medical doctors.
Unfortunately, the list provided contained names of many that had either relocated or
emigrated, and lacked the names of some that had entered private practice in the preceding
three to four years.
It was thus decided to go the route of area sampling, specifically a one-stage cluster sample
where data is collected from all the elements (census) in the cluster (McDaniel and Gates,
1998: 318). All general medical practices in the two selected suburbs were identified
(through the researcher's knowledge of the two suburbs, by driving through the two suburbs,
and asking colleagues about the other GPs in the area). A total of 67 GPs were identified and
were included in the research. By restricting the research to the selected geographical area,
travel time and expenses were also reduced. Area sampling overcomes the problems of high
sampling cost and the unavailability of a practical sampling frame for individual elements
(Cooper and Schindler, 2001: 187). When using the area-sampling method, it is assumed that
the elements in an area are just as heterogeneous as the total population (McDaniel and
Gates, 1998: 318). However, overrepresentation of one ethnic group (Asian) was identified.
Forty-one of the 67 GPs identified, were Asian. As regards to the suburbs selected, the
preponderance ofAsian GPs in the sample is representative ofthe general population in these
areas, which is a legacy of the previous Group Areas Act under apartheid. To my knowledge,
there are no previous studies showing any relationship between ethnicity and the manner in
which the medical practitioner carries out hislher professional duties. Therefore, identification
ofethnic origin as a demographic variable was not included in the questionnaire.
6.5 DATA COLLECTION
Each questionnaire with a covering letter was hand delivered to the GP's medical practice and
given to the receptionist or to the doctor where possible. Over the following three weeks,
completed questionnaires were personally collected from the respondent/respondent's
receptionist. Where the completed questionnaire was not ready subsequent to the distribution,
follow-up phone calls were made 2 to 3 days later to determine if they were ready for
collection. These phone calls served as reminders to the practice staff to request the doctors to
respond to the questionnaire. Cal/backs are the most reliable solution to nonresponse
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problems (Cooper and Schindler, 2001: 306). Some respondents necessitated up to five such
phone calls to their practices.
A cut-off date for final collection was set at three weeks after the initial distribution. Finally,
59 responses were collected. Two respondents refused to take part in the survey. One of the
latter commented that the questions were too personal and the other did not provide a reason.
Four questionnaires were misplaced/lost either by the respondent or by the respondent's
administration staff. Two ofthe respondents failed to answer by the cut-offdate. Out ofthe 59
responses collected, one was found to be incompletely answered and was thus excluded from
the research.
The data in the questionnaire was validated for adherence to the instructions and completeness
(McDaniel and Gates, 1998: 351). Validity in this context refers to determining that all
questionnaires were properly completed (McDaniel and Gates, 1998: 351). It was also edited
to exclude mistakes and to note the respondents who answered the open-ended questions. The
editing process includes determining if the respondent failed to answer any question, ensure
that skip patterns are followed, and to check responses to open-ended questions (McDaniel
and Gates, 1998: 352). The data was numerically coded. Coding involves assigning numeric
values to the various responses to facilitate grouping of responses into limited categories
(Cooper and Schindler, 2001: 423; McDaniel and Gates, 1998: 356). The respondents were
also numerically coded from 1 to 58.
6.6 DATA ANALYSIS
The coded responses were entered into Microsoft Excel® and SPSS (Statistical Package for
the Social Sciences) version 11, for data analysis. The data was checked for error in SPSS
with the use of a marginal report. A marginal report is " a computer generated table of the
frequencies of the responses to each question to monitor entry of valid codes and correct use
of the skip pattern" (McDaniel and Gates, 1998: 361). Thereafter, descriptive analysis was
conducted. A data output was generated in SPSS (appendix Ill). One-way frequency tables
were generated in both Microsoft Excel and SPSS to determine the total number of responses
to each question and the total number of respondents (58) was used as a base for the
calculation of percentages. The responses were cross-tabulated against corresponding
variables. Cross-tabulation examines the responses to one question relative to responses to
68
one or more other questions (McDaniel and Gates, 1998: 365). In addition, significance
testing was conducted for certain cross-tabulations using the non-parametric tests (in SPSS)
owing to the nonmetric (nominal and ordinal) nature ofthe data (Cooper and Schindler, 2001:
495). The data analyses are shown in appendix Ill.
The data that was entered in Microsoft Excel®, was imported into Microsoft Access 2000® (a
database). The database was used to summarise questions with ranking and weightings (Likert
Scales) using the SQL (Structured Query Language) Query function. Furthermore, cross-
tabulations were carried out using the Crosstab Query Wizard. Microsoft Excel® was then
used to generate bar charts to graphically represent the results ofthese cross-tabulations.
6.7 RELIABILITY AND VALIDITY OF THE QUESTIONNAIRE
Reliability is assessment of the degree to which the measures are free from random or
unstable error, and therefore providing consistent data at different times under different
conditions (Cooper and Schindler, 2001: 215; McDaniel and Gates, 1998: 231). The internal
consistency of the measurements was tested with Cronbach's-Alpha. This procedure
calculates the mean reliability coefficients estimates for all possible ways of splitting a set of
items in half (McDaniel and Gates, 1998: 233).A lack of correlation of an item with other
items in the scale indicates that the item does not belong in the scale and should be omitted
(McDaniel and Gates, 1998: 233). Cronbach 's-Alpha was consistently less than 0.7 except for
questions 12.4, 12.7, and 13.8. (Appendix Ill) therefore if the questions 12.4, 12.7, and 13.8
were to be removed from the questionnaire, it would improve the reliability.
Validity is the extent to which the differences found with the measuring tool reflect the true
differences among the respondents tested (Cooper and Schindler, 2001: 211). The
questionnaire is accepted to have internal content validity since the questions were based on
the literature survey (McDaniel and Gates, 1998: 234).
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CHAPTER 7: ANALYSIS OF RESULTS
There were 58 completed questionnaires out of 67 handed out. This gave a response rate of
87%. This is improvement on the 42% response rate to mailed-questionnaires by Pitt and Nel
(1988) and 73% response rate to hand-delivered questionnaires by Gillingham (1995), but
lower than the 95% response rate, to hand-delivered questionnaires, achieved by Friedman
(1991).
Demographic Data
The demographic information collected was: the gender, type of general practice based on
criteria as listed in question 2 of the questionnaire, the number of years in private practice,
and years since qualification. The frequency of the pharmaceutical reps' visits and the
duration ofthe reps' visits were also determined.
Question I.Gender
Ofthe 58 respondents, 51(87.9%) were male and 7 (12.1%) were females.
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The majority (70.7%) of the respondents were in solo medical practices with 29.3% in
partnership. 58.6% were predominantly dispensing practices and 41.1% were predominantly
prescribing practices. The vast majority (87.9%) of the practitioners were contracted to the
medical aid schemes and only 12.1% were not contracted. In terms of the patient profile, 81%
of the practices' predominant patients were on medical aids with only 19% of the practices
having predominantly cash paying patients. 70.7% of the practitioners consulted without
appointments (on walk-in basis) and the remaining 29.3% consulted mainly by appointments
only.
Question 3 & 4: Duration in Private Practice and Period since Qualification:
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Figure: 6
The majority (70.7%) of the responding GPs were practicing for more than 10 years, 15.5%
GPs for between 5 to 10 years, and 13.8% GPs for less than five years. 50% of GPs had
qualified more than 20 years ago, 36.2% had qualified between 10 to 20 years ago, and only
13.8% had qualified less than 10 years ago.
71
Question 5.Frequency of the Pharmaceutical Representatives' Visits:
















The pharmaceutical reps called on 57 (98.3) of the respondents and the majority of the GPs
(72.4%) saw the pharmaceutical reps on walk-in basis without prior appointments. The GPs
were asked about the average frequency of visits by the pharmaceutical reps and what their
actual preference was.
From the Figure 7, it is evident that there are noticeable differences between the GPs'
preferences and the existing frequencies of sales calls by the pharmaceutical reps. Although
the majority (58.6%) still prefer the reps to visit every 4 to 6 weeks, it is significantly lower
than the actual 79.3% of the GPs receiving 4 to 6 weekly visits by the reps. Also there is just
over 10% further increases in the GPs' preferred frequencies of reps' call rates as opposed to
the actual fmdings for sales calls once every 7 - 11 weeks and once every 12 -16 weeks
respectively. These differences were statistically significant and were confirmed with the
Wilcoxon Signed Ranks Test (Appendix Ill). Wilcoxon Signed Ranks Test detects differences
in the distribution oftwo related variables (SPSS Results Coach). Small significance values
« 0.5) indicates that the two variables differ in distribution (SPSS Results Coach).
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Question 6 & 7: Duration of Visits by the Pharmaceutical Representatives:
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Again, there were significant differences between the actual and the preferred duration of the
time spent by the pharmaceutical representatives. On average, 65.5% of the promotional visits
by the reps lasted between 6-10 minutes when only 48.3% of the GPs preferred the visits to
last this duration. In addition, 48.3% of the GPs actually preferred the reps' visits to be
between 1-5 minutes compared to the current 25.9% receiving visits for the duration of 1-5
minutes. The preferences were also lower for the sales calls lasting between 11-15 minutes
and more than 15 minutes respectively, with no one preferring it to last more than 15 minutes.
These differences were also confirmed to be statistically significant with Wilcoxon Signed
Ranks Test (Appendix Ill).
Factors Relating to the Pharmaceutical Representative
Based upon the literature survey, twelve factors relating to the pharmaceutical representative
were established. Question 8 examined the relative importance of nine ofthe twelve factors to
the responding GPs. The respondents had to rank the relative importance based upon the
designed Likert Scale (from 1 = not important to 5 = absolute must). The remaining three
factors (Questions 9, 10, and 11) were presented as statements and the respondents had to
offer their opinion based upon Likert Scale (from No Opinion to Strongly Agree).
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8.1: The rep's expertise and knowledge of the drug and the medical condition for which it is
intended.
The majority of the GPs rated it an absolute must (62.1%) and very important (29.3%). The
remaining 8.6% rated it moderately important.
8.2: The rep's physical attractiveness.
25.9% of the GPs considered it as not important. It was slightly important to 29.3% and
moderately important to 31% ofthe GPs. Only 10.3% considered rep's physical attractiveness
very important and remaining 3.4% regarded it, as an absolute must factor.
8.3:The rep's personal grooming andpersonal attire.
The majority of the GPs considered this to be moderately to very important factor, 37.9% and
39.7% respectively. It was slightly important to 12.1% of the GPs and absolute must to 8.6%
ofthe GPs. Only 1.7% ofthe GPs did not considered it to have any importance.
8.4: The rep's command ofthe language and articulation.
The majority of the GPs (48.3%) considered this to be very important with further 15.5%
rating it as an absolute must. 31% of the GPs considered it moderately important, 1.7% as
slightly important and 3.4% said it was not important.
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8.5: The rep's educational background and qualification.
The majority (50%) of the GPs regard it as very important, 12.1% as an absolute must, and
31% as moderately important. 5.2% said it was not important and 1.7% said it was slightly
important.
8.6: The apparent honesty and integrity ofthe rep.
The majority (50%) of the GPs considered this to be an absolute must as a factor. Further
39.7% rated it as very important. 6.9% said it was moderately important and equal number
(1.7%) rated it as not important and slightly important.
8. 7: The use ofdetail-aids in their presentations.
The majority ofthe GPs rated it as moderately (36.2%) and very important (34.5%). 13.8% of
the GPs rated it as an absolute must, 10.3% as slightly important and 5.2% as not important.
8.8: The personality and the friendliness ofthe rep.
53.4% of the GPs rated this as very important and further 29.3% rated it as an absolute must.
The remaining 17.2% rated it as moderately important.
8.9: The professionalism ofthe presentation.
50% of the GPs considered it as very important and 39.7% considered it to be an absolute
must factor. 6.9% of the GPs rated it as moderately important and the remaining 3.4% rated it
as slightly important.
8.10: Others specify.
The following comments were made.
• "Not to slate/degrade competitors", rated as an absolute must.
• "Long standing experience", rated as very important.
• "Avoidance ofrepetitive detailing, i.e. know your doctor", rated as very important.
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Mean Rating of the Factors Relating to the Pharmaceutical Representatives
Mean Rating of Factors Relating to Reps
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Figure 10 shows the mean rating of the 'relative importance of the factors relating to the
pharmaceutical representatives', which are ranked in descending order according to their
mean scores in Table 8.
Rank Factors Relating to the Pharmaceutical Representatives Mean Score
1 8.1: The rep's expertise and knowledge ofthe drug 4.6
2 8.6: The apparent honesty and integrity ofthe rep 4.4
3 8.9:The professionalism ofthe presentation 4.3
4 8.8: The personality and the friendliness ofthe rep 4.2
5 8.4:The rep's command ofthe language and articulation 3.8
6 8.5:The rep's educational qualification 3.7
7 8.3: The rep's personal grooming and neatness in attire 3.5
7 8.7: The use ofdetail-aids in their presentations 3.5
9 8.2: The rep's physical attractiveness 2.5
Table: 8
The pharmaceutical rep's expertise and knowledge o/the drug and the condition/or which it
is intended, was found to be the most important factor. This confIrms the importance of the
credibility of the source in communication, as discussed in chapter 2. The next three
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important factors (ranked 2, 3, and 4 in the Table 8) were very close in their respective mean
scores. The professionalism ofthe presentation and the apparent honesty and the integrity of
the rep are also important factors contributing to the credibility of the source. The personality
and the friendliness of the rep contribute to the "attractiveness" in terms of familiarity and
likeability of the sender of the message as discussed by Koekemoer (1998). The rep's
command of the language used by the doctor was found to be the 5th most important factor
ahead of the rep's educational background (6th). The rep's personal grooming and attire and
the use of the detail-aids, were found to be joint 7th according to their mean score rating.
Despite the pharmaceutical companies' use of attractive well-groomed sales-persons,
especially ladies, to increase the persuasiveness of their message, the rep's physical
attractiveness was found to be the least important factor.
A Paired Samples Tests (t-tests) (appendix Ill) were done on above ranked successive factors
based on their mean scores. A result showing a low significance value « 0.05) implies that
there is a significant difference between the two variables. (SPSS Result Coach) Based upon
the results, there was statistically significant difference between factors 8.8 (the personality
and the friendliness of the rep) and 8.4 (the rep's command of your language and
articulation). There was also statistically significant difference between factors 8.7 (the use of
detail-aids in their presentations) and 8.2 (the rep's physical attractiveness). The remaining
Paired Samples Test did not show statistically significant differences between the ranked
factors.
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Question 9. The Reps from Scientific/Medical Background is More Persuasive.

























The vast majority (62.1%) of the respondents agreed and 5.2% strongly agreed with the
statement. 190.10 disagreed, 3.4% strongly disagreed and 10.3% had no opinion. This confirms
the previous discussion in chapter 2, that the reps from medical or scientific fields are
perceived to have greater credibility.
Question 10. Generally, Female Reps are More Persuasive than the Male Reps.






















24.1% ofthe responding GPs agreed that the female reps were generally more persuasive than
the male reps, but the majority (62.1%) of the responding GPs disagreed with the statement.
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5.2% strongly disagreed and 8.6% had no opinion. The responses were cross-tabulated with
the gender of the respondents. The result showed no correlation, i.e. the majority of male and
female respondents disagreed with the statement.
Question 11. Pharmaceutical Reps from Similar Cultural Background to the GP are More
Persuasive.
























Only 24.1% agreed and 3.4% strongly agreed that the reps from cultural background similar
to the GP are more persuasive in their presentations. The majority (63.8%) of the responding
GPs disagreed with the statement. 3.4% of the respondents strongly disagreed and 5.2% had
no opinion. Cross-tabulations with various demographic variables showed no statistical
significant relationships with any ofthe demographic variables.
Questions 12 & 13: Sources of New Drug Information and Sources ofInfluence to Induce Trial
Based upon the literature survey, seven sources/factors were established to assess their
relative importance as sources of new drug information and as sources of influence to induce
trial use of a new drug. An additional factor of 'sampling' was included in the assessment of
sources of influence to induce trial of a new drug. Question 12 examines the leading sources
of new drug information as ranked (from 1 = most common source to 3 = 3rd most common
source). Question 13 examines the leading sources of influence to induce trial of a new drug
(from 1 = most common influence to 3 = 3rd most common influence). After individual
analysis ofQuestion 12 and 13, the two are compared to determine the presence or absence of
any correlation between the two questions.
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Figure: 14
12.1: The pharmaceutical rep.
56.6% of the responding GPs rated the pharmaceutical rep as the most common source of
information for a new drug. 29.3% rated the rep as r most common and 8.6% rated the rep as
jrd most common sources of information.
12.2: The advertisement in the medicaljournal.
This was the most common source for 19%, 2"d most common source for 22.4%, and jrd most
common source for 25.6%, of information for a new drug for the responding GPs.
12.3: Research article in a medica/journal.
This was the most common source for 3.4%, r most common source for also another 3.4%,
and 3
rd
most common source for 6.9% ofthe respondents.
12.4: The specialist consultant in the field.
No one rated the specialist as the most common source. 10.3% of the respondents rated them
as r most common source and 15.5%of the respondents rated them as jrd most common
source.
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12.5: Other medical practitioners.
1.7% of the respondents rated it as the most common source. 3.4% of the respondents rated it
as r d most common source and was rated as 3rd most common source by 8.6% of the
respondents.
12.6: Direct mailfrom the drug company.
It was rated as the most common source by 8.6%, r d most common source for 5.2%, and 3rd
most common source for 6.9% ofthe respondents.
12. 7: Lecture sponsored by the drug company.
It was rated as the most common source by 10.3%, r d most common source by 25.9%, and 3rd
most common source by 27.6% ofthe respondents.
12.8: Other. Specify.
There were no respondents to this option.
Leading Three Sources ofInformation for a New Drug
Total
Total Not Most Common 2nd Most Common 3rd Most Common Percentage
Option Selecting Source Source Source Selecting
012.1 Respndents 3.0 33.0 17.0 5.0
Percentage 5.2% 56.9% 29.3% 8.6% 94.8%
012.2 Respndents 19.0 11.0 13.0 15.0
Percentage 32.8% 19.0% 22.4% 25.9% 67.3%
012.3 Respndents 50.0 2.0 2.0 4.0
Percentage 86.2% 3.4% 3.4% 6.9% 13.7%
012.4 Respndents 43 0.0 6 9
Percentaae 74.1% 0.0% 10.3% 15.5% 25.80%
012.5 Respndents 50 1 2 5
Percentage 86.2% 1.7% 3.4% 8.6% 13.70%
012.6 Respndents 46 5 3 4
Percentage 79.3% 8.6% 5.2% 6.9% 20.70%
012.7 Respndents 21 6 15 16
Percentage 36.2% 10.3% 25.9% 27.6% 63.80%
Table: 9
From Table 9 above, it can be seen that overall, the option 12.1 (the pharmaceutical rep) had
the best overall individual response rate (56.9%), with only 3 respondents not choosing it as
one of the leading three sources of information for a new drug, i.e. the pharmaceutical rep
had the highest individual response for the most common source (56.9%). The
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pharmaceutical rep also had the highest individual response rate for the category 2"d most
common source at 29.3%. This confIrms the views ofMacLean (2001) and Reekie and Weber
(1979: 120), that the pharmaceutical reps are the most important source of information about a
new drug. The findings also support the conclusion of Gillingham (1995) that the
pharmaceutical reps had an important role to play in continuing medical education ofdoctors.
Overall, the options 12.7 (lecture sponsored by the drug company) and 12.2 (the
advertisement in the medical journal) are rated joint third individual responses, based upon
their individual response rates of 25.9% each. However, option 12.7 (lectured sponsored by
the drug company) was ranked as r most common source of information, as opposed to
option 12.2 (the advertisement in medical journal), which had the highest individual response
rate for the category of3rd most common source of information.
When considering the total response rate (Table 9 ), i.e.selecting the option for any of the
three ranking alternatives for the common sources of drug information for a new drug, then
the following four options had the best cumulative responses (in descending order according
to the percentage):
1. (12.1) The pharmaceutical rep. (Total response rate= 94.8%)
2. (12.2) The advertisement in the medical journal. (Total response rate = 67.3%)
3. (12.7) Lecture sponsored by the drug company. (Total response rate = 63.8%)
4. (12.4) The specialist consultant in the field. (Total response rate = 25.8%)
From the above discussion, it is reasonable to conlude that the latter four options
(12.1 ;12.2;12.7 and 12.4) are, on average, the leading four sources ofdrug information for the
respondents according to their ranking as shown above.
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Question 13. Leading Three Factors Influencing the Use of a New Drug for the First Time
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Figure: 15
13.1: The pharmaceutical rep.
37.9% of the respondents rated it as the most common influence, 17.2% as the r d most
common influence, and 24.1% as the 3rd most common influence in encouraging the
respondent to use (trial) a new drug for the first time.
13.2: The advertisement in the medicaljournal.
3.4% ofthe respondents rated it as the most common influence, 5.2% as the r most common
influence, and 6.9% as the 3rd most common influence.
13.3:Research article in a medicaljournal.
13.8% of the respondents rated it as the most common influence, 5.2% as the r d most
common influence, and 5.2% as the 3rd most common influence.
13.4:The specialist consultant in the field.
8.6% of the respondents rated it as the most common influence, 25.9% as the r d most
common influence, and 17.2% as the 3rd most common influence.
13.5: Other medical practitioners.
No respondents chose it as the most common influence. 1.7% rated it as r d most common
influence, and 10.3% rated it as the 3rd most common influence.
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13.6: Direct mailfrom the drug company.
No respondents chose it as the most common influence. 1.7% rated it as the 2"'" most common
influence, and 6.9% rated it as the 3rd most common influence.
13. 7: The sample given by the rep.
20.7% of the respondents rated it as the most common influence. Further 31% of the




13.8: Lecture sponsored by the drug company.
15.5% of the respondents rated it as the most common influence, 10.3% as the 2"d most
common influence, and 24.1% rated it as the 3rd most common influence.
13.9: Other. Specify.
There were no respondents to this option.
Leading Three Factors Influencing the Use of a New Drug for the First Time
uptlonlfoT rPVfost Common 12nd Most common 3rd Most-Common lotal
Option Selected Influence Influence Influence Selecting
013.1 Respondents 12 22 10 14
Percentaoe 20.7% 37.9% 17.2% 24.1% 79.2%
013.2 Respondents 49 2 3 4
Percentaoe 84.5% 3.4% 5.2% 6.9% 15.5%
013.3 Resoondents 44 8 3 3
Percentaoe 75.9% 13.8% 5.2% 5.2% 24.2%
013.4 Respondents 28 5 15 10
Percentaoe 48.3% 8.6% 25.9% 17.2% 51.7%
013.5 Respondents 51 0 1 6
Percentage 87.9% 0.0% 1.7% 10.3% 12.0%
013.6 Respondents 53 0 1 4
Percentaae 91.4% 0.0% 1.7% 6.9% 8.6%
013.7 Resoondents 25 12 18 3
.Percentaoe 43.1% 20.7% 31.0% 5.2% 56.9%
013.8 Respondents 29 9 6 14
Percentage 50.0% 15.5% 10.3% 24.1% 49.9%
Table: 10
From Table 10 above, based upon the percentage of the respondents, option 13.1 (the
pharmaceutical rep) has the highest overall individual response rate which is also the highest
response rate for the most common influence at 37.9%. Option 13.7(The sample given by the
rep) had the second highest overall individual response rate at 31 % and it also had the highest
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response rate for the 2"'" most common influence. Option 13.4 (the specialist consultant in the
field) had the third highest individual response rate at 25.9% and it was also the second
highest individual response rate for the ranking of 2"d most common influence. Options 13.1
(the pharmaceutical rep) and 13.8 (lecture sponsored by the drug company) had the next
(fourth) highest individual response rates at 24.1% each. The latter two were also the joint
fIrst in the category of3rd most common influence.
When considering the total response rate (Table 10 ), i.e.selecting the option for any of the
three ranking alternatives for the sources of influence to encourage trial of a new drug, then
the following four options had the best cumulative responses (in descending order according
to the percentage):
1. (13.1) The pharmaceutical rep. (Total response rate = 79.2%)
2. (13.7) The sample given by the rep. (Total response rate = 56.9%)
3. (13.4) The specialist consultant in the field. (Total response rate = 51.7%)
4. (13.8) Lecture sponsored by the drug company. (Total response rate = 49.9%)
The leading source of drug information and the leading influence encouraging trial use of a
new drug, are identical, i.e. the pharmaceutical rep. The research supports the finding by
Wysong (1998) that the pharmaceutical reps are more likely to influence the doctors to
prescribe newer, more expensive drugs. The second most iIUluential factor to induce a new
drug trial, 'The sample given by the rep' is inextricably linked to 'the pharmaceutical rep', as
there can be no free sample without the rep to give it to the doctor. The findings of this
research contradict the findings of Gonul et al (2001) that detailing and sampling mostly have
an informative effect, but the findings are confirm that ofIMS Health (2002, paragraph 4) that
drug sampling "continues to play a significant role in physicians' prescribing decisions, more
than advertising".
Although 'the advertisement in a medical journal' was found to be the second most common
source of drug information for a new drug, it was a distant 6th factor for encouraging the trial
use of a new drug (based upon their cumulative response rates). Similar to the fmdings for the
sources ofdrug information, 'the specialist consultant in the field' and the' lecture sponsored
by a drug company' are also important influencers for encouraging the trial use 0 f a new drug,
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with 'the specialist consultant in the field' having a slightly greater influence than the 'lecture
sponsored by a drug company'.
Questions 14 & 15: Evaluation of Factors Influencing the prescribing Decisions
Questions 14 and 15 evaluate the relative influences of established factors on the GPs'
prescribing decisions for an existing and a new drug respectively. Identical factors were
evaluated for the both categories ofdrugs, with the inclusion ofdoctor's 'previous experience
with the drug' under Question 14 only, as for an obvious reason the latter cannot be
applicable for a new drug.
Question 14. The Relative Influence of Various Factors on the Prescribing Decision for an
Existing Drug
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Figure: 16
14.1: Your previous experience with the drug.
The majority of the respondents (72.4%) considered it to have a very strong influence. A
further 22.4% of the responding GPs considered it a strong influence. 3.4% rated it as a
moderate influence and the remaining 1.7% rated it to have no influence.
14.2: Recommendations by the specialist consultant.
22.4% of the respondents rated it to have a very strong influence, 46.6% rated it as a strong
influence, 27.6% rated it as moderate influence, and the remaining 3.4% rated it as a minor
influence.
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14.3: Information from the pharmaceutical rep.
60.3% of the respondents rated it as a moderate influence, 31% rated it as a strong influence,
6.9% rated it as a minor influence, and the remaining 1.7% rated it to have no influence.
14.4: Information from the medical journals.
44.8% of the respondents rated it as a strong influence, 12.1% rated it as a very strong
influence, 36.2% rated it as a moderate influence, and the remaining 6.9% rated it as a minor
influence.
14.5: Informationfrom the CMEICPD meetings.
The majority (55.2%) of the respondents rated it as a strong influence, with further 29.3%
rating it as a very strong influence. The percentage of respondents for no influence, minor
influence, and moderate influence were 3.4%,5.2%, and 6.9010 respectively.
14.6: Requestfrom the patient.
The majority (37.9%) ofthe respondents rated it to have a minor influence and further 29.3%
rated it to have a moderate influence. 22.4% of the respondents said it had no influence, with
6.9% and 3.4% of the respondents saying it had strong influence and very strong influence
respectively.
14. 7: The retail prices ofthe drug.
The majority (60.3%) of the respondents rated it to be a strong influence, with another 10.3%
stating it to be a very strong influence. The percentage of the respondents rating it no
influence, minor influence, and moderate influence were 3.4%, 6.9010, and 19% respectively.
14.8: Whether the drug is on the Medical Scheme's EDL.
The majority of the respondents rated it to have moderate to strong influence with 34.5%
rating it as moderate influence and 32.8% rating it as a strong influence. Only 8.6% rated it to
be a very strong influence. 10.3% ofthe respondents felt it had no influence and the remaining
13.8% rated it to have a minor influence.
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14.9: Product reminders, e.g. pens/note pads.
The majority of the respondents rated it to have minor to no influence with 24.1% stating no
influence and 43.1% stating it to have a minor influence. The percentage rating it moderate,
strong, and very strong influence were 190,/0, 12.1%, and 1.7% respectively.
14.10: An appealfrom the rep for your support.
The majority (46.6%) rated it to have a minor influence and 27.6% stated it to have no
in!Zuence. The percentage of the respondents rating it to have moderate, strong, and very
strong influences were 19%,5,2%, and 1.7% respectively.
14.11: How well you get along with the rep for that drug.
The majority (37.9%) of the respondents rated it to have a minor influence with another
29.3% rating it to have a moderate influence. 22.4% felt it had no influence. 8.6% rated it to
have a strong influence and 1.7% rating it to have a very strong influence.
14.12: The reputation/image ofthe drug company.
37.9% of the respondents felt it had a strong influence. 34.5% stated it to have a minor
influence and 20.7% stated it to have a moderate influence. The remaining 6.9% felt it had no
influence.
14.13. Other. Please specifY.
The following additional factors/comments were mentioned.
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Mean Scores of Factors Influencing Prescribing Decision for
an Existing Drug




Figure 17 shows the mean influential scores for the factors influencing the prescribing
decisions for an existing drug. These factors are listed in table 11: (Ranked in descending
order based on their mean scores)
Factors influencing the Prescribing Decision for an Existing Drug
Rank Factor Mean Score
1 (14.1) Doctor's previous experience with the drug 4.8
2 (14.5) Information from the CME/CPD meetings 4.2
3 (14.2) Recommendation by the specialist consultant 4.1
4 (14.7) The retail price ofthe drug 3.9
5 (14.4) Information from the medical journals 3.8
6 (14.3) Information from the pharmaceutical rep. 3.4
6 (14.8) Whether the drug is on Medical Scheme's EDL 3.4
8 (14.12) The reputation/image of the company 3.1
9 (14.6) Request from the patient 2.5
9 (14.9) Product reminders, e.g. pens/note pads. 2.5
9 (14.11) How well the doctor gets along with the rep 2.5
12 (14.10) An appeal from the rep for the doctor's support 2.3
Table: 11
From Table 11 above, factor 14.1 (doctor's previous experience with the drug) was the
highest rated factor. The findings of this research show a reversal of ranking compared to the
fmdings ofFriedman (1991) who ranked the specialist consultant as 2nd and CME meetings as
3
rd
according to their mean influential scores. This is possibly due to the increased importance
of CME/CPD meetings to the GPs to obtain CPD points for continued registration with the
regulatory body, Health Professional Council of South Africa (HPCSA). Factors 14.3 and
14.8 had identical mean influential scores and are therefore ranked joint 6th• Similarly, factors
14.6, 14.9, and 14.11 also had identical mean influential scores and are thus ranked joint 9th•
Paired Samples Tests (appendix Ill) demonstrated statistically significant difference between
factors 14.1 (ranked 1st) and 14.5 (ranked 2nd) at 95% confidence level. Thereafter Paired
Samples Tests were done pairing factors 14.5, 14.2, 14.7, and 14.4 with factor 14.3. The
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results show all of them to be statistically different from factor 14.3, i.e. there were
statistically significant differences when information from CMEICPD meetings,
recommendation by the specialist consultant, the retail price of the drug, and information
from the medicaljournals where paired with information from the pharmaceutical rep.
Question 15. The Relative Influence of Various Factors on the Prescribing Decision for a
New Drug
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Figure: 18
15.1: Recommendation by the specialist consultant.
The majority (46.6%) of the respondents rated it as a strong influence, with further 25.9%
rating it as a very strong influence. 25.9% considered it a moderate influence and the
remaining 1.7% rated it as a minor influence.
This factor was cross-tabulated with factor 12.4 (the specialist consultant in the field as the
source ofnew drug information). The result is shown in Figure 19.
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Figure: 19
The cross-tabulation (Figure 19) showed that, from the respondents who ranked the Specialist
consultant as the r d most common source of new drug information, 4 rated it to have a strong
influence, and 2 rated it as a very strong influence. Those respondents who ranked the
Specialist consultant as the 3rd most common source, 2 rated it as moderate influence, 5 rated
it as strong influence, and 2 rated it as a very strong influence.
15.2: Information from the pharmaceutical rep.
The majority (53.4%) of the respondents considered it a moderate influence, 32.8% a strong
















This factor was cross-tabulated with factor 12.1 (the pharmaceutical rep as the source of new
drug information). The result is shown in Figure 20.
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Figure: 20
From the respondents who ranked the pharmaceutical rep as the most common source, 17
respondents rated the information from the rep to have a moderate influence, 13 respondents
rated it to have a strong influence, and 1 respondent rated it to have a very strong influence.
From the respondents who ranked the rep as the 2"d most common source of new drug
information, 10 also rated it to have a moderate influence, 2 rated it as a strong influence, and
2 rated it as a very strong influence. Those respondents who ranked the pharmaceutical rep as
3
rd
most common source, 1 rated it as moderate influence and 4 rated it as a strong influence.
Factors 15.2 and 12.1 were further cross-tabulated with the factor 13.1 (the pharmaceutical
rep as the influence to induce trial use ofthe drug). The result (Figure: 21) revealed that from
the respondents who ranked the pharmaceutical rep as the most common source of new drug
information and the most common influence to induce trial use, 8 rated it as moderate
influence, 8 rated it as strong influence, and 1 rated it as a very strong influence. Also those
that rated the reps as the most common source but rated them as the 2"d most common
influence, 1 rated it as moderate influence and 1 rated it as a strong influence.
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Figure: 21
15.3: Informationfrom the medicaljournal.
The majority (50%) rated it as a strong influence, 34.5% as a moderate influence and 12.1%
as a very strong influence. The remaining 3.4% rated it as a minor influence.
This factor was cross-tabulated with factor 12.2 (the advertisement in the medicaljournals as
the source ofnew drug information). The result is shown in Figure 22.











Most CommonSource 2nd Most Common Source 3rd Most Common Source
Answers
OModerate Influence DStrong Influence • Very Strong Influence
Figure: 22
From the respondents who ranked the advertisement in the medical journals as the most




influence, 7 respondents rated it to have a strong influence, and 2 respondents rated it to have
a very strong influence. From the respondents who ranked the journals as the ;rJ most
common source of new drug information, 6 also rated it to have a moderate influence, 5 rated
it as strong influence, and 2 rated it as a very strong influence. Those respondents who ranked
the medical journals as 3rd most common source, 4 rated it as moderate influence, 7 rated it as
strong influence, and 3 rated it as a very strong influence.
15.4: Informationfrom the CMEICPD meetings.
The majority (62.1 %) rated it as a strong influence with further 27.6% rating it as a very
strong influence. 8.6% rated it as a moderate influence and the remaining 1.7% rated it as a
minor influence.
This factor was cross-tabulated with factor 12.7, lectures sponsored by the drug company,
(Figure 23).
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Figure: 23
From the respondents who ranked the sponsored lectures as the most common source, I
respondents rated the information from the CME/CPD meetings to have a moderate influence,
4 respondents rated it to have a strong influence, and 1 respondent rated it to have a very
strong influence. From the respondents who ranked the sponsored lectures as the ;rJ most
common source of new drug information, 10 rated it as strong influence, and 4 rated it as a
very strong influence. Those respondents who ranked the sponsored lectures as the 3rd most
common source, 2 rated it as moderate influence, 9 rated it as strong influence, and 5 rated it
as a very strong influence.
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15.5: Requestfrom the patient.
The majority (41.4%) rated it as a minor influence, 22.4% as a moderate influence and 10.3%
as a strong influence. The remaining 25.9% said that it had no influence.
15.6: The retail price ofthe drug.
The majority (39.7%) rated it as a strong influence, followed by 37.9% rating it as a moderate
influence. 10.3% rated it as a very strong influence. 8.6% rated it as a minor influence and the
remaining 3.4% rated it as no influence.
15. 7: Whether the drug is on the Medical Scheme's EDL.
36.2% rated it as a moderate influence, followed by 24.1% who rated it as a strong influence.
10.3% rated it to have a very strong influence. 15.5% rated it as a minor influence and the
remaining 13.8% said it had no influence.
15.8: Product reminders, e.g. pens/note pads.
32.8% rated it to have a minor influence, followed by 31 % rating it have no influence. 25.9%
rated it to have a moderate influence and the remaining 10.3% rating it to have a very strong
influence.
15.9: An appealfrom the rep for your support.
The majority (43.1%) rated it to have a minor influence, followed by 32.8% rating it to have
no influence. 19% rated it as a moderate influence, 1.7% as a strong influence and the
remaining 3.4% as a very strong influence.
15.10: How well you get along with the rep for that drug.
The majority (39.7%) rated it to have a minor influence, followed by 27.6% rating it to have
no influence. 17.2% rated it as a moderate influence, 13,8% rated it as a strong influence and
the remaining 1.7% as a very strong influence.
15.11: The reputation/image ofthe drug company.
31.1% rated it to have a strong influence. Equal number (27.6%) rated it to have moderate and
minor influence. The remaining 13.8% rated it to have no influence.
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5.12: Other. Specify.
The following were mentioned.
• "Adverse reactions."
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Figure: 24
Figure 24 depicts the mean influential scores for the prescribing decision for a new drug.
These factors are ranked in descending order, based on their mean scores, and listed in Table
12.
Factors influencing the Prescribing Decision for a New Drug
Rank Factor Mean score
1 (15.4) Information from the CME/CPD meetings 4.3
2 (15.1) Recommendation by the specialist consultant 4.2
3 (15.3) Information from the medical journals 3.9
4 (15.6) The retail price ofthe drug 3.7
5 (15.2) Information from the pharmaceutical rep 3.5
6 (15.7) Whether the drug is on the Medical scheme's EDL 3.2
7 (15.11) The reputation/image ofthe drug company 3.0
8 (15.5) Request from the patient 2.4
8 (15.8) Product reminders, e.g. pens, note pads. 2.4
8 (15.10) How well you get along with the rep for that drug 2.4
11 (15.9) An appeal from the rep for your support 2.2
Table: 12
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The additional factor of doctor's previous experience with the drug (as an influential factor
for an existing drug, in Question 14) was the highest rated influential factor for the
prescribing decision for an existing drug (mean score = 4.8). As this factor cannot be
applicable for a prescribing decision of new drug, the factors rated subsequently in the Table
11 will be compared with the findings in Table 12.
The highest rated influential factor for a new drug (informationfrom the CMElCPD meetings)
is also the highest rated (after ignoring factor 14.1) for an existing drug with similar mean
score ratings (4.3 for an existing vs. 4.2 for a new drug). The recommendation by the
specialist consultant is the following factor in both categories, i.e. existing vs. new drug. The
latter factor also has similar mean scores for both existing and new drugs. Again, there was
reversal ofranking compared to the findings ofFriedman (1991), as discussed under Question
14.
Information from the medical journal is slightly more important influential factor for a new
drug compared to the retail price of the drug, which has a slightly more importance than the
Information from the medicaljournal in the case of an existing drug. The high ranking for the
retail price ofthe drug (price-sensitivity), supports the finding by Gonul et al (2001) that the
physicians were more price-sensitive for private insurance patients (similar to the medical aid
schemes in South Africa). The information from the pharmaceutical rep as an influential
factor follows all above factors in both categories, i.e. it is ranked 6th for an existing drug and
ranked 5th for a new drug. The research fmdings also support the Marplan Study (1981) where
the medical journals and CME meetings were found to be more influential than the
pharmaceutical reps. Factors 15.5, 15.8, and 15.10 have identical mean influential scores and
are thus ranked joint 8th•
Paired Samples Tests (appendix Ill) were done comparing the mean influential scores. The
difference between factors 15.4 and 15.1 was not statistically significant at 95% confidence
level. However, the differences between factors 15.1 and 15.3 individually paired with factor
15.2 showed them to be statistically significant. The difference between factors 15.6 and 15.2
was not statistically significant. Therefore the mean influential scores for recommendation by
the specialist consultant and information from the medical journals were significantly
different from the mean influential score for information from the pharmaceutical rep.
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Question 16. Evaluation of basic statistical knowledge of the GPs.
Three questions were designed to evaluate the respondents' appreciation of basic statistics
since majority of the reps use 'statistical' data to demonstrate the supposed superiority oftheir
drug.
16.1: Do you generally check if the study quoted in the rep's detail-aids is an independent or
a company sponsored study?











56.9% ofthe respondents stated YES and 43.1 % stated NO.
16.2: Do you check ifthe statistical information is misquoted or misleading?













65.5% ofthe respondents stated YES and 34.5% stated NO.
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16.3:Are you reasonably able to critically evaluate the statistical elements ofthe information
presented to you? For example, the 'p' value.











53.4% ofthe respondents stated NO and 46.6% stated YES. 10 respondents answered YES to
all 3 questions. From the Respondents who said YES to 16.1 and 16.2, 17 respondents went
on to say NO to 16.3.
Question 17. Evaluates the Respondents' Opinion on Promotion of Pharmaceutical Drugs.
17.1: In your opinion, do you feel that the free non-medically related give-aways {'Gifts') by
the pharmaceutical companies are unethical promotional practices?













The majority (79.3%) of the respondents stated NO, with only 20.7% answering YES.
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17.2: Do the 'Gifts" result in the doctor feeling obligated to prescribe the sponsoring
company's drug?











The majority (77.6%) stated NO with only 22.4 stating YES.












17ii Yes 17ii No
Answers
1-17iYes C17i No I
Figure: 30
Forty respondents said NO to both. Seven respondents answered YES to both 17.1 and 17.2.
Six respondents, who said NO to 17.1, went on to say YES to 17.2. Five respondents, who said
YES to 17.1, went on to say NO to 17.2. The differences in opinions with the majority of the
respondents believing that there is minimal ethical risk are consistent with the fmdings of
Waud (1992).
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Question 18: Please specify if there are any other factors not mentioned in the questionnaire,
which may influence your decision to prescribe a pharmaceutical drug.
The following additional factors/comments were mentioned:
• "Sponsorship to medical congresses by a pharmaceutical company, in my opinion,
will greatly influence a doctor to prescribe a particular drug. "
• "The community I am dealing with and the illness ofthe patient. "
• "The restrictions imposed by managed care organisations. Threats by medical aids to
stop payment if the practice profiles are out of 'norm'. "
• "Sampling ofdrugs esp. new is essential. Often poorfeedback from patient esp. if they
get better. They tend to forget to notify you. "
• "Companies that slate other companies should be censured. The individual companies
must sell us product on its own merit. "
• "Where there are numerous ofthe same type ofdrug on the market - relationship with
the reps andpromotional perks are deciding factors. "
•
1. The cost-effectiveness (price) ofthe drug.
2. Being provided with samples.
3. Attending a product launch.
4. Influence ofcolleagues.
5. Promotional literature and review articles.
6. Product monographs and literature. "
• "The govt. meddling is pissing me offand killing offthe multinationals. "
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CHAPTER 8: CONCLUSIONS AND RECOMMENDATIONS
8.1 CONCLUSIONS
This research study has attempted to determine and grade the perceived influences of various
factors on the general practitioners' (GPs') choice of prescription drugs. One of the crucial
aims of the study was to investigate the promotional activity of the pharmaceutical
representatives in order to determine the relative importance of various characteristics of the
promotion by the pharmaceutical reps. Previous studies by Piu and Ne! (1988), Wysong
(1998), and MacLean (2001) had shown that, of all promotional activities undertaken by the
pharmaceutical companies, the pharmaceutical representatives had the greatest influence on
the GPs' prescribing behaviour.
This research had a very good response rate of 87%, which minimises but does not exclude
non-response error. The opinions of the non-respondents stay unquantifiable. The descriptive
nature of the research allows inferences to be drawn for a larger population. The results ofthe
research satisfied all stated objectives, as well as offered an insight into some additional
issues.
There was a predominance of male respondents in the survey, similar to the surveys Pitt and
Nel (1988), Friedman (1991), and Gillingham (1995). Similar to the latter mentioned studies,
the gender of the respondents was not found to have any significant influence on the GPs'
receptiveness to the various determinants of prescribing behaviour. This is bearing in mind
that similar to Pitt andNel (1988), only 12% ofthe respondents were female. The majority of
the respondents were in solo, predominantly dispensing practices that were contracted to
medical aid schemes and had predominantly medical aid patients on their register. The fact
that the majority of the respondents were contracted to the medical aid schemes and thus
reimbursed by the said third party health care funders, appears to have a significant influence
on the GPs' choice ofprescription drugs as will be discussed below. Similar to the findings by
Piu and Nel (1988), there was no clear relationship between the number of years in private
practice and the perceived influence of identified factors on the GPs' prescribing habits. The
majority (50%) of the GPs were in private practice for more than 10 years and had qualified
more than 20 years ago.
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The GPs' personal experience with a drug was established to be the most important
prescribing influence for an existing drug. The mean score rating for the influential factor of
"previous experience with the drufi' was consistent with the GPs' perception of it as a very
strong influence. This finding is consistent with the fmdings by Pitt and Nel (1988) and
Friedman (1991), who also ranked the doctor's personal experience with a drug as the most
influential factor on the doctor's prescribing habits. The finding also supports Srivastava
(2003) who notes that the doctors most readily accepted the drugs that were experienced to
have a "better efficacy", and Koekemoer (1987:33) who states that the learning experience is
critical in bringing about a change in prescribing habit.
There were major differences noted in the subsequent ranking of the influential factors.
Information from CME/CPD meetings was the second most influential factor for an existing
drug and the most dominant influence on prescribing decision of a new drug. The mean score
rating for the latter factor was consistent with the GPs perception of it as a strong influence.
This factor was also ranked 2nd in the Marplan Study (1981) and 4th in the study by Pitt and
Net (1988), and 3rd in the study by Friedman (1991). The most likely explanation for the
strong perceived influence ofCME/CPD meetings is the introduction in 1999, of compulsory
attainment of annual prescribed minimum CPD points by the medical practitioners, to
maintain their annual registration with the Health Professions Council of South Africa
(HPCSA).
The third most influential factor for prescribing an existing drug, as perceived by the GPs was
the "recommendations from the specialist'. The latter was also the second most influential
factor for the prescribing of a new drug. It was perceived to be a strong influence for both
existing and new drugs. Friedman (1991) found the specialist's advice to be the second most
important influence. The information from the medical journals and the retail price of the
drug were found to be fourth and fifth influential factors for an existing drug and third and
fourth for a new drug respectively. They were more influential than the pharmaceutical rep
that was ranked sixth for prescribing an existing drug. These fmdings applied to the
prescribing decisions for the existing as well as the new drugs. The fourth and fifth ranked
factors were also perceived to have strong influences. Pitt and Nel (1988) did not consider the
influence of articles from medical journals in their research. The fmding of this research
shows the iriformation from medical journals to be a strong and more influential than the
pharmaceutical rep.
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The retail price of the drug emerged as an important factor for the prescribing decisions of
both existing and new drugs. The importance of price-sensitivity of the prescribing doctors,
confirm the similar finding by Friedman (1991) and Gonul et al (2001). Significantly, it was
ranked above the pharmaceutical rep as an influential factor. Srivastava (2003) also found the
cost-effectiveness of the drug to be the third most important factor for better acceptance of a
pharmaceutical drug. The finding can also be ascribed to the fact that the majority of the
responding GPs were contracted to the medical schemes and had a patient profile of
predominantly medical aid patients. Most medical schemes will only pay for the generic drugs
where available and require special motivation from the prescribing doctor for more
expensive ethical drugs.
In this study, the pharmaceutical rep was ranked sixth and fifth as an influential factor for the
prescribing decision of an existing and a new drug respectively. This is notable departure
from the finding ofPitt and Nel (1988) where it was ranked third and Friedman (1991) where
it was ranked tenth. In the Marplan Study (1981) it was also ranked sixth. It also contradicts
Srivastava's (2003) finding of "regular reminder by medical representatives" to be the second
most reason for better acceptance of pharmaceutical drugs by the doctors. This demonstrates
that more doctors now rely on the information from CME meetings, the advice of a specialist
(opinion leader), the information from the scientific/ medical journals, and the cost ofthe drug
more than the information obtained from the pharmaceutical representative. This will be an
appreciated fmding for Komesaroff and Kerridge (2002) and Wazana (2000), who raised
concerns about the ethical controversy with respect to the influence of the pharmaceutical
representatives on the doctors' prescribing decisions.
As mentioned previously, one of the main objectives of this research study was to determine
the relative importance of various characteristics of the promotion by the pharmaceutical
representatives. The key factors (according to their ranking) relating to the pharmaceutical
representatives were established to be: (1) the rep's expertise and knowledge of the drug and
the relevant medical condition, (2) the apparent honesty and integrity of the rep, (3) the
professionalism ofthe presentation, and (4) the personality and the friendliness of the rep.
"The rep's expertise and knowledge ..." was assessed to be an absolute must with its mean
score rating of almost 5. The three subsequently ranked attributes (2 to 4) were concluded to
be very important with their mean score ratings between 4.0 and 4.4. The top three ranked
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factors reflect on the credibility of the sender in persuasive communication and confrrm them
as the key variables influencing communication as described by Koekemoer (1998) and
Schiffman and Kanuk (1994). The fourth ranked factor, "The personality and the friendliness
of the rep", reflects on the' source attractiveness' in terms of ,likeability' as put forward by
Koekemoer (1998). It also supports Koekemoer's (1998) view that the communication is
more likely to be persuasive when the receiver finds the source of the message 'attractive'.
The actual physical attractiveness ofthe reps was found to be the least important factor. There
was also an additional comment (question 18) by one of the respondents that "where there are
numerous [brands] of the same type of drug on the market - [the] relationship with the reps
and promotional perks are deciding factors".
The majority of the respondents also agreed that the pharmaceutical rep from a scientific or a
medically allied field was likely to be more persuasive in his/her presentation than a rep from
another background. The majority ofthe respondents did not fmd the female reps and the reps
from a cultural background similar to the doctor, to be more persuasive in their presentations
as was suggested by Koekemoer (1998: 45).
There were significant differences in the respondent's preferences with respect to the current
frequency and the duration of the rep's visits to the GPs. Many preferred less frequent calls
and shorter duration of the visits. Only 56% preferred the current 4 to 6 weekly call rates used
by the reps and an equal percentage of respondents (48.3%) preferred the duration of the calls
to be between 1 to 5 minutes or between 6 to 10 minutes. The fmdings support the
recommendation by Gonul et at (2001) that the scope of personal selling be more carefully
scheduled in terms of frequency of sales calls on physicians and the length of the detailing
visits.
The pharmaceutical rep emerged as the most common source of new drug information. This
confirms the fmding of MacLean (2001) that the pharmaceutical reps are the most important
source of information about a new drug. The advertisement in the medical journal, the lecture
sponsored by the drug company, and the specialist were established to be the second, third,
and fourth most common sources of information for a new drug. The findings also support
lones et at (2001) who found that the pharmaceutical promotions and the specialist especially
influenced general practitioners.
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The most dominant influence to induce trial of a new drug was also the pharmaceutical
representative. Sampling as a promotional practice was found to be the second most common
influence to induce trial of a new drug. These fmdings support Srivastava (2003) whose
research revealed that repeated visits by medical reps (ranked 1st ) and sample (ranked 2
nd
)
improved doctors' brand recall and drug trial. The practice of sampling also facilitates direct
experience by the doctor, thus increasing the prescriber's personal product experience. It is
yet too early to determine the impact of the recent legislative change, prohibiting the drug
sampling as a promotional tool, which came into effect on the 2nd May 2003.
The specialist consultants (opinion leaders) were third most common influence to induce trial
use of a new drug. The lectures (CME/CPD meetings), which are largely sponsored by the
drug companies, were ranked fourth as an influential factor to induce a trial use ofa new drug.
Advertisement in medical journals, which emerged as the 2nd most common source of new
drug information, was rated 6th, as the influential factor to induce trial use ofa new drug.
When the factors that influence a trial use of a new drug were compared to the factors that
influence more regular prescribing of a new drug, differences were noted. Although, the
pharmaceutical representative was the most influential factor to induce a new drug trial by a
doctor, it was ranked fifth as an influence for more regular prescribing of a new drug.
CME/CPD meetings were found to be the most dominant influence for regular prescribing of
a new drug followed by the recommendation by the specialist consultant. Wazana (2000) had
also established that there was an increased prescription rate of sponsor's medication from
attending sponsored CME by the pharmaceutical speaker.
The evaluation of the respondents' understanding of basic statistical information used by the
pharmaceutical representatives in their presentations, revealed that the majority ofthe GPs did
check if the clinical studies quoted in the detail-aids originated from an independent source or
not and whether, there was any misrepresentation. However, a significant proportion (53.4%)
of the GPs subsequently cited inability to critically evaluate the statistical elements of the
excerpts of the clinical studies quoted in the detail-aids. This raises the question of how
exactly did the GPs verify that the quoted statistical information was not misrepresented or
misleading. It is the researcher's opinion that this limitation may cause the GPs to fail to take
notice when there are discrepancies in the comparative data or when biased views are
presented at the pharmaceutical company sponsored CME/CPD meeting(s) as suggested by
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Schuklenk (2001). The research has already established the important influence of the
CME/CPD meetings on the GPs' prescribing behaviour.
Most surprisingly, the majority of the GPs felt that the "gifts" were not unethical promotional
practices and that these "gifts" did not result in the obligation to prescribe the sponsoring
company's drug. This is contrary to the findings of MacLean (2001 :3), who found that as
many as 70% ofthe physician's prescribing could be compromised by accepting "gifts".
The additional comments by the respondents augment the study's fmding of importance of
direct experience with the drug, the importance of credibility and professionalism of the
pharmaceutical representative, the influence of third parties such as medical aid schemes and
government, and the importance ofCME/CPD meetings.
8.2 LIMITATIONS
Only general practitioners in private practice were surveyed. All specialists and general
practitioners in public service were excluded. Area sampling was limited to two suburbs. The
ethnic predominance of Asian doctors in the study as a limitation was discussed under
research methodology. Although every precaution was taken, the possibility of missing
elements cannot be excluded. A possibility of response bias with respect to the assessment of
the influence of "gifts' on the GPs' prescribing behaviour cannot be excluded. While
inferences can be drawn for a larger population, the results are strictly valid for the area
(Pietermaritzburg) where the survey was conducted. The relatively small size of the sample
(although statistically significant) is obviously a limitation.
8.3 RECOMMENDATIONS
Firstly, it is recommended that an attempt be made to duplicate this study in other regions
with a larger randomly chosen sample size. The study should also be carried out with a
random sample of specialist consultants only. It will be useful to determine the influential
factors for the specialist since the specialists were found to have a significant influence on the
prescribing behaviour of the GPs. The findings support the recommendation by Pitt and Nel
(1988) of identifying the important influential factors on specialists (opinion leaders).
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Due to the prohibition on drug sampling from 2nd May 2003, the pharmaceutical companies
can no longer facilitate the medical practitioners' direct experience by means of a free drug
sample. Personal experience with the drug was shown to have the strongest influence on the
GPs' prescribing behaviour in this research as well as those of Friedman (1991) and Pitt and
Nel (1988. It is thus recommended that the pharmaceutical companies make available in the
marketplace, the same 'starter packs' that were previously used for drug sampling, for
initiation of therapy by the physicians. This will help to drastically lower the cost of initiation
of therapy by virtue of the small quantity ofdrug in the starter pack, as well as facilitate direct
.experience by the prescribing doctors.
The pharmaceutical compames should also critically evaluate their allocation of the
promotional budget. Greater promotional allocation is recommended towards the sponsorship
ofCME/CPD meetings and clinical trials by the local specialists based on the findings of their
compelling influential factor ranking in this research as discussed under conclusion. It is also
recommended that the specialists selected, are those who are not only regarded and respected
as authorities in the field, but also perceived to render independent, unbiased opinions. This
will greatly improve the source (specialist's) credibility and the acceptance of the message by
the receivers (GPs) as suggested by Koekemoer (1998: 45-49). The companies will also have
to take into consideration the emergence of price-sensitivity as a very important influential
factor for prescribing decisions and give an added consideration to the pricing component of
the marketing mix.
The companies should preferably employ people from scientific/medically-allied fields as
pharmaceutical reps. There should also be regular review and training of the pharmaceutical
reps to maintain a high level of credibility and professionalism as the latter were perceived to
be the most important characteristics of the pharmaceutical reps. The pharmaceutical reps
should also frankly determine the doctor's preferred frequency and duration of calls and
comply with these preferences rather than strictly following the pharmaceutical companies'
existing guidelines of 4-6 weekly calls on the selected segment ofdoctors. This will improve
the doctor-pharmaceutical rep relationship and improve persuasiveness of the pharmaceutical
reps.
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Based on the findings of this study, the persuasiveness of the "gifts" to the doctor is
questionable and together with the independent ethics views expressed, this promotional
practice should be severely curtailed or stopped completely.
Furthermore, the medical schools should undertake to educate the undergraduate students in
basic statistical evaluation ofresearch articles and create awareness offactors that may lead to
inappropriate prescribing.
8.4 AREAS OF FURTHER RESEARCH
Future research should explore the impact of the various new legislative changes that have
come into effect in South Africa recently, as well as those coming into effect over the next
two years. The important influential factors for the prescribing behaviour of the specialists
should also be researched. An area not covered in this research was the medical practitioner's
motivation/reason for agreeing to see the pharmaceutical reps. For example, is it to obtain
information on drugs? Does it represent a break in the routine? Alternatively, is it because
they enjoy receiving "gifts"? Given the unique history of South Africa, future researchers
should also attempt to determine if there are any differences in the prescribing behaviour of
doctors from different ethnic backgrounds.
Other important areas of future research are the extent and the type ofthe influence exerted by
the managed care organisations such as medical schemes/insurance groups and the criteria
used by the medical practitioners in choosing between ethical and generic drugs. With respect
to the latter, it is important to determine the additional factors besides the lower cost of the
generic medications. It may also be interesting to see, by means of consumer (patients)
research, the effectiveness of the current direct-to-consumer corporate advertising and if its
influence extends to the other drugs manufactured by the pharmaceutical company.
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I am currently completing my Masters in Business Administration at the University of
Natal, Pietermaritzburg. As a part ofthe qualification I am required to carry out primary
research towards a masters thesis. My research topic is an evaluation of the factors
influencing family practitioners' choice ofprescription drugs.
Like you, I am a family practitioner in Pietermaritzburg and I fully understand the
demands made on your valuable time. Therefore please accept my apologies for this
imposition. It would be appreciated if you would spare ten minutes of your valuable
time to answer this questionnaire, which will aid my research.
You are not required to fill in your name or other personal identifying information.
Therefore, all respondents will remain totally anonymous. The information collected is
strictly confidential and for research purposes only. The research is not for commercial
publication or for sale to any company.
I would appreciate it if you could answer the questions as openly as possible and not
discuss the questionnaire with your colleagues, so as to make the findings as reliable
and accurate as possible.
I would be happy to clarify any concerns or questions and can be reached at above given
contact details or at the following cellular number: 083 786 8798. Please accept my




Please indicate your answer with a (X) in the appropriate box/over the appropriate
number. Pharmaceutical representative herein also referred to as 'sales reps/reps'.
1. Gender:
2. Type ofgeneral practice:























3. Number of years in private practice:
a) More than 10 years:
b) Between 5 to 10 years:
c) Less than 5 years:
4. When did you qualify as a medical doctor?
a) Less than 10 years ago: §
b) Between 10 to 20 years ago:
c) More than 20 years ago:
5. Do pharmaceutical representatives call on your practice') Yes: D No: D
If yes, then,
a) How do you see them? By appointment only: D Walk-in basis: 0
b) On average, how often do the reps call on you?
i) Once every 4 - 6 weeks ... . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . §
ii) Once every 7 - 11 weeks .
iii) Once every 12 - 16 weeks .
c) How often would YOU prefer for the sales reps to call on you?
i) Once every 4 - 6 weeks '" §
ii) Once every 7 - 11 weeks .
iii) Once every 12 - 16 weeks .
1
10. Female reps are generally more persuasive than the male reps in their






11. The reps from the cultural background similar to the doctor are generally more






12. Generally, how do you first learn about a new drug? i.e. what is your first source
of information for a new drug? Please read all options given below, and then
select the LEADING THREE OPTIONS and rank them in order of
importance; i.e. 1 = most common source, 2 = 2nd and 3 = 3n1 most common
sources.
12.1) The pharmaceutical rep .
1:2.2) The adveltisement in a medical journal .
123) Research alticle in a medical journal .
12.4) The specialist consultant in the field .
12.5) Other medical practitioners .
1:2.6) Direct mail from the drug company ..
12.7) Lecture sponsored by the drug company .
12.8) Other: specify .
13. Please indicate who/what encouraged you to use a new drug for the first time.
Please read all options given below, and then select the LEADING THREE
OPTIONS and rank them in ORDER OF INFLUENCE: i.e.
t = most common influence, 2 = 2nd and 3 = 3n1 most common influences.
13.1) The pharmaceutical rep ..
13.2) The advertisement in a medical journal. .
13.3) Research article in a medical journal. .
13.4) The specialist consultant in the field .
13.5) Other medical practitioners .
13.6) Direct mail from the dmg company ..
13.7) The sample given by the rep ..
13.8) Lecture sponsored by the drug company .
13.9) Other: specify .
3
14. Please rate the relative influence of the following on your prescribing decision
for an EXISTING DRUG.
(Where: 1 = no influence; 2 = minor influence; 3 = moderate influence;
4 = strong influence; 5 = very strong influence)
14.1) Your previous experiences with the drug.
14.2) Recommendations by the specialist consultant.
14.3) Information from the pharmaceutical rep.
14.4) Information from the medical journals.
14.5) Information from the CME/CPD meetings.
14.6) Request from the patient.
14.7) The retail price of the drug.
14.8) Whether the drug is on Medical scheme's EDL.
14.9) Product reminders, e.g. pens/note pads.
14.10) An appeal from the rep for your support.
14. 11) How well you get along with the rep for that drug.
14.12) The reputation/image of the drug company.
14.13) Other: please specify .
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
15. Please rate the relative influence of the following on your prescribing decision
for a NEW DRUG.
(Where: 1 = no influence; 2 = minor influence; 3 = moderate influence;
4 = strong influence; 5= very strong influence)
15.1) Recommendations by the specialist consultant.
15.2) Information from the pharmaceutical rep.
15.3) Information from the medical journals.
15.4) Information from the CME/CPD meetings.
15.5) Request from the patient.
15.6) The retail price of the drug.
15.7) Whether the drug is on Medical scheme's EDL.
15.8) Product reminders, e.g. pens/note pads.
15.9) An appeal from the rep for your support.
15. 10) How well you get along with the rep for that drug.
15. 11) The reputation/image of the drug company.
15.12) Other: please specify .
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
(1) (2) (3) (4) (5)
16. With regards to the detail-aids/graphical extracts from clinical studies, used in
the presentations by the pharmaceutical reps:
16.1) Do you generally check if the study quoted was an independent
or a company sponsored study?
Yes:D No:D
16.2) Do you generally check if the statistical information quoted in the
presentation is accurate or distorted/misleading? For example, do you




16.3) Are you reasonably able to critically evaluate the statistical elements
of the information presented to you? For example, the 'p' value.
Yes:D No: D
17. In your opinion, do you feel that the free non-medically related give-aways by
pharmaceutical companies (e.g. pens, towels, sweets/chocolates, meals at
restaurants, movies, sponsored conferences at holiday resorts, and other
presents):
i) Are unethical promotional/marketing practices?
ii) Result in the doctor feeling obligated to prescribe





18. Please specify in the space below, if there are any other factors not mentioned in
the questionnaire, which may influence your decision to prescribe pharmaceutical
drugs.
•••••• ••• •••••••••••••••••• •••••••••••• ••• ••• ••••••••• "0 •••••••••••••••••••••••••••••••••••••••••••
............ - .
... - .
••••••••• ••••••••• ••• •••••• •• 0 •••••••••••••••••••••••••• 0 •••••••••••••••••••••••••••••••••••••••••••
...... - .
...... .
Thank you once again for your valuable time and assistance with my research.
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Appendix 11:
Examples of Reports from IMS and TMS
__I








Month: Cycle 04-03 Cycle/Month YTD ~6
J4




Days Not w.orked If "-~ ~ ~ J' § ~ .t ~ eY 5- q~ l'~ "S "S co ~ q"Total No days in Month
Month f
Targeted doctors seen
Targeted doctors seen >1














Pharmacy Call Rate 1.0 ... "v '" '"
.., <0 Mbnth Cb 0, ::i? .:::- ;::- ~
YTD % Frequency - Div Ave I YTD % Frequency - Total Tgted
100%
80%





Ox 1x 2x 3x 4x 5x 6x 7x 8x 9x 10x >11x Ox 1x 2x 3x 4x 5x 6x 7x 8x 9x 10x >11x
SRA - A Doctors - Totals
T9t Seen %Pen T9t Seen % Pen T9t Seen % Pen T9t Seen % Pen
1 0 0 - 50 27 54.0% 0 0 - 50 27 54.0%
2 0 0 - 11 9 81.8% 0 0 - 11 9 81.8%
3 0 0 - 32 17 53.1% 0 0 - 32 17 53.1%
4 0 0 - 8 8 100.0% 0 0 - 8 8 100.0%
5 0 0 - 18 9 50.0% 0 0 - 18 9 50.0%
6 0 0 - 22 9 40.9% 0 0 - 22 9 40.9%
0 0 - 141 79 56.0% 0 0 - 141 79 56.0%
PERIOD UP TO 12/2002




TYPE OF REPORT: VALUES





Data output and Analyses
R ELl A B I LIT Y A N A L Y S I S S C A L E (A L P H A)
Mean Std Dev Cases
1. Q1 1. 1207 .3286 58.0
2. Q2A 1. 2931 .4592 58.0
3. Q2B 1. 4138 .4968 58.0
4. Q2C 1.1207 .3286 58.0
5. Q2D 1.1897 .3955 58.0
6. Q2E 1. 7069 .4592 58.0
7. Q3 1.4310 .7282 58.0
8. Q4 2.3621 .7181 58.0
9. Q5 1. 0172 .1313 58.0
10. Q5A 1.7241 .4509 58.0
11. Q5B 1. 2414 .5065 58.0
12. Q5C 1. 5517 .7296 58.0
13. Q6 1. 8621 .6609 58.0
14. Q7 1. 5517 .5673 58.0
15. Q8.1 4.5345 .6547 58.0
16. Q8.2 2.3621 1.0874 58.0
17. Q8.3 3.4138 .8793 58.0
18. Q8.4 3.7069 .8788 58.0
19. Q8.5 3.6207 .9144 58.0
20. Q8.6 4.3448 .8283 58.0
21. Q8.7 3.4138 1. 0266 58.0
22. Q8.8 4.1207 .6774 58.0
23. Q8.9 4.2586 .7389 58.0
24. Q8.10 .2931 1. 0924 58.0
25. Q9 3.4828 1.0301 58.0
26. Q10 3.0172 .8055 58.0
27. Qll 3.1724 .7755 58.0
28. Q12.1 1. 4138 .7263 58.0
29. Q12.2 1.4138 1.1999 58.0
30. Q12.3 .3103 .8420 58.0
31. Q12.4 .6724 1. 1756 58.0
32. Q12.5 .3448 .9091 58.0
33. Q12.6 .3966 .8774 58.0
34. Q12.7 1.4483 1.2450 58.0
35. Q13.1 1.4483 1.0789 58.0
36. Q13.2 .3448 .8696 58.0
37. Q13.3 .3966 .8152 58.0
38. Q13.4 1. 1207 1. 2005 58.0
39. Q13.5 .3448 .9469 58.0
40. Q13.6 .2414 .8015 58.0
41. Q13.7 .9828 .9821 58.0
42. Q13.8 1. 0862 1. 2605 58.0
43. Q14.1 4.6379 .7181 58.0
44. Q14 .2 3.8793 .7964 58.0
45. Q14.3 3.2069 .6423 58.0
46. Q14.4 3.6207 .7909 58.0
47. Q14.5 4.0172 .9457 58.0
48. Q14.6 2.3103 1. 0123 58.0
Page 2
R E L I A B I LIT Y A N A L Y S I S S C A L E (A L P H A)
Mean Std Dev Cases
49. Q14.7 3.6724 .8863 58.0
50. Q14.8 3.1552 1.1050 58.0
51. Q14.9 2.2414 1. 0141 58.0
52. Q14.10 2.0690 .9150 58.0
53. Q14.11 2.2931 .9735 58.0
54. Q14.12 2.8966 1. 0033 58.0
55. Q14.13 .1552 .8335 58.0
56. Q15.1 3.9655 . '7715 58.0
57. Q15.2 3.3448 .7146 58.0
58. Q15.3 3.7069 .7257 58.0
59. Q15.4 4.1552 .6435 58.0
60. Q15.5 2.1724 .9392 58.0
61. Q15.6 3.4483 .9210 58.0
62. Q15.7 3.0172 1.1771 58.0
63. Q15.8 2.1552 .9877 58.0
64. Q15.9 2.0000 .9551 58.0
65. Q15.10 2.2241 1. 0603 58.0
66. Q15.11 2.7586 1.0481 58.0
67. Q15.12 .0000 .0000 58.0
68. Q16.1 1.4310 .4995 58.0
69. Q16.2 1.3448 .4795 58.0
70. Q16.3 1.5345 .5032 58.0
71. Q17.1 1.7931 .4086 58.0
72. Q17.2 1. 7759 .4207 58.0
N of
Statistics for Mean Variance Std Dev Variables
SCALE 155.2759 154.0278 12.4108 72
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R E L I A B I LIT Y A N A L Y S I S S C ALE (A L P H A)
Item-total Statistics
Scale Scale Corrected
Mean Variance Item- Alpha
if Item if Item Total if Item
Deleted Deleted Correlation Deleted
Q1 154.1552 153.8176 .0125 .6827
Q2A 153.9828 155.3506 -.1340 .6866
Q2B 153.8621 156.1912 -.1941 .6886
Q2C 154.1552 157.6071 -.4469 .6906
Q2D 154.0862 154.9223 -.1067 .6854
Q2E 153.5690 152.2495 .1383 .6799
Q3 153.8448 156.1685 -.1468 .6904
Q4 152.9138 155.9398 -.1354 .6898
Q5 154.2586 153.9495 .0188 .6824
Q5A 153.5517 151.7604 .1858 .6788
Q5B 154.0345 154.8760 -.0876 .6859
Q5C 153.7241 153.8173 -.0178 .6855
Q6 153.4138 154.8433 -.0761 .6870
Q7 153.7241 157.1857 -.2446 .6912
Q8.1 150.7414 155.8091 -.1352 .6890
Q8.2 152.9138 142.2205 .4097 .6633
Q8.3 151.8621 148.6473 .2149 .6757
Q8.4 151.5690 146.7057 .3077 .6712
Q8.5 151. 6552 150.2650 .1306 .6797
Q8.6 150.9310 152.6267 .0349 .6839
Q8.7 151.8621 147.4894 .2200 .6749
Q8.8 151.1552 150.3439 .1941 .6774
Q8.9 151. 0172 151. 3155 .1192 .6801
Q8.10 154.9828 154.3681 -.0565 .6910
Q9 151.7931 145.4301 .3033 .6702
Q10 152.2586 151.9846 .0702 .6823
Q11 152.1034 147.9540 .2901 .6729
Q12.1 153.8621 152.3315 .0652 .6822
Q12.2 153.8621 146.7175 .2020 .6758
Q12.3 154.9655 153.0514 .0128 .6850
Q12.4 154.6034 162.4540 -.3273 .7083
Q12.5 154.9310 156.8373 -.1597 .6937
Q12.6 154.8793 156.2483 - .1363 .6921
Q12.7 153.8276 157.7592 -.1689 .7002
Q13.1 153.8276 149.0575 .1445 .6793
Q13.2 154.9310 155.3987 -.0981 .6903
Q13.3 154.8793 150.9852 .1187 .6802
Q13.4 154.1552 153.2211 -.0214 .6902
Q13.5 154.9310 157.6443 -.1898 .6958
Q13.6 155.0345 154.1391 -.0379 .6869
Q13.7 154.2931 157.6143 -.1846 .6962
Page ~
R E L I A B I LIT Y A N A L Y S I S S C ALE (A L P H A)
Item-total Statistics
Scale Scale Corrected
Mean Variance Item- Alpha
if Item if Item Total if Item
Deleted Deleted Correlation Deleted
Q13.8 154.1897 162.9634 -.3270 .7105
Q14.1 150.6379 154.0596 -.0307 .6859
Q14.2 151.3966 146.4540 .3600 .6696
Q14.3 152.0690 147.9250 .3642 .6715
Q14.4 151.6552 151.5632 .0944 .6812
Q14.5 151.2586 149.7039 .1482 .6789
Q14.6 152.9655 144.6304 .3439 .6680
Q14.7 151.6034 144.7698 .3972 .6667
Q14.8 152.1207 139.8273 .4967 .6576
Q14.9 153.0345 140.2444 .5310 .6572
Q14 .10 153.2069 139.7108 .6232 .6545
Q14.11 152.9828 141. 7716 .4878 .6605
Q14 .12 152.3793 141.3624 .4887 .6599
Q14.13 155.1207 148.4940 .2382 .6748
Q15.1 151.3103 145.0599 .4505 .6661
Q15.2 151.9310 147.0127 .3754 .6701
Q15.3 151.5690 149.7934 .2087 .6766
Q15.4 151.1207 150.8448 .1752 .6782
Q15.5 153.1034 142.3751 .4806 .6615
Q15.6 151.8276 143.7592 .4266 .6647
Q15.7 152.2586 138.1600 .5233 .6545
Q15.8 153.1207 140.7396 .5254 .6581
Q15.9 153.2759 140.1331 .5741 .6561
Q15.10 153.0517 140.6113 .4888 .6589
Q15.11 152.5172 140.7453 .4899 .6590
Q15.12 155.2759 154.0278 .0000 .6824
Q16.1 153.8448 153.4316 .0280 .6828
Q16.2 153.9310 154.1706 -.0313 .6842
Q16.3 153.7414 151.4232 .1899 .6784
Q17.1 153.4828 153.8330 .0027 .6831













































MEDICAL AIDS 47 810%
PATIENTS



















BETWEEN 5 AND 10
9 15.5%YEARS
LESS THAN 5 YEARS 8 13.8%
Total 58 100.0%
Tables

















































Wilcoxon Signed Ranks Test
Page
Ranks
N Mean Rank Sum of Ranks
Q5C - Q5B Negative Ranks 33 12.00 36.00
Positive Ranks 18b 10.83 195.00
Ties 37c
Total 58
a. Q5C < Q5B
b. Q5C > Q5B




Asymp. Sig. (2-tailed) .003
a. Based on negative ranks.




























N Mean Rank Sum of Ranks
07-06 Negative Ranks 16a 8.50 136.00
Positive Ranks Ob .00 .00
Ties 42c
Total 58
a. 07 < 06
b. 07> 06




Asymp. Sig. (2-tailed) .000
a. Based on positive ranks.
b. Wilcoxon Signed Ranks Test
Tables
RELATIVE IMPORTANCE OF THE FOLLOWING.
NOT SLIGHTLY MODERATELY VERY ABSOLUTE
.00 IMPORTANT IMPORTANT IMPORTANT IMPORTANT MUST Total
08.1 Count 5 17 36 58
% 8.6% 29.3% 62.1% 100.0%
08.2 Count 15 17 18 6 2 58
% 25.9% 29.3% 31.0% 10.3% 3.4% 100.0%
08.3 Count 1 7 22 23 5 58
% 1.7% 12.1% 37.9% 39.7% 8.6% 100.0%
08.4 Count 2 1 18 28 9 58
% 3.4% 1.7% 31.0% 48.3% 15.5% 100.0%
08.5 Count 3 1 18 29 7 58
% 5.2% 1.7% 31.0% 50.0% 12.1% 100.0%
08.6 Count 1 1 4 23 29 58
% 1.7% 1.7% 6.9% 39.7% 50.0% 100.0%
08.7 Count 3 6 21 20 8 58
% 5.2% 10.3% 36.2% 34.5% 13.8% 100.0%
08.8 Count 10 31 17 58
% 17.2% 53.4% 29.3% 100.0%
08.9 Count 2 4 29 23 58
% 3.4% 6.9% 50.0% 39.7% 100.0%
08.10 Count 54 3 1 58
% 93.1% 5.2% 1.7% 100.0%
Tables
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RELATIVE IMPORTANCE BASED ON MEANS, MEDIANS, AND MODES
Count Mean Median Mode
Q8.1 59 4.53 5.00 5.00
Q8.2 59 2.36 2.00 3.00
Q8.3 59 341 3.00 4.00
Q8.4 59 3.71 4.00 4.00
Q8.5 59 3.62 4.00 4.00
Q8.6 59 4.34 4.50 5.00
Q8.7 59 3.41 3.00 3.00
Q8.8 59 4.12 4.00 4.00
Q8.9 59 4.26 4.00 4.00
Q8.10 59 .29 .00 .00
RELATIVE IMPORTANCE BY NUMBER OF YEARS IN PRACTICE BASED ON MEANS, MEDIANS, AND MODES
Count Mean Median Mode
Q3 MORE Q8.1 41 4.56 5.00 5.00
THAN 10 08.2 41 2.46 2.00 3.00
YEARS 08.3 41 3.44 3.00 3.00
08.4 41 3.76 4.00 4.00
08.5 41 3.63 4.00 4.00
08.6 41 4.32 4.00 5.00
08.7 41 3.41 3.00 3.00
08.8 41 4.07 4.00 4.00
08.9 41 4.27 4.00 4.00
08.10 41 .32 .00 .00
BETWEEN 08.1 9 4.44 5.00 5.00
5 AND 10 08.2 9 2.11 2.00 2.00
YEARS 08.3 9 3.44 4.00 2.00
08.4 9 4.11 4.00 4.00
08.5 9 3.89 4.00 4.00
08.6 9 4.56 5.00 5.00
08.7 9 3.33 3.00 3.00
08.8 9 4.11 4.00 4.00
08.9 9 4.11 4.00 4.00
08.10 9 .44 .00 00
LESS Q8.1 8 4.50 5.00 5.00
THAN 5 08.2 8 2.13 2.50 3.00
YEARS 08.3 8 3.25 300 3.00
Q8.4 8 3.00 3.00 3.00
08.5 8 3.25 3.00 3.00
08.6 8 4.25 4.50 5.00
08.7 8 3.50 4.00 4.00
08.8 8 4.38 4.00 4.00
08.9 8 4.38 4.00 4.00
08.10 8 .00 .00 .00
Tables
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RELATIVE IMPORTANCE BY NUMBER OF YEARS QUALIFIED BASED ON MEANS, MEDIANS, AND MODES
Count Mean Median Mode
04 MORE 08.1 29 4.59 5.00 5.00
THAN 20 08.2 29 2.52 3.00 3.00
YEARS 08.3 29 3.45 3.00 300
AGO
08.4 29 3.79 4.00 4.00
08.5 29 3.62 4.00 4.00
08.6 29 4.38 4.00 5.00
08.7 29 3.48 3.00 3.00
08.8 29 4.00 4.00 4.00
08.9 29 4.14 4.00 400
08.10 29 .45 .00 00
BETWEEN 08.1 21 4.48 5.00 5.00
10 TO 20 08.2 21 2.10 2.00 2.00
YEARS 08.3 21 3.24 4.00 4.00
AGO
08.4 21 3.71 4.00 4.00
08.5 21 3.81 4.00 4.00
08.6 21 4.29 5.00 5.00
08.7 21 3.19 3.00 3.00
08.8 21 4.19 4.00 4.00
08.9 21 4.38 4.00 4.00
08.10 21 .19 .00 .00
LESS 08.1 8 4.50 5.00 5.00
THAN 10 08.2 8 2.50 2.50 3.00
YEARS 08.3 8 3.75 3.50 3.00AGO
08.4 8 3.38 3.00 300
08.5 8 3.13 3.00 3.00
086 8 4.38 4.50 5.00
08.7 8 3.75 4.00 4.00
08.8 8 4.38 4.50 5.00
08.9 8 4.38 4.00 4.00
0810 8 .00 .00 .00
Tables
ARE PHARMACEUTICAL REPS FROM AN ALLIED OF SCIENTIFIC FIELD MORE PERSUASIVE?
09
Count %













Count % Count %
NO OPINION 5 9.8% 1 14.3%
STRONGLY
1 2.0% 1 14.3%DISAGREE
DISAGREE 8 15.7% 3 42.9%
AGREE 34 66.7% 2 28.6%
STRONGLY AGREE 3 5.9%
Total 51 100.0% 7 100.0%
Tables
ARE FEMALE REPS MOREPERSUASWE?
Q10
Count %











Count % Count %
NO OPINION 4 7.8% 1 14.3%
STRONGLY
2 3.9%DISAGREE 1 14.3%
DISAGREE 31 60.8% 5 71.4%
AGREE 14 27.5%




ARE REPS FROM SIMilAR CULTURAL BACKGROUND MORE PERSUASIVE?
011
Count %





STRONGLY AGREE 2 3.4%
Total 58 100.0%
Tables




Count % Count %
NO OPINION 3 5.9%
STRONGLY
2 3.9%DISAGREE
DISAGREE 33 64.7% 4 57.1%
AGREE 12 23.5% 2 28.6%
STRONGLY AGREE 1 2.0% 1 14.3%
Total 51 100.0% 7 100.0%
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HOW DO YOU FIRST LEARN ABOUT A NEW DRUG?
MOST
COMMON SECOND MOST THIRD MOST
.00 SOURCE COMMON SOURCE COMMON SOURCE Total
Q12.1 Count 3 33 17 5 58
% 5.2% 56.9% 29.3% 8.6% 100.0%
Q12.2 Count 19 11 13 15 58
% 32.8% 19.0% 22.4% 25.9% 100.0%
Q12.3 Count 50 2 2 4 58
% 86.2% 3.4% 3.4% 6.9% 100.0%
Q12.4 Count 43 6 9 58
% 74.1% 10.3% 15.5% 100.0%
Q12.5 Count 50 1 2 5 58
% 86.2% 1.7% 3.4% 8.6% 100.0%
Q12.6 Count 46 5 3 4 58
% 79.3% 8.6% 5.2% 6.9% 100.0%
Q12.7 Count 21 6 15 16 58
% 36.2% 10.3% 25.9% 27.6% 100.0%
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HOW DO YOU FIRST LEARN ABOUT A NEW DRUG - ANALYSIS BASED NUMBER OF YEARS THE DOCTOR
HAS BEEN IN PRIVATE PRACTICE.
SECOND
MOST MOST THIRD MOST
COMMON COMMON COMMON
.00 SOURCE SOURCE SOURCE Total
Q3 MORE Q12.1 Count 2 22 13 4 41
THAN 10 % 4.9% 53.7% 31.7% 9.8% 1000%
YEARS Q12.2 Count 13 9 9 10 41
% 31.7% 22.0% 22.0% 24.4% 1000%
Q12.3 Count 34 2 2 3 41
% 82.9% 4.9% 4.9% 73% 100.0%
Q12.4 Count 29 6 6 41
% 70.7% 14.6% 14.6% 100.0%
Q12.5 Count 37 1 3 41
% 90.2% 2.4% 7.3% 100.0%
Q12.6 Count 32 4 1 4 41
% 78.0% 9.8% 2.4% 9.8% 100.0%
Q12.7 Count 17 4 9 11 41
% 41.5% 98% 22.0% 26.8% 100.0%
BETWEEN Q12.1 Count 1 5 2 1 9
5 AND 10 % 11.1% 55.6% 22.2% 11.1% 100.0%
YEARS Q12.2 Count 3 2 2 2 9
% 333% 22.2% 22.2% 22.2% 100.0%
Q12.3 Count 8 1 9
% 88.9% 111% 100.0%
Q12.4 Count 8 1 9
% 88.9% 11.1% 100.0%
Q12.5 Count 8 1 9
% 88.9% 11.1% 100.0%
Q12.6 Count 6 1 2 9
% 66.7% 11.1% 22.2% 100.0%
Q12.7 Count 2 3 4 9
% 22.2% 33.3% 44.4% 1000%
LESS Q12.1 Count 6 2 8
THAN 5 % 750% 25.0% 100.0%
YEARS Q12.2 Count 3 2 3 8
% 37.5% 25.0% 375% 100.0%
Q12.3 Count 8 8
% 100.0% 100.0%
Q12.4 Count 6 2 8
% 75.0% 250% 100.0%
Q12.5 Count 5 1 2 8
% 625% 12.5% 25.0% 1000%
Q12.6 Count 8 8
% 100.0% 1000%
Q12.7 Count 2 2 3 1 8
% 25.0% 25.0% 37.5% 12.5% 100.0%
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HOW DO YOU FIRST LEARN ABOUT A NEW DRUG - ANALYSIS BASED NUMBER OF YEARS THE DOCTOR
HAS QUALIFIED.
SECOND
MOST MOST THIRD MOST
COMMON COMMON COMMON
00 SOURCE SOURCE SOURCE Total
04 LESS 012.1 Count 7 1 8
THAN 10 % 87.5% 12.5% 100.0%
YEARS 012.2 Count 1 3 4 8
AGO
% 125% 37.5% 500% 100.0%
012.3 Count 7 1 8
% 87.5% 12.5% 1000%
012.4 Count 8 8
% 100.0% 100.0%
012.5 Count 6 1 1 8
% 75.0% 12.5% 125% 100.0%
012.6 Count 7 1 8
% 87.5% 12.5% 100.0%
012.7 Count 3 1 2 2 8
% 37.5% 12.5% 25.0% 25.0% 1000%
BETWEEN 012.1 Count 1 12 6 2 21
10 TO 20 % 4.8% 57.1% 28.6% 9.5% 100.0%
YEARS 012.2 Count 9 4 5 3 21
AGO
% 42.9% 19.0% 23.8% 14.3% 100.0%
012.3 Count 17 1 2 1 21
% 81.0% 48% 9.5% 4.8% 1000%
012.4 Count 14 2 5 21
% 66.7% 9.5% 23.8% 100.0%
0125 Count 19 1 1 21
% 90.5% 4.8% 4.8% 100.0%
012.6 Count 16 2 3 21
% 76.2% 9.5% 14.3% 100.0%
012.7 Count 8 1 6 6 21
% 381% 4.8% 28.6% 28.6% 1000%
MORE 012.1 Count 2 14 10 3 29
THAN 20 % 6.9% 48.3% 34.5% 10.3% 100.0%
YEARS 012.2 Count 9 7 5 8AGO 29
% 31.0% 24.1% 17.2% 27.6% 100.0%
012.3 Count 26 1 2 29
% 897% 3.4% 6.9% 100.0%
012.4 Count 21 4 4 29
% 724% 13.8% 138% 1000%
012.5 Count 25 1 3 29
% 86.2% 3.4% 10.3% 100.0%
012.6 Count 23 3 2 1 29
% 79.3% 10.3% 6.9% 3.4% 100.0%
012.7 Count 10 4 7 8 29
% 34.5% 13.8% 24.1% 276% 100.0%
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WHOIWHAT ENCOURAGED YOU TO USE A NEW DRUG?
SECOND
MOST MOST THIRD MOST
COMMON COMMON COMMON
.00 INFLUENCE INFLUENCE INFLUENCE Total
013.1 Count 12 22 10 14 58
% 20.7% 37.9% 17.2% 24.1% 100.0%
013.2 Count 49 2 3 4 58
% 84.5% 3.4% 5.2% 6.9% 100.0%
013.3 Count 44 8 3 3 58
% 75.9% 13.8% 5.2% 5.2% 100.0%
013.4 Count 28 5 15 10 58
% 48.3% 8.6% 25.9% 17.2% 100.0%
013.5 Count 51 1 6 58
% 87.9% 1.7% 10.3% 100.0%
013.6 Count 53 1 4 58
% 91.4% 1.7% 6.9% 100.0%
013.7 Count 25 12 18 3 58
% 43.1% 20.7% 31.0% 5.2% 100.0%
013.8 Count 29 9 6 14 58
% 50.0% 15.5% 10.3% 24.1% 100.0%
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WHOIWHAT ENCOURAGED YOU TO USE A NEW DRUG - ANALYSIS BY NUMBER OF YEARS DOCTOR HAS BEEN
IN PRIVATE PRACTICE.
SECOND
MOST MOST THIRD MOST
COMMON COMMON COMMON
.00 INFLUENCE INFLUENCE INFLUENCE Total
03 MORE 013.1 Count 7 17 6 11 41
THAN 10 % 17.1% 41.5% 14.6% 26.8% 100.0%
YEARS 013.2 Count 35 1 3 2 41
% 85.4% 2.4% 7.3% 4.9% 100.0%
013.3 Count 31 7 1 2 41
% 75.6% 17.1% 2.4% 4.9% 100.0%
013.4 Count 18 4 11 8 41
% 439% 9.8% 26.8% 19.5% 100.0%
013.5 Count 36 5 41
% 87.8% 12.2% 100.0%
013.6 Count 38 1 2 41
% 92.7% 2.4% 4.9% 100.0%
013.7 Count 20 6 12 3 41
% 48.8% 14.6% 29.3% 7.3% 100.0%
013.8 Count 21 6 6 8 41
% 51.2% 14.6% 14.6% 19.5% 100.0%
BETWEEN 013.1 Count 3 2 2 2 9
5 AND 10 % 33.3% 22.2% 22.2% 22.2% 100.0%
YEARS 013.2 Count 7 1 1 9
% 77.8% 11.1% 11.1% 100.0%
013.3 Count 7 1 1 9
% 778% 11.1% 11.1% 100.0%
013.4 Count 4 1 3 1 9
% 44.4% 11.1% 33.3% 11.1% 100.0%
013.5 Count 8 1 9
% 88.9% 11.1% 100.0%
013.6 Count 7 2 9
% 77.8% 22.2% 100.0%
013.7 Count 4 3 2 9
% 44.4% 33.3% 22.2% 100.0%
013.8 Count 5 1 3 9
% 55.6% 11.1% 33.3% 100.0%
LESS 013.1 Count 2 3 2 1 8
THAN 5 % 25.0% 37.5% 25.0% 12.5% 100.0%
YEARS 013.2 Count 7 1 8
% 87.5% 12.5% 100.0%
013.3 Count 6 1 1 8
% 75.0% 12.5% 12.5% 100.0%
013.4 Count 6 1 1 8
% 75.0% 12.5% 12.5% 1000%
013.5 Count 7 1 8
% 87.5% 12.5% 100.0%
013.6 Count 8 8
% 1000% 100.0%
013.7 Count 1 3 4 8
% 12.5% 37.5% 50.0% 100.0%
013.8 Count 3 2 3 8
% 37.5% 25.0% 37.5% 100.0%
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WHOIWHAT ENCOURAGED YOU TO USE A NEW DRUG - ANALYSIS BY NUMBER OF YEARS DOCTOR HAS QUALIFIED.
SECOND
MOST MOST THIRD MOST
COMMON COMMON COMMON
.00 INFLUENCE INFLUENCE INFLUENCE Total
04 LESS 013.1 Count 2 2 2 2 8
THAN 10 % 25.0% 25.0% 25.0% 25.0% 100.0%
YEARS 013.2 Count 7 1 8
AGO
% 87.5% 12.5% 100.0%
013.3 Count 5 2 1 8
% 62.5% 25.0% 12.5% 100.0%
013.4 Count 6 1 1 8
% 75.0% 12.5% 12.5% 100.0%
013.5 Count 8 8
% 100.0% 100.0%
013.6 Count 7 1 8
% 87.5% 12.5% 100.0%
013.7 Count 1 3 4 8
% 12.5% 37.5% 50.0% 100.0%
013.8 Count 4 2 2 8
% 50.0% 25.0% 25.0% 100.0%
BETWEEN 013.1 Count 6 6 5 4 21
10 TO 20 % 28.6% 28.6% 23.8% 19.0% 100.0%
YEARS 013.2 Count 19 1 1 21
AGO
% 90.5% 4.8% 4.8% 100.0%
013.3 Count 14 5 1 1 21
% 66.7% 23.8% 4.8% 4.8% 100.0%
013.4 Count 7 2 6 6 21
% 33.3% 9.5% 28.6% 28.6% 100.0%
013.5 Count 20 1 21
% 95.2% 4.8% 100.0%
013.6 Count 20 1 21
% 95.2% 4.8% 100.0%
013.7 Count 9 5 6 1 21
% 42.9% 23.8% 28.6% 4.8% 100.0%
013.8 Count 10 3 2 6 21
% 47.6% 14.3% 9.5% 28.6% 100.0%
MORE 013.1 Count 4 14 3 8 29
THAN 20 % 13.8% 48.3% 10.3% 27.6% 100.0%YEARS
AGO
013.2 Count 23 2 2 2 29
% 79.3% 6.9% 6.9% 6.9% 1000%
013.3 Count 25 3 1 29
% 86.2% 10.3% 3.4% 1000%
013.4 Count 15 2 9 3 29
% 51.7% 6.9% 31.0% 10.3% 100.0%
013.5 Count 23 1 5 29
% 79.3% 3.4% 17.2% 100.0%
013.6 Count 26 1 2 29
% 89.7% 3.4% 6.9% 100.0%
013.7 Count 15 4 8 2 29
% 51.7% 13.8% 27.6% 6.9% 100.0%
013.8 Count 15 4 4 6 29
% 51.7% 13.8% 13.8% 20.7% 100.0%
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INFLUENCE ON PRESCRIBING DECISION FOR EXISTING DRUG.
VERY
NO MINOR MODERATE STRONG STRONG
.00 INFLUENCE INFLUENCE INFLUENCE INFLUENCE INFLUENCE Total
Q14.1 Count 1 2 13 42 58
% 1.7% 3.4% 22.4% 72.4% 100.0%
Q14.2 Count 2 16 27 13 58
% 3.4% 27.6% 46.6% 22.4% 100.0%
Q14.3 Count 1 4 35 18 58
% 1.7% 6.9% 60.3% 31.0% 100.0%
Q14.4 Count 4 21 26 7 58
% 6.9% 36.2% 44.8% 12.1% 100.0%
Q14.5 Count 2 3 4 32 17 58
% 3.4% 5.2% 6.9% 55.2% 29.3% 100.0%
Q14.6 Count 13 22 17 4 2 58
% 22.4% 37.9% 29.3% 6.9% 3.4% 100.0%
Q14.7 Count 2 4 11 35 6 58
% 3.4% 6.9% 19.0% 60.3% 10.3% 100.0%
Q14.8 Count 6 8 20 19 5 58
% 10.3% 13.8% 34.5% 32.8% 8.6% 100.0%
Q14.9 Count 14 25 11 7 1 58
% 24.1% 43.1% 19.0% 12.1% 1.7% 100.0%
Q14.10 Count 16 27 11 3 1 58
% 27.6% 46.6% 19.0% 5.2% 1.7% 100.0%
Q14.11 Count 13 22 17 5 1 58
% 22.4% 37.9% 29.3% 8.6% 1.7% 100.0%
Q14.12 Count 4 20 12 22 58
% 6.9% 34.5% 20.7% 37.9% 100.0%
Q14.13 Count 56 1 1 58
% 96.6% 1.7% 1.7% 100.0%
Tables
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INFLUENCE ON PRESCRIBING DECISION FOR EXISTING DRUG - ANALYSIS BY GENDER OF DOCTOR.
VERY
NO MINOR MODERATE STRONG STRONG
.00 INFLUENCE INFLUENCE INFLUENCE INFLUENCE INFLUENCE Total
GENDER MALE 014.1 Count 1 2 12 36 51
% 2.0% 3.9% 23.5% 70.6% tOO.O%
014.2 Count 2 16 23 10 51
0' 3.9% 31.4% 45.1% 19.6% 100.0%/0
014.3 Count 1 4 32 14 51
"i. 2.0% 7.8% 62.7% 27.5% 100.0%.D
014.4 Count 4 19 21 7 51
°io 7.80/0 37.3% 41.2% 13.7% 100.0%
014.5 Count 2 3 4 25 17 51
% 3.9% 5.9% 7.8% 49.0% 33.3% 100.0%
014.6 Count 12 20 14 4 1 51
% 23.5% 39.2% 27.5% 7.8% 2.0% 100.0%
014.7 Count 2 3 10 31 5 51
% 3.9% 5.9% 19.6% 60.8% 9.8% 100.0%
014.8 Count 6 6 17 17 5 51
% 11.8% 11.8% 33.3% 33.3% 9.8% 100.0%
014.9 Count 13 22 9 6 1 51
% 25.5% 43.1% 17.6% 11.8% 2.0% 100.0%
014.10 Count 14 25 8 3 1 51
~o 27.5% 49.0% 15.7% 5.9% 2.0% 100.0%
014.11 Count 10 20 16 5 51
% 19.6% 39.2% 31.4% 9.8% 100.0%
014.12 Count 3 17 9 22 51
% 5.9% 33.3% 17.6% 43.1% 100.0%
014.13 Count 49 1 1 51
0/0 96.1% 2.0% 2.0% 100.0%
FEMALE 014.1 Count 1 6 7
% 14.3% 85.7% 100.0%
014.2 Count 4 3 7
% 57.1% 42.9% 100.0%
014.3 Count 3 4 7
% 42.9% 57.1% 100.0%
014.4 Count 2 5 7
% 28.6% 71.4% 100.0%
014.5 Count 7 7
% 100.0% 100.0%
014.6 Count 1 2 3 1 7
% 14.3% 28.6% 42.9% 14.3% 100.0%
014.7 Count 1 1 4 1 7
% 14.3% 14.3% 57.1% 14.3% 100.0%
014.8 Count 2 3 2 7
% 28.6% 42.9% 28.6% 100.0%
014.9 Count 1 3 2 1 7
% 14.3% 42.9% 28.6% 14.3% 100.0%
014.10 Count 2 2 3 7
°/0 28.6% 28.6% 42.9% 100.0%
014.11 Count 3 2 1 1 7
% 42.9% 28.6% 14.3% 14.3% tOO.O%
014.12 Count 1 3 3 7
% 14.3% 42.9% 42.9% 100.0%




INFLUENCE ON PRESCRIBING DECISION FOR EXISTING DRUG - ANALYSIS BY TYPE OF GENERAL PRACTICE.
VERY
NO MINOR MODERATE STRONG STRONG
.00 INFLUENCE INFLUENCE INFLUENCE INFLUENCE INFLUENCE Total
02C CONTRACTED 014.1 Count 1 2 9 39 51
TO MEDICAL ~~ 2.0% 3.9% 17.6% 76.5% 100.0%
SCHEMES 014.2 Count 1 13 24 13 51
%. 2.0% 25.5% 47.1% 25.5% 100.0%
014.3 Count 1 3 29 18 51
% 2.0% 5.9% 56.9% 35.3% 100.0%
014.4 Count 3 19 22 7 51
% 5.9% 37.3% 43.1% 13.7% 100.0%
014.5 Count 1 1 4 29 16 51
% 2.0% 2.00/0 7.8% 56.9% 31.4% 100.0%
014.6 Count 10 18 17 4 2 51
% 19.6% 35.3% 33.3% 7.8% 3.9% 100.0%
014.7 Count 1 2 11 31 6 51
% 2.0% 3.9% 21.6% 60.8% 11.8% 100.0%
014.8 Count 2 6 20 18 5 51
% 3.9% 11.8% 39.2% 35.3% 9.8% 100.0%
014.9 Count 10 22 11 7 1 51
% 19.6% 43.1% 21.6% 13.7% 2.0% 100.0%
014.10 Count 13 23 11 3 1 51
% 25.5% 45.1% 21.6% 5.9% 2.0% 100.0%
014.11 Count 11 20 15 4 1 51
% 21.6% 39.2% 29.4% 7.8% 2.0% 100.0%
014.12 Count 4 15 11 21 51
% 7.8~~ 29.4% 21.6% 41.2% 100.0%
014.13 Count 49 1 1 51
% 96.1% 2.0% 2.0% 100.0%
NOT 014.1 Count 4 3 7
CONTRACTED % 57.1% 42.9% 100.0%
TO MEDICAL 014.2 Count 1 3SCHEMES 3 7
% 14.3% 42.9% 42.9% 100.0%
014.3 Count 1 6 7
% 14.3% 85.7% 100.0%
014.4 Count 1 2 4 7
% 14.3% 28.6% 57.1% 100.0%
014.5 Count 1 2 3 1 7
0/0 14.3% 28.6% 42.9% 14.3% 100.0%
014.6 Count 3 4 7
% 42.9% 57.1% 100.0%
014.7 Count 1 2 4 7
% 14.3% 28.6% 57.1% 100.0%
014.8 Count 4 2 1 7
% 57.1% 28.6% 14.3% 100.0%
014.9 Count 4 3 7
% 57.1% 42.9% 100.0%
014.10 Count 3 4 7
% 42.9% 57.1% 100.0%
014.11 Count 2 2 2 1 7
% 28.6% 28.6% 28.6% 14.3% 100.0%
014.12 Count 5 1 1 7
% 71.4% 14.3% 14.3% 100.0%




RELATIVE INFLUENCE ON PRESCRIBING DECISION FOR NEW DRUG
VERY STRONG
.00 NO INFLUENCE MINOR INFLUENCE ~DERATEINFLUENCE STRONG INFLUENCE INFLUENCE Total
015.1 Count 1 15 27 15 58
% 1.7% 25.9% 46.6% 25.9% 100.0%
015.2 Count 5 31 19 3 58
% 8.6% 53.4% 32.8% 5.2% 100.0%
015.3 Count 2 20 29 7 58
% 3.4% 34.5% 50.0% 12.1% 100.0%
015.4 Count 1 5 36 16 58
% 1.7% 8.6% 62.1% 27.6% 100.0%
015.5 Count 15 24 13 6 58
% 25.9% 41.4% 22.4% 10.3% 100.0%
015.6 Count 2 5 22 23 6 58
% 3.4% 8.6% 37.9% 39.7% 10.3% 100.0%
015.7 Count 8 9 21 14 6 58
% 13.8% 15.5% 36.2% 24.1% 10.3% 100.0%
015.8 Count 18 19 15 6 58
% 31.0% 32.8% 25.9% 10.3% 100.0%
015.9 Count 19 25 11 1 2 58
% 32.8% 43.1% 19.0% 1.7% 3.4% 100.0%
015.10 Count 16 23 10 8 1 58
% 27.6% 39.7% 17.2% 13.8% 1.7% 100.0%
015.11 Count 8 16 16 18 58
% 13.8% 27.6% 27.6% 31.0% 100.0%




'tELATIVE INFLUENCE ON PRESCRIBING DECISION FOR NEW DRUG· ANALYSIS BY HOW MANY YEARS DOCTOR HAS BEEN IN PRIVATE PRACTICE
VERY
NO MINOR MODERATE STRONG STRONG
00 INFLUENCE INFLUENCE It~FLUENCE INFLUENCE INFLUENCE Total
03 MORE 0151 Count 11 19 11 41
THAN 10 % 26.8% 46.3% 26.13% 100.0%
YEARS Q15.2 Count 4 23 12 2 41
% 9.8% 56.1% 29.3% 4.9% 100.0%
015.3 Count 1 13 22 5 41
% ~.40/0 31.7% 53.7% 12.~% 100.0%
0154 Count 4 24 13 41
% 9.8% 58.5% 31.7% 100.0%
Q15.5 Count 11 17 9 4 41
% 26.8% 41.5% :22.0% 9.8% 100.0%
015.6 Count 1 3 14 17 6 41
% 2.4% 7.3% 34.1% 41.5% 14.6% 100.0%
015.7 Count 6 5 16 11 3 41
% 14.6% 12.2% 39.0% 26.8% ,.3% 100.0%
015.8 Count 13 13 12 3 41
% 31.7% 31.7% 29.3% 7.3% 100.0%
015.9 Count 13 19 7 -, 41
% 31.7% 46.3% 17.1% 4.9% 100.0%
01510 Count 11 16 6 7 1 41
% 26.8% 39.0% 14.6% 17.1% 2.4% 100.0%
015.11 Count '5 10 11 15 41
% 12.2% 24.4% 26.8% 36.6% 100.0%
015.12 Count 41 41
% 100.0% 100.0%
BETVVEEI'J Q15.1 Count 1 2 4 2 9
5 AND 10 % 11.1% 2~.2% 44.4% 22.2% 100.0%
YEARS
Q15.~ Count 1 4 4 9
% 11.1% 44.4% 44.4% 100.0%
0153 Count 4 4 1 9
Q/o 444% 44.4% 11.1% 100.0%
Q15.4 Count 8 1 9
% 813.9% 11.1% 100.0%
Q15.5 Count 2 5 2 9
% 22.2% 55.6% 22.2% 100.0%
015.6 Count 4 5 9
% 44.4% 55.6~/O 100.0%
Q157 Count 1 3 3 2 9
% 11.1% 33.3% 33.3% .... '" ~IOI 100.0%_~ .... 10
015.8 Count 3 '5 1 9
% 33.3% 55.6% 11.1% 100.0%
015.9 Count 3 4 2 9
% 33.3% 44.4% 22.2% 100.0%
Q15.10 Count 3 3 3 9
% 33.3% 33.3% 33.3% 100.0%
01511 Count 2 3 3 1 9
% 22.2% 33.3% 33.3% 11.1% 100.0%
015.12 Count
'" 9% 100.0% 100.0%
LESS 015.1 Count 2 4 2 8
TI-lA.N 5 % 25.0% SO.O% 25.0%YEARS 100.0%015.2 Count 4 3 1 8
"''" 50.0% 37.5% 12.5% 100.0%
Q15.3 Count 1 3 3 1 8
% 12.5% 37.5% 37.5% 12.5% 100.0%
0154 Count 1 1 4 2 13
% 12.5% 12.5% SO.O% 25.0% 100.0%
015.5 Count 2 2 ~ ~ 84 4
%, 25.0% 25.0% 25.0% 25.0% 1000%
015.6 Count 1 2 4 1 8
% 125% 25.0% 50.0% 12.5% 1000%
015.7 Count 2 3 2 1 8
% 25.0% 37.5% 25.0% 12.5% 100.0%
015.8 Count 2 1 3 2 e
% 25.0% 12.5% 37.5% 25.0% 100.0%
015.9 Count 3 2 2 1 8
% 37.5% 25.0% 25.0% 12.5% 100.0%
015.10 Count 2 4 1 1 8
% 25.0% 50.0% 12.5% 12.5% 100.0%
015.11 Count 1 3 2 2 8







RELATlVE INFLUENCE ON PRESCRIBING DECISION FOR NEW DRUG - ANALYSIS BY NUMBER OF YEARS QUALIFIED
VERY
NO MINOR MODERATE STRONG STROI~G
.00 INFLUENCE INFLUENCE INFLUENCE INFLUENCE INFLUENCE Total
04 LESS 015.1 Count 3 2 3 8
THAN 10 % 375% 25.0% 37.5% 100.0%
YEARS 015.2 Count 5 2 1 8
AGO % 6~.50/0 25.0% 12.5% 100.0%
015.3 Count 2 4
~ 8-
% 25.0% 50.0% ~5.0% 100.0%
015.4 Count 1 4 3 8
% 12.5% 50.0% 37.5% 100.0%
015.5 Count 1 2 3 2 8
% 12.5% 25.0% 37.5% 25.00/l> 100.0%
015.6 Count 1 1 2 4 8
% 12.5% 12.5% 25.0% 50.0% 100.0%
015.7 Count 1 2 3 2 8
% 12.5% 25.0% 375% 25.0% 100.0%
015.8 Count 2 2 :2 2 8
% 25.0% 25.0% 25.0% 25.0% '100.0%
015.9 Count 3 2 2 '1 8
% 37.5% 25.C'% 25.0% 12.5% 100.0%
015.10 Count 2 3 2 1 8
% 25.0% 37.5% 25.0% 12.5% '100.0%
015.11 Count 1 2 2 3 8
% 12.5% 25.0% 25.0% 37.5% 100.0%
015.12 Count 8 8
% 100.0% 100.0%
BETVvEEH 015.1 Count 1 3 12 5 21
10 TO 20 % 4.8% 14.3% 57.1% 23.8% 100.0%
YEARS 015.2 Count 3 .. 8 1 21
AGO % 14.3% 42.8% 38.1% 4.8% 100.0%
015.3 Count 1 7 10 3 21
% 4.8% 33.3% 47.6% 14.3% 100.0%
015.4 Count 1 14 a 21
% 4.8% 00.7% 28.6% 100.0%
015.5 Count 4 9 6 2 21
% 19.0% 42.fI% 28.6% 9.5% 100.0%
015.6 Count 2 9 8 2 21
% 9.5% 42.9% 38.1% 9.5% 100.0%
015.7 Count 1 4 9 6 1 21
% 4.8% 19.0% 42.9% 28.6% 4.8% 1000%
015.8 Count 6 6 7 :2 21
% 28.6% 28.6% 33.3% 9.5% 100.0%
015.~) Count 6 9 6 21
% 28.6% 4:.9% 28.13% 100,0%
015.10 Count 7 8 4 - 21
% 33.3% 38.1% 19.0% 9.5% 100.0%
015.11 Count 4 6 7 4 21
% 19.0% 28.6% 33.3% 19,0% 100.0%
015.12 Count 21 21
% 100.0% 100.0%
MORE 015.1 Count 9 13 7 29
THAN :0 % 31.0% 44.8% 24.1% 100.0%
YEA.RS 015.2 Count 2 17 fIAGO 1 29% 6.9% 58.6% 31.0% 3.4% 100.0%
015.3 Count 1 11 15 2 :::9
% 3.4% 37.9% 51.7% 6.9% 100.0%
015.4 Cc·unt 4 18 7 29
% 13.8% 62.1% 24.1% 100.0%
015.5 Count 10 13 4 2 29
% 34.5% 44.8% 13.8% 6.9% 100.0%
015.6 Count 1 2 11 11 4 29
% 3.4% 6.9% 37.9% 37.9% 13.8% 100.0%
015.7 Count 6 3 9 8 3 ::g
% 20.7% 10.3% 31.0% "':.7.6% 10.3% 100.0%
015.8 Count 10 11 6 ~ ::g~
% 34.5% 37.9% 20.7% 6.9% 100.0%
015.9 Count 10 14 3 2 ::g
% 34.5% 48.3% 10.3% 6.9% 100.0%
015.10 Count i 12 4 5 1 29
% :4.1% 41.4% 13.8% 17.2% 3.4% 100.0%
015.11 Count 3 8 7 11 29







QUESTIONS 16 & 17
YES NO Total
016.1 Count 33 25 58
% 56.9% 43.1% 100.0%
016.2 Count 38 20 58
% 65.5% 34.5% 100.0%
016.3 Count 27 31 58
% 46.6% 53.4% 100.0%
017.1 Count 12 46 58
% 20.7% 79.3% 100.0%
017.2 Count 13 45 58







Mean N Std. Deviation Mean
Pair 08.1 4.5345 58 .65469 .08596
1 08.6 4.3448 58 .82827 .10876
Pair 08.6 4.3448 58 .82827 .10876
2 08.9 4.2586 58 .73890 .09702
Pair 08.8 4.1207 58 .67739 .08895
3 08.9 4.2586 58 .73890 .09702
Pair 08.4 3.7069 58 .87877 .11539
4 08.8 4.1207 58 .67739 .08895
Pair 08.4 3.7069 58 .87877 .11539
5 08.5 3.6207 58 .91436 .12006
Pair 08.3 3.4138 58 .87928 .11546
6 08.5 3.6207 58 .91436 .12006
Pair 08.3 3.4138 58 .87928 .11546
7 08.7 3.4138 58 1.02657 .13479
Pair 08.2 2.3621 58 1.08738 .14278
8 08.7 3.4138 58 1.02657 .13479
Paired Samples Correlations
N Correlation Sig.
Pair 1 08.1 & 08.6 58 .334 .011
Pair 2 08.6 & 08.9 58 .310 .018
Pair 3 08.8 & 08.9 58 .427 .001
Pair 4 08.4 & 08.8 58 .090 .502
Pair 5 08.4 & 08.5 58 .405 .002
Pair 6 08.3 & 08.5 58 .046 .732
Pair 7 08.3 & 08.7 58 -.096 .474




Std. Error of the Difference
Mean Std. Deviation Mean Lower Upper t df Sig. (2-lailed)
Pair 1 08.1 - 08.6 .1897 .86768 .11393 -.0385 .4178 1.665 57 .101
Pair 2 08.6- 08.9 .0862 .92309 .12121 -.1565 .3289 .711 57 .480
Pair 3 08.8- 08.9 -.1379 .75969 .09975 -.3377 .0618 -1.383 57 .172
Pair 4 08.4- 08.8 -.4138 1.06020 .13921 -.6926 -.1350 -2.972 57 .004
Pair 5 08.4- 08.5 .0862 .97844 .12848 -.1711 .3435 .671 57 .505
Pair 6 08.3- 08.5 -.2069 1.23911 .16270 -.5327 .1189 -1.272 57 .209
Pair 7 08.3- 08.7 .0000 1.41421 .18570 -.3718 .3718 .000 57 1.000





Mean N Std. Deviation Mean
Pair 014.1 4.6379 58 .71814 .09430
1 014.5 4.0172 58 .94575 .12418
Pair 014.3 3.2069 58 .64233 .08434
2 014.5 4.0172 58 .94575 .12418
Pair 014.2 3.8793 58 .79643 .10458
3 014.3 3.2069 58 .64233 .08434
Pair 014.3 3.2069 58 .64233 .08434
4 014.7 3.6724 58 .88631 .11638
Pair 014.3 3.2069 58 .64233 .08434
5 014.4 3.6207 58 .79090 .10385
Paired Samples Correlations
N Correlation Sig.
Pair 1 014.1 & 014.5 58 .242 .067
Pair 2 014.3 & 014.5 58 .196 .140
Pair 3 014.2 & 014.3 58 .255 .053
Pair 4 014.3 & 014.7 58 .090 .500






Mean Std. Deviation Mean Lower Upper t
Pair 1 014.1 - 014.5 .6207 1.04003 .13656 .3472 .8942 4.545
Pair 2 014.3 - 014.5 -.8103 1.03376 .13574 -1.0822 -.5385 -5.970
Pair 3 014.2 - 014.3 .6724 .88631 .11638 .4394 .9055 5.778
Pair 4 014.3 - 014.7 -.4655 1.04656 .13742 -.7407 -.1903 -3.388
Pair 5 014.3 - 014.4 -.4138 .95577 .12550 -.6651 -.1625 -3.297
Paired Samples Test
df Si!=!. (2-tailedl
Pair 1 014.1 - 014.5 57 .000
Pair 2 014.3 - 014.5 57 .000
Pair 3 0142 - 014.3 57 .000
Pair 4 0143 - 014.7 57 .001





Mean N Std. Deviation Mean
Pair 0151 3.9655 58 .77154 .10131
1 015.4 4.1552 58 .64350 .08450
Pair 015.1 3.9655 58 .77154 .10131
2 015.2 3.3448 58 .71455 .09383
Pair 015.2 3.3448 58 .71455 .09383
3 015.3 3.7069 58 .72568 .09529
Pair 015.2 3.3448 58 .71455 .09383
4 015.6 3.4483 58 .92095 .12093
Paired Samples Correlations
N Correlation Sig.
Pair 1 015.1 & 015.4 58 .117 .382
Pair 2 015.1 & 015.2 58 .149 .264
Pair 3 015.2 & 015.3 58 .029 .828




Std. Error of the Difference
Mean Std. Deviation Mean Lower Upper t df Sia. 12-tailed)
Pair 1 Q15.1 - Q15.4 -.1897 .94511 .12410 -.4382 .0588 -1.528 57 .132
Pair 2 Q15.1 - Q15.2 .6207 .97022 .12740 .3656 .8758 4.872 57 .000
Pair 3 Q15.2 - Q15.3 -.3621 1.00347 .13176 -.6259 -.0982 -2.748 57 .008
Pair 4 Q15.2 - Q15.6 -.1034 1.02066 .13402 -.3718 .1649 -.772 57 .443
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